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ABSTRACT 
Identification and characterization of tissue-resident memory T cells in humans 
Brahma Vencel Kumar  
 
Memory T cells are critical for maintaining lifelong immunity by protecting against 
reinfection with previously encountered pathogens. In recent years, a subset of memory T cells 
termed tissue-resident memory T cells (TRM) has emerged as the primary mediator of protection 
at many tissue sites. Numerous studies in mice have demonstrated that TRM accelerate pathogen 
clearance compared with other subsets of memory T cells. The defining characteristic of TRM is 
that they are retained within tissues and do not circulate in the blood. The lack of TRM in blood 
has proved to be a barrier for investigating the role of TRM in healthy humans. As a result, there 
are many outstanding questions about TRM biology in humans, including which phenotypic 
markers identify TRM, if TRM represent a unique memory subset, as well as defining 
transcriptional and functional characteristics of this subset.  
Through a unique collaboration with the local organ procurement agency, we obtained 
samples from >15 tissue sites from healthy organ donors of all ages. We found that the surface 
marker CD69 was expressed by memory CD4+ and CD8+ T cells in multiple tissues including 
spleen and other lymphoid tissues, lung, and intestines, but not in blood, suggesting that this 
marker may identify TRM in human tissues. We identify a core transcriptional signature that 
distinguishes CD69+ memory T cells in tissues from CD69- memory T cells in tissues and blood 
with key homologies to the transcriptional profile of TRM in mice, suggesting that CD69 
expression identifies TRM in humans. We show that human TRM have a distinct profile of 
adhesion and migration markers, and a unique dual functional capacity encompassing effector 
cytokine production but also the upregulation of inhibitory markers and the ability to produce IL-
10 upon stimulation. These results suggest unique adaptations for TRM to maintain long-term 
residence within tissues and carry out pathogen clearance.    
 We found substantial heterogeneity within human TRM in lymphoid and mucosal tissue 
sites, including a substantial fraction (40-60%) of TRM in various human tissues with the ability 
to efflux fluorescent dyes. These efflux(+) TRM had phenotypic and transcriptional characteristics 
associated with quiescence, including expression of immunomodulatory markers, reduced 
expression of exhaustion markers, and reduced turnover at steady state. Upon TCR stimulation, 
efflux(+) TRM produced lower levels of proinflammatory cytokines and cytotoxic molecules but 
had a superior ability to proliferate compared with efflux(-) TRM. However, efflux(+) also had an 
enhanced capacity for IL-17 production along with transcriptional features of IL-17 signaling 
following stimulation. Overall, these studies establish universal properties of human TRM and hint 
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CHAPTER 1: Introduction 
Adapted and expanded significantly from: Kumar, B.V., Connors, T., and Farber D.L. (2017) 
Human T cells and immune responses: impact of place and time. Immunity. Accepted.  
 
Section 1.1: Overview of T cell immunity in humans 
 T lymphocytes, or T cells, are part of the adaptive immune system and play a major role in 
combatting pathogens via a variety of mechanisms including killing of infected cells, coordination 
of immune responses, and secretion of anti-viral cytokines. T cells also play an important role in 
protecting against tumors and maintaining immune self-tolerance, and further are implicated as 
major drivers of many inflammatory and autoimmune diseases. In order to carry out these diverse 
functions, T cells exist as many different subtypes, with each subtype having unique characteristics 
and a distinct role in the immune response.  
T cells development occurs in the thymus, where progenitors originating from the bone 
marrow develop into mature naïve T cells that together are capable of recognizing millions of 
diverse antigens. These naïve T cells populate virtually all tissues sites of the human body early in 
life, and upon infection, naïve T cells that are specific for an invading pathogen become activated 
and expand into a large population of effector T cells [1, 2]. This marks the first phase of the T 
cell immune response: clonal expansion. This large pool of effector T cells eliminates the invading 
pathogen from the body via diverse mechanisms. The next phase of the T cell response is the 
contraction phase, during which the majority of the effector T cells that were generated to combat 
infection die by apoptosis [1, 2]. The third and final phase of the T cell response is memory 
generation, in which a small fraction of the effectors generated differentiate into a variety of 
memory subsets. An overview of this process, as well as basic events in T cell development, is 
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shown in Figure 1.1. These memory T cells protect the body against subsequent encounters with 
the same pathogen. Memory T cells are extremely long-lived and can protect the body for years or 
even decades after the initial infection.  
 The establishment and maintenance of immune responses, homeostasis, and memory 
depends on T cells. T cells express a receptor with the potential to recognize diverse antigens from 
pathogens, tumors, and the environment, and also maintain immunological memory and self-
tolerance. T cells are also implicated as major drivers of many inflammatory and autoimmune 
diseases. The in vivo functional role of T cells in immunity and immunopathology and the 
underlying mechanisms involved have been largely elucidated from mouse models, and have led 
to the development and advancement of immune-based cures and immunotherapies in humans [3, 
4]. However, the power and utility of mouse models to test hypotheses depends on reducing the 
scope of inquiry to one type of infection or disease perturbation over a defined time period in 
sterile, pathogen-free conditions. By contrast, humans are continuously exposed to multiple benign 
and pathogenic microorganisms, harbor chronic pathogens, yet can survive for many decades free 
of major infections even in advanced years [5].  
Additionally, the role of T cells in the immune response is not uniform throughout the 
human body. Recent studies from both mice and humans have shown that anatomic localization is 
intimately linked to T cell function and that each tissue has a unique immune microenvironment 
[6-9]. Different T cell subsets are maintained in different tissues, and immune responses are highly 
compartmentalized. An example of this is a subset of memory T cells termed tissue-resident 
memory T cells (TRM) that do not circulate out their tissue of residence, and these cells are the 
primary mediators of protection against infection at many sites [10]. By maintaining TRM specific 
for pathogens that are encountered in a particular tissue, the immune system is able to clear 
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pathogens efficiently without expending resources to maintain unnecessary populations. Thus, to 
understand the role of T cells in humans it is critical to examine T cells within a variety of tissues 
and not just blood, which only contains 2-3% of the total T cell complement [11, 12]. To address 
this, our laboratory has established a collaboration with LiveOnNY, the local organ procurement 
agency, through which we receive samples from >15 tissues from healthy organ donors across all 
ages. This unique tissue resource has enabled investigation of T cells not found in the blood and 




Figure 1.1. Overview of the T cell development and response to infection.  
(A) Overview of T cell development. T cell precursors emerge from the bone marrow and travel 
to the thymus, which is the primary site of T cell development. In the thymus, the cells undergo 
TCR rearrangement and positive and negative selection to generate mature naïve T cells. These 
naïve T cells emerged from the thymus and seed virtually all tissues of the body in early life. 
(B-C) Overview of the T cell response to infection. (B) Kinetics of the T cell response to infection. 
Following infection, there are 3 phases of the T cell response to infection: the expansion phase, 
during which activated cells proliferate to generate effectors; the contraction phase, during which 
effectors die following infection clearance; and the memory phase, during which memory T cells 
form and remain in the body for time periods up to years or decades. (C) A naïve T cell is first 
activated upon recognition of cognate antigen and appropriate costimulatory signals presented by 
dendritic cells. Activated naïve cells expand into a large population of effector cells which help 
clear the infection. Following infection, the majority of effector T cells die by apoptosis while a 
small fraction persist in the form of various memory T cell subsets which all have unique tissue 
distributions.  

















Section 1.2: Human T cell development and maintenance of naïve T cells 
Thymopoiesis 
The thymus is the primary site of T cell development, where progenitors from the bone 
marrow lacking CD4+ and CD8+ coreceptor expression undergo TCR rearrangement to generate 
CD4+CD8+ double positive (DP) thymocytes [20]. DP cells undergo selection giving rise to CD4+ 
or CD8+ single positive (SP) thymocytes that ultimately emerge into the periphery as naïve T cells 
exhibiting CD45RA+CCR7+ phenotypes. This process can generate an enormous repertoire of 
naïve T cells with up to 100 million different specificities in humans [21]. A less frequent, but 
critical subset of CD4+CD25+ cells expressing the Foxp3 transcription factor designated 
regulatory T cells (Tregs) [22] represents 9-10% of human CD4+ SP thymocytes [23], and also 
expresses naïve CD45RA+CCR7+ phenotypes [24]. Tregs are responsible for restraining immune 
responses to maintain tolerance to self-antigens and prevent autoimmunity. Most of our knowledge 
of thymopoiesis, on the genesis of new T cells and mechanisms for their selection and development 
derive from studies in mouse models using thymectomy, bone marrow reconstitution, and genetic 
manipulation [25, 26]. In humans, similar manipulations are not possible; however, “natural” 
experiments involving thymectomy and thymic transplantation and studies of recent thymic 
emigrants (RTE) provide key insights into human thymopoiesis and how it differs from mice. 
Unlike mice who are born lymphopenic, with T cells populating secondary lymphoid 
organs only at the end of gestation, humans are born with a full complement of T cells [27]. In 
utero, human T cell progenitors are detected in the fetal thymus as early as 9 weeks of gestation, 
with mature T cells appearing in the thymus by 12-13 weeks and the spleen and lymph nodes by 
24 weeks of gestation [28]. Human Tregs also develop early in fetal life and are detected in the 
thymus at 12 weeks and in lymph nodes at 14 weeks [29, 30]. It was established some time ago 
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that neonatal thymectomy in mice results in both profound immunodeficiency and multi-organ 
lymphocytic infiltration [31, 32], due to defects in development of both naïve T cells and Tregs, 
respectively [33]. Neonatal thymectomy in humans is performed during cardiac surgery to repair 
congenital abnormalities, and these patients (many now in their third-to-fourth decade of life) do 
not experience increased incidence of infections [34, 35]. Adults who underwent neonatal 
thymectomy remain healthy despite having more extensive declines in naïve T cell frequencies 
with age compared to control individuals [36, 37]. Moreover, neonatally thymectomized adults 
show no increases in the incidence of autoimmunity or allergy compared to aged-matched controls 
[38], consistent with their maintenance of normal blood Treg frequencies and numbers [39]. By 
contrast, infants born with a congenital defect in Treg development (based on deletion or mutation 
of the Foxp3 transcription factor) present with Immune dysregulation, Polyendocrinopathy, 
Enteropathy, X-linked (IPEX) syndrome manifested by systemic autoimmunity and  multi-organ 
infiltrates [40]. Therefore, the critical events in T cell development commence prior to birth in 
humans, and humans are born with a T cell complement sufficient to effect anti-pathogen 
immunity and immunoregulation. 
T cell development in the thymus involves rigorous selection events as determined in 
mouse models with newly generated DP thymocytes undergoing positive selection for self HLA 
recognition based on interactions with thymic epithelial cells (non-hematopoietic) and negative 
selection to remove strongly self-reactive clones through interactions with thymic DC [20]. Tregs 
undergo a different type of selection, and tend to be more self-reactive [41]. It is unclear whether 
thymic selection events occur similarly in humans, but novel insights have emerged from studies 
of thymus transplantation, a rare surgery used to successfully reconstitute the T cell compartment 
in infants with complete DiGeorge syndrome who are born lacking a functional thymus [42]. 
9 
 
Pioneering work of Dr. Louise Markert and colleagues showed that transplantation of completely 
allogeneic thymus tissues from unrelated infants resulted in thymopoiesis, generation of polyclonal 
functional naïve T cells and anti-pathogen immunity, enabling these individuals who otherwise 
would have died of infections to survive [43, 44]. Interestingly, thymic recipients are tolerant of 
self and the thymic transplant (they require no immunosuppression) and also generate Tregs with 
diverse repertoires [43, 45], suggesting unique flexibility of the early neonatal period for tolerance 
induction. Based on mouse studies, the generation of functional immunity requires positive 
selection on thymic epithelial cells (TEC); however, in human thymic transplants the TEC are of 
donor origin, yet functional T cells emerge that can respond to antigens presented by the host 
antigen presenting cells (APCs) [46]. Whether human thymocyte selection is more permissive than 
mouse, occurring based on interactions with donor epithelium and/or recipient thymic APC is not 
known but suggests that rules for selection in mice do not apply wholly to humans.  
How long does thymopoiesis persist in humans? The thymus is largest at birth, and age 
related changes in the thymus including a reduction in thymic volume, loss of epithelial cells, 
increase in perivascular space, and replacement of thymic tissue by fat begin relatively early in life 
[47]. Thymic function can be assessed in peripheral T cells based on CD31 surface expression [48, 
49] and measuring TCR excision circles (TREC) as products of rearrangement, which are both 
indicators of recent thymic emigrants [50, 51]. There are well-documented decreases in CD31 
expression and TREC content of peripheral blood T cells with age [48, 52, 53]. The greatest decline 
in thymopoiesis was generally believed to occur during puberty; however, more recent studies 
suggest that this steep reduction may occur later in life. In human thymic tissue obtained from 
organ donors aged several months to >70 years, DP thymocytes (indicating ongoing selection) 
were detected at the expected frequency (60-80%) in active thymus tissue from donors <40 years 
10 
 
of age, while few DP cells were detected in thymus tissues of adults >40 years of age [15]. 
Similarly, TREC levels of naïve T cells derived from human spleen and LN of these donors 
exhibited a steep reduction in individuals over 40 years of age [15], also observed in earlier studies 
quantitating TREC in peripheral blood naïve T cells [53]. Residual thymic activity can still persist 
beyond the fifth decade of life, as RTE-like cells can be detected in peripheral blood [52] and in 
renal transplant recipients following T cell depletion therapy [54]. Taken together, these findings 
indicate a profound age-related decline in thymic function after the fourth decade of life. 
Persistence of residual active thymus tissue may produce new T cells under lympho-depleting 
conditions and be amenable to regeneration therapies to rejuvenate the human immune system.  
 
Naïve and Treg cell maintenance 
In light of declining thymic output, how do individuals maintain a functional and diverse 
naïve T cell repertoire for responding to new antigens? Studies examining T cell turnover in human 
volunteers and mice administered deuterated water demonstrated important differences between 
the two species regarding thymopoiesis and naïve T cell maintenance. In both young and old mice, 
the majority of naïve T cells derive from thymic output, with minimal peripheral division of naïve 
T cells, while in humans, the majority of naïve T cells derived from peripheral turnover, even in 
younger adults with active thymic output [55, 56]. These studies also showed that the while the 
average life span of mouse naïve T cells is only 6-10 weeks, in humans, individual naïve T cells 
can persist 5-10 years  [55, 56]. The intrinsic long lifespan and turnover of human naïve T cells 
can account for their persistence well into old age.   
A mechanistic view of human naïve T cell maintenance has emerged from newer studies 
using high throughput DNA sequencing for assessing TCR repertoires and through study of naïve 
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T cells in tissue sites. TCR sequencing can measure clonal diversity and quantitate expanded 
clones. Human naïve T cells exhibit a highly diverse TCR encompassing up to 100 million 
different specificities [21]. Naïve phenotype cells in the blood of elderly individuals (70-85 years 
old) still maintain a diverse repertoire of unique TCR amino acid sequences that, while reduced 
compared to that of young adults [21], suggests that humans are capable of responding to novel 
antigens even at advanced ages. Studies from our laboratory examining naïve T cells in circulation 
and multiple tissue sites has enabled a novel assessment of how naïve T cells are maintained over 
the lifespan, from infancy to old age [15, 16, 18]. Naïve T cells comprise a significant proportion 
(20-50%) of total T cells within multiple lymph nodes for decades after the cessation of functional 
thymic output and even into the seventh and eight decade of life. Naïve T cells also maintain 
functionality with age, with no apparent functional differences between naïve T cells from younger 
individuals with active thymic output and older individuals with no thymic output [15]. TCR 
repertoire analysis of lymphoid naïve and memory T cells via CDR3 sequencing revealed high 
diversity (and corresponding low clonality) of CD4+ and CD8+ naïve T cells compared to the 
corresponding memory subset in spleen and multiple LN [15], indicating that naïve T cells in 
tissues maintain their capacity to respond to diverse antigens.  
Tregs also emerge from the thymus and exist in high frequencies in tissues during early 
life; however their persistence and frequency differs from naïve T cells. The early establishment 
of Tregs in utero is followed by elevated levels in early life with up to 10-30% of all CD4+ T cells 
in blood, lymphoid tissue, and mucosal sites being Tregs compared to less than 5% in adults [16, 
57]. Despite differences in overall frequency, pediatric and adult Tregs share similar features. 
Tregs maintain a TCR repertoire entirely distinct from corresponding non-Treg populations, with 
minimal overlap of TCR sequences between these subsets in umbilical cord blood and in adult 
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peripheral blood [58]. These results also suggest distinct thymic selection involved in development 
of Tregs from naïve T cells in humans. At all ages, Tregs in blood and lymphoid tissues are 
CD45RA+CCR7+, indicating a naïve phenotype, while Tregs in mucosal sites are CD45RA- and 
express CD45RO, like conventional memory T cells [16]. Functionally, pediatric Tregs in LN can 
express increased levels of FoxP3 compared to adult LN Tregs [16]; however, more studies are 
needed to assess how early life Tregs differ from those which persist in later life.    
The decline in Treg frequency in humans begins earlier in childhood than the decline in 
conventional naïve populations [16], suggesting both thymic and peripheral mechanisms at play. 
Studies in mice along with complementary analyses in humans indicates that age-associated 
reductions in Treg generation is due to interactions between thymic output, peripheral induction 
and maintenance. In mice, mature Tregs migrate back to the thymus and suppress thymic 
production of Tregs but not conventional naïve T cells [59]. Mature Tregs were also detected in 
human pediatric thymii [59], suggesting a similar mechanism controlling Treg production in 
humans. Compared with naïve T cells, human Tregs exhibit higher turnover, as measured by Ki67 
expression [16, 39], which along with reduced thymic output could also contribute to their reduced 
frequency with age. Treg frequency may also be affected by changes in Dendritic cell (DC) 
populations. Recent studies showed that human fetal dendritic cells could promote Treg induction 
and inhibit pro-inflammatory cytokine production more readily than adult DCs [60]. Together, 
these results suggest multiple interacting mechanisms for control of Treg frequencies after 





Section 1.3: T cell activation and subset differentiation 
Naïve T cells become activated primarily by dendritic cells, and this activation requires 
presentation of both antigen/MHC ligands and costimulatory molecules for engagement of the T 
cell receptor (TCR) and the CD28 costimulatory receptor, respectively. This initiates a complex 
signaling cascade within the naïve T cell that results in IL-2 production, proliferation, and 
differentiation to effector populations [61]. These effector populations carry out pathogen 
clearance and can be divided in many subsets, each with unique functional roles.  
Effector CD4+ T cells, or T helper (Th) cells, have diverse functions including promoting 
antibody secretion by B cells [62], helping the development of CD8+ effector T cells (also known 
as cytotoxic T lymphocytes or CTLs) [63], and direct pathogen clearance [64]. T helper subtypes 
are delineated based on function including Th1, Th2, Th17, T follicular helper (Tfh), and induced 
Tregs, as well as expanding array of subtypes such as Th9 and Th22 [65, 66]. These T helper 
subsets are crucial to the immune response, with each having a unique role; Th1 cells produce 
IFN- to promote responses against intracellular pathogens and Th2 cells produce IL-4 for B cell 
help and immune responses against extracellular pathogens. Tregs exert their suppressor functions 
by secreting inhibitory cytokines (IL-10, TGF-, and IL-35), stimulating apoptotic pathways, 
inducing metabolic disruption via cytokine deprivation, and modulation of DC maturation and 
function [67]. Different signals promote the development of different Th subsets, and key 
transcription factors have been identified that are associated with each subset. These key 
transcription factors are: T-bet for Th1 cells, GATA3 for Th2 cells, RORt for Th17, AhR for 
Th22 cells, and FoxP3 for Tregs [65]. It should also be noted that while the classification of CD4+ 
effector cells into discrete Th1/Th2/Th17 subsets can apply in a general way, there is considerable 
functional heterogeneity and plasticity within Th subsets [66, 68]. For example, populations of 
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CD4+ effector cells can secrete multiple cytokines characteristic of more than one subtype, and 
under certain conditions Th cells can switch their pattern of cytokine secretion [66, 68]. 
Activated CD8+ T cells differentiate into cytotoxic T cells (CTLs), which secrete high 
levels of IFN- and TNF and acquire cytotoxic capacities, expressing perforin and granzyme, with 
the ability to directly kill infected cells [69]. Functionally, CTLs kill infected cells by inducing the 
target cells to undergo apoptosis. This takes place when CTLs recognized MHC bound cognate 
antigen on the surface of the target cell, and then release granules containing cytotoxic molecules 
like perforin, which creates holes in the membrane of the target cells, and granzymes, which are 
enzymes that can induce apoptosis in the target cell after diffusing through pores created by 
perforin. Additionally, granzyme may directly inhibit the production of viral proteins [70] and 
directly kill intracellular bacteria by targeting the electron transport chain to produce reactive 
oxygen species that are lethal to the bacteria [71]. Overall however, the actions and lifespan of 
these effector cells are generally short-lived in vivo in humans, with a subset of previously 
activated cells undergoing further differentiation to persist as long-lived resting memory T cells.  
A number of transcription factors play an important role in the development of CTLs. T-
bet and eomesodermin (eomes) are two T-box transcription factors that play critical roles in 
mediating CTL formation and function, and these transcription factors also control CD8+ memory 
T cell function and development [72, 73]. The expression of T-bet and eomes is somewhat 
reciprocal, with high T-bet expression driving effector function and terminal differentiation and 
high eomes expression being associated with memory formation and longevity [72, 73]. TCF-1 is 
another transcription factor that plays an important role in controlling T cell fate. Specifically, 
TCF-1 is expressed at high levels by naïve T cells but needs to be downregulated in CTLs to allow 
for effector function [74-76]. Finally, expression of the transcription factor IRF4 is required for 
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effector CD8+ T cell differentiation [77-79]. While these represent a few key transcription factors 
that influence T cell differentiation, several other transcription factors also cooperate to determine 
CD8+ T cell fates [73].  
In humans, studying the dynamics of T cell activation and differentiation to effector and 
memory T cell fates requires specific cohorts that are challenged and followed over time. Elegant 
studies using the live-attenuated Yellow fever virus vaccination (YFV-7D) show activated CD4+ 
and CD8+T cells co-expressing CD38 and HLA-DR detectable in the blood within 2-3 days; YFV-
specific CD8+ T cells are subsequently detectable in blood and exhibit peak responses after 14-21 
days [80-83]. As in mouse infection models, the kinetics of the T cell response is delayed relative 
to infectious viral titers, with the magnitude of the effector CD8+ T cell response correlating with 
initial viral load [80]. This virus-induced effector response contracts rapidly, returning to near 
baseline levels by 30 days [80-82]. Virus-specific memory T cells subsequently persist in 
frequencies reduced from the effector response (5-6%) [82, 84, 85], yet are detectable 25 years 
after vaccination [85, 86]. Similar kinetics of effector expansion and memory development were 
observed following smallpox (vaccinia) and influenza vaccination [82], with vaccinia-specific 
memory T cells detected after many decades [87]. Together, these studies indicate that human 
effector T cell expansion, contraction, and memory formation following viral infection is similar 
in kinetics and magnitude to many acute viruses investigated in mice.   
While the majority of effector T cells contract rapidly and are not present in significant 
proportions at steady state in humans, a population of terminal effector cells (TEMRA) exhibiting 
CD45RA+CCR7- phenotypes can persist in circulation. TEMRA cells are mostly present within 
the CD8+T cell lineage, exhibit high capacity for IFN- production and low proliferative capacity, 
and their frequency in blood is correlated with persistent CMV infection [88]. The proportion of 
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CD8+ TEMRA cells in blood and bone marrow increases with age, specifically in CMV 
seropositive donors [14, 89], suggesting a role for TEMRA in persistent infections. CD4+ TEMRA 
cells are rarely detected, but expansion of CD4+ TEMRA cells with cytotoxic function occurs in 
individuals infected with Dengue virus and is associated with protection [90]. These findings 
suggest that certain viruses trigger terminal effector differentiation, which is important for 
protection or long-term control. Interestingly, TEMRA cells appear to be particular to human T 
cells, with no clear correlate in mouse infection models.    
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Section 1.4: Memory T cells 
As detailed in the previous sections, the majority of effector T cells contract following 
pathogen clearance but a limited fraction (approximately 5%) persist long-term as memory T cells, 
which at steady state represent the predominant T cell population that exists in virtually all human 
tissue sites and blood. Human memory T cells are classically distinguished from naïve T cells by 
the expression of CD45RO and the lack of CD45RA expression [91, 92]. Memory T cells are 
classically divided into two primary subtypes based on the expression homing receptors into 
central memory (TCM), which express CCR7, and effector-memory (TEM), which are CCR7- 
[93]. Stem-cell memory (TSCM) is an additional, more recently described T cell subset that exists 
in low frequencies, and can be identified by the phenotype CD45RA+CCR7+CD95+CD122+ [94]. 
Finally, tissue-resident memory T cells (TRM) are another recently identified subset of memory T 
cells that exist in high proportions within tissues [10] and will be covered in detail in the next 
section of this chapter. 
Functionally, both TCM and TEM are both capable of producing IL-2 and effector 
cytokines upon stimulation. However, TCM exhibit properties more similar to naïve T cells, 
including gene expression and homing receptor profile, high proliferative capacity, and ability to 
produce elevated levels of IL-2, while TEM have a greater ability to produce effector cytokines 
such as TNF and IFN- and have greater cytotoxic capabilities [6, 93-95]. TSCM are a relatively 
rare subset with high proliferative and self-renewal capabilities, but no effector function [94]. 
TSCM resemble naïve T cells based on the phenotype CCR7+CD45RA+, but also by the fact that 
they express CD62L and have high levels of the costimulatory receptors CD28 and CD27. These 




Within the adult human, each memory subset has a unique tissue distribution. Via a unique 
tissue resource, recent studies from our laboratory have analyzed T cell subsets in tissues over six 
decades of adult life and revealed that TEM were the predominant T cell population in lungs, small 
and large intestines, spleen, and blood, and represented 30-50% of the T cell complement in 
multiple lymph nodes [14, 17, 18]. By contrast, in most healthy adults naïve T cells were primarily 
found in blood, spleen, and lymph nodes, although still at lower frequencies than memory T cells.  
For CD4+T cells, TCM cells were present in similar frequencies (average 20%) in lymphoid sites 
with lower frequencies in mucosal tissues, and there were few TEMRA phenotype cells. For 
CD8+T cells, significant fractions (~30%) of TEMRA cells were found within blood and blood-
rich tissues (spleen, bone marrow, and lung) but not in other sites. Studies from our lab found 
negligible (approximately 5% for most tissues) CD8+ TCM-phenotype cells in any site [14, 18]; 
other studies also found low but somewhat higher (~20%) frequencies of TCM within the CD8+ T 
cell lineage in peripheral blood [93, 96, 97]. Overall however, most subset frequencies were quite 
stable across highly diverse donors, suggesting tissue-specific compartmentalization of human T 
cell subsets.  
The developmental relationship between T cell subsets is the subset of ongoing research. 
Models for the linear and bifurcated generation of human memory T cell subsets have been 
previously inferred from functional analysis, differentiation markers, and analysis of cell division 
[98]. However, recent studies using epigenetic and transcriptional analysis have provided new 
insights into the differentiation hierarchy of memory T cells. For CD4+ T cells, epigenomic 
profiling based on assessment of methylation status, DNA accessibility, and histone modifications 
revealed a progressive loss of DNA methylation of key genes that control memory development 
in the order naïve – TCM – TEM – TEMRA [99]. The authors observed a similar progression in 
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terms of transcriptional profile and telomere length. A linear progression of differentiation for 
human CD8+ T cells in the order naïve—TSCM—TCM—TEM was suggested by methylation 
analysis and chromatin accessibility [100, 101]. Compared with naïve T cells, TEM had the most 
number of differentially methylated regions and TSCM had the least, with TCM falling in between. 
The different CD4+ and CD8+ memory T cell subsets all contained specific elements of effector 
cells such as demethylation of effector genes (e.g., IFN-), suggesting an effector precursor and 
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Section 1.5: Tissue-resident memory T cells (TRM) 
Overview of TRM 
Memory T cells were originally divided into central and effector memory subsets which 
patrolled lymphoid and peripheral tissues, respectively [93]. However, this analysis was done in 
blood and a number of studies were unable to reconcile these findings in tissues, leading to the 
designation of another subset called tissue-resident memory T cells (TRM), which exists solely 
within tissues and does not recirculate [10, 102]. TRM have been described in virtually every tissue 
studied, including barrier sites such as skin, gut, lung, and reproductive tract, organs such as liver 
and kidney, secondary lymphoid organs, exocrine sites such as pancreas and salivary glands, and 
brain [10, 103-113]. Functionally, TRM mediate rapid in situ protection against diverse viral, 
bacterial, and parasite infections, and are more effective than circulating memory T cells in 
pathogen clearance [103, 105-107, 114-116]. In fact, TRM can clear pathogens without any 
contribution from circulatory T cells or antibodies. The clinical importance of TRM is further 
underscored by the fact that protective TRM can be generated in response to vaccination and 
cancer [117-120], and in addition to having protective roles, TRM can be pathogenic and are 
implicated in many human diseases [121, 122].  
The existence of TRM and demonstration that these TRM enhance protection was 
demonstrated a number of years ago for both CD8+ [107, 123] and CD4+ [105] lineages. Since that 
time, many studies as well as reviews on TRM have focused on CD8+ TRM [10, 102]. However, 
several additional studies have proven the existence of bona fide CD4+ TRM, which like their 
CD8+ counterparts, are also important for optimal protective responses [111, 115, 118, 124-127]. 
In mice, TRM can be identified using parabiosis assays [103, 104, 128], in vivo antibody labeling 
[105, 124, 129], or by using photoconversion of T cells to track migration [111, 127, 130]. 
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Phenotypically, TRM can be distinguished from circulating memory T cells based on the 
expression of CD69 [10, 124, 129], a surface marker which promotes retention through 
sequestration of S1PR1 [131, 132], and for certain subsets of CD8+ TRM by the expression of 
CD103 [10, 133].  
 
Phenotypic and transcriptional properties of TRM 
A number of studies have established that TRM are a distinct subset from circulating 
memory T cells based on phenotypic and transcriptional properties. At first glance, TRM have 
some similarities to TEM in that TRM do not express CCR7 or CD62L, which are two key markers 
used to delineate memory subsets [10]. However, a key difference between TEM and TRM shown 
by numerous studies is that CD4+ and CD8+ TRM from both barrier and lymphoid tissues 
upregulate the cell surface marker CD69 [103, 105, 109-112, 134-136]. CD69 promotes tissue-
retention by leading to the downregulation of sphingosine-1 phosphate receptor 1 (S1PR1), a 
receptor which promotes tissue egress and migration towards sphingosine-1 phosphate found in 
the blood and lymph [131, 132, 137, 138]. In fact, it has even been shown that downregulation of 
S1PR1 (and its associated transcription factor KLF2) is required for TRM formation, and that 
forced S1PR1 expression inhibits TRM generation [139]. CD103, a cell surface integrin which 
binds E-cadherin on epithelial cells, is also commonly used as a marker of CD8+ TRM [10]. 
However, CD8+ TRM lacking CD103 expression have also been described, and it has been shown 
that CD103+ and CD103- TRM are developmentally distinct subsets [10, 133]. Further, CD4+ 
TRM do not highly express CD103. Therefore, at present, CD69 appears to be the most reliable 
phenotypic marker of CD4+ and CD8+ TRM in mice, short of methods such as in vivo labelling or 
parabiosis.    
23 
 
Transcriptional profiling comparing CD8+ TRM with circulatory T cells in mice has been 
done via microarray [108, 110, 140] and RNA sequencing [109]. (RNA-Sequencing has a superior 
ability to detect low abundance transcripts and a greater dynamic range compared with microarray 
[141].) These studies have shown that TRM are a transcriptionally distinct subset compared with 
circulating memory T cells (either TEM or TCM). This result reinforces the designation of TRM 
as a separate memory subset. A number of key features of TRM can be determined by comparing 
the results of these studies. However, a core gene signature of TRM remains to be established as 
these studies that performed gene expression profiling of TRM used different infection models, 
different tissue sites, and sometimes different TRM subsets (i.e. CD103+ vs CD103- TRM). 
Further, these studies have compared TRM from a barrier site to circulating memory from the 
spleen [108-110]. As tissue microenvironments can have powerful effects on T cells [134], 
differentially expressed genes in these studies might include those that result from tissue 
differences rather than TRM vs. TEM/TCM differences. Finally, no published studies have 
performed whole transcriptome profiling of CD4+ TRM or of TRM from lymphoid tissues.   
These studies that performed gene expression profiling of TRM confirmed the 
downregulation of S1PR1 and also showed that TRM may downregulate other sphingosine-1-
phosphate receptors such as S1PR4 and S1PR5. Further, these studies showed that TRM 
downregulate of KLF2 as well as the related transcription factor KLF3. Overall, these results 
confirm S1PR1 downregulation as a critical way that TRM are able to avoid egress cues and 
maintain residence. TRM have also been shown to have differential expression of other homing 
receptors and certain adhesion markers. Examples include downregulation of SELL (encoding 
CD62L) [139, 140, 142] and CXCR4 [109], and upregulation of CXCR6 [109, 142] and ITGA1 
(encoding the adhesion marker CD49a) [108, 110]. These results reinforce that unique migratory 
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properties of TRM may be required to maintain tissue residence. These studies further uncovered 
notable transcriptional differences related to T cell function (e.g. upregulation of transcripts 
encoding cytokines and cytotoxic molecules by TRM), and these will be detailed in the later 
section that covers TRM function. These studies have also identified differences between TRM 
and circulatory memory T cells with respect to transcription factors. The roles of these 
transcription factors will be discussed in the section on TRM generation and maintenance. Overall, 
however, the key results from studies performing transcriptional profiling of TRM indicate that 
TRM are a transcriptionally distinct subset from TEM and TCM, with unique functional and 
phenotypic properties and unique transcriptional regulators. 
  
TRM function and protective responses to pathogens 
It is well established that TRM are the primary mediators of pathogen clearance at many 
tissue sites and that TRM accelerate pathogen clearance compared with circulating memory T cells 
[10]. For example, one study generated CD8+ memory T cells in response to vaccinia virus skin 
infection, and the authors showed using a parabiosis model that TRM were superior to TCM in 
clearing a subsequent infection [103]. In fact, previously infected mice containing TRM but whose 
TCM were depleted (using FTY720) were still able to clear infection, but mice containing only 
TCM were unable to clear infection [103]. Another study found that protection against skin HSV 
infection was correlated with the number of skin CD8+ TRM but not with the number of circulating 
memory T cells [143]. CD4+ TRM appear to have similar characteristics; in a study from our lab, 
mice containing CD4+ TRM in the lung enjoyed greater protection against influenza infection (as 
measured by weight loss and survival) compared with mice containing circulatory memory T cells 
[105]. Enhanced protection by TRM has been demonstrated in several other studies [107, 108, 
25 
 
144, 145], including in studies where protective TRM were generated by vaccination [117, 118, 
146, 147]. The mechanisms for this superior protection appear to result from: 1. Proximity to the 
site of infection which allows faster response compared with circulating T cells which would have 
to be recruited, and 2. Cell intrinsic abilities which give TRM the ability to be superior defenders. 
These cell intrinsic abilities including unique functional properties, including increased expression 
of a number of genes involved in function including transcripts encoding granzyme B, TNF, and 
IFN- [108-110, 140, 148]. Some of these studies also showed that TRM upregulate the 
transcription factor IRF4 [108, 109], which is an important mediator of T cell effector function 
[77-79]. These transcriptional properties strongly suggest unique functional properties of TRM 
and that TRM are “poised” for rapid effector function upon stimulation, and the ability of CD8+ 
TRM to produce these cytokines has also been validated [10]. While transcriptional profiling of 
CD4+ TRM has not been done, studies suggest that these cells are also capable of secreting IFN-
 [126, 149], as well as TNF and IL-2 [126]. 
Numerous studies have investigated the cell-intrinsic functional properties of CD8+ TRM 
that allow pathogen clearance. Broadly, it appears that the function of TRM can be divided into 
two main roles: 1. Direct effector function mediated by TRM, and 2. a “sound the alarm” function, 
whereby TRM are sentinels that recruit T cells and other leukocytes to the site of infection. These 
properties are not always mutually exclusive, and “sound the alarm” function has been reported in 
a few recent high profile articles [114, 150, 151]. Upon reactivation, TRM induced VCAM-1 
expression on endothelial cells via IFN- production, allowing for the recruitment of circulating 
lymphocytes, induced dendritic cell maturation via TNF production, and induced NK cell 
activation via IL-2 production [114, 135]. One of these studies performed transcriptional profiling 
of skin tissue near TRM upon secondary challenge and found that TRM induce an antiviral state 
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in surrounding cells via IFN- production [150]. These surrounding cells upregulated a number 
of genes involved in anti-pathogen responses, and in fact this TRM-mediated effect was sufficient 
to protect against an antigenically unrelated pathogen. Direct effector function by TRM is apparent 
by fact that TRM are able to clear pathogens without any contribution from circulating T cells 
(such as when an agent is administered to deplete circulating leukocytes) [103, 106, 118]. The fact 
that protection after circulating leukocyte depletion exists even against heterosubtypic strains of 
influenza implies that it is mediated by TRM rather than antibodies which were formed during the 
primary response [118]. To carry out these effector functions, TRM must come into contact with 
and recognize invading pathogens. Two studies examining TRM motility have shown TRM patrol 
the epidermis and have a unique dendritic morphology (as opposed to the ameoboid shape of 
circulating T cells), whereby dendrites are continuously extended and retracted to sample the local 
environment [152, 153]. Upon recognition of antigen, these patrolling TRM reduced their motility 
to stay in the area of infection [153]. Overall, these data suggest that mouse TRM continuously 
patrol regions of prior infection and upon antigen encounter, mediate protection via direct effector 
function as well as by recruiting other leukocytes from circulation.  
 
TRM in human tissues 
While the majority of studies on TRM have been conducted in mice, the presence of TRM 
(or at least TRM-phenotype cells) within multiple human tissues has also been demonstrated [140, 
142, 154-159]. For example, transplant patients who were administered alemtuzumab, an agent 
which depletes all circulating T cells, still retained T cells in their skin [154, 155]. The retained 
memory T cells expressed CD69, similar to TRM in mice. Further, analysis of memory T cells 
from healthy organ donors in our lab revealed that CD69 is expressed by the majority of memory 
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T cells in multiple tissues sites including mucosal sites, lymphoid sites, and exocrine tissues such 
as salivary glands, while blood memory T cells are largely CD69– [18]. Some additional studies 
have identified memory T cells expressing the TRM markers CD69 or CD103 in human tissues, 
suggesting the presence of TRM [158, 159]. Nonetheless, it has not been formally established that 
CD69 identifies TRM in humans, nor have any other phenotypic markers been established that 
reliably identify TRM in human tissues. Phenotypically, these TRM phenotype cells appear to 
have certain common features with TRM in mice. These include downregulation of S1PR1 
transcriptionally [160], low CD62L expression [158, 159], low CCR7 expression [155, 160], and 
upregulation of CD49a [159]. Further, similar to mice, it appears that both CD103+ and CD103- 
subsets of TRM exist within the skin [155]. Overall, these limited studies suggest the presence of 
TRM in human tissues with features analogous to mouse TRM. However, additional studies are 
needed to establish core phenotypic properties of human TRM.  
Several lines of evidence suggest that these TRM have a protective role in humans 
analogous to their established roles in mice. Patients given alemtuzumab, an agent which depletes 
circulating T cells while preserving TRM, do not have higher rates of infections [154], suggesting 
memory T cells residing within tissues adequately control ongoing and new infections. Two 
studies examining responses to herpes simplex virus (HSV), which is used as a model system for 
studying TRM in mice [107, 161], identified long-lived CD8+ αα resident T cells that were formed 
following infection in humans [160, 162]. These TRM clustered around infected cells, expressed 
cytolytic molecules and upregulated antiviral genes, and were associated with control of 
symptoms. TRM in other tissues also display enhanced specificity for site-specific pathogens, 
including influenza-specific CD8+T cells within the lung TRM subset [124, 159], hepatitis B virus 
(HBV)-specific CD8+ T cells within liver CD69+ memory T cells [163], and EBV specific CD8+ 
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TRM in the spleen and tonsils [157]. The tissue distribution of T cells specific for systemic viruses 
that infect and/or persist in multiple sites is more complex. CMV-specific T cells exhibit different 
distribution patterns with predominance in either blood, bone marrow (majority of donors), or lung 
and lung lymph nodes, with higher frequencies of total and activated virus specific T cells being 
associating with lower viral loads [14]. Bone marrow was also found to be enriched compared to 
blood for specificities to multiple systemic pathogens [164], suggesting compartmentalization of 
long-lived memory populations in the bone marrow. Finally, it has been shown that human TRM 
from the lung, GI tract, and other sites are capable of producing multiple effector and pro-
inflammatory cytokines including IFN-, TNF, and IL-17 [142, 158, 159]. Taken together, these 
findings suggest that human TRM are generated at sites of infection, and upon pathogen encounter, 
TRM exhibit cytotoxic abilities, produce anti-viral cytokines like IFN-, and recruit other 
leukocytes to the site of inflammation. 
While TRM are critical for protection at many sites, emerging evidence strongly suggests 
that TRM can also be pathogenic and that TRM are implicated in a number of human illnesses (for 
detailed reviews, see [121, 122]). In the skin for example, studies suggest that TRM contribute to 
the pathogenesis of several skin disease including psoriasis, vitiligo, mycosis fungoides (MF), and 
fixed drug eruption. The clinical characteristics of these diseases strongly suggest TRM 
involvement: lesions occur within a fixed area rather than being diffuse; lesions recur at exactly 
the same location, suggesting that the T cells have not circulated; and the onset of inflammation 
tends to occur very rapidly after antigen exposure, suggesting that the T cells contributing to 
inflammation are already located within the tissue [121]. Further, these conditions tend to worsen 
over time [121], which is consistent with the fact that TRM accumulate with repeated antigen 
exposure (see prior sections).  
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In MF, T cells from lesioned skin do not expression CCR7 or CD62L, consistent with a 
TRM phenotype, while T cells from conditions that affect the skin diffusely do express these 
markers of circulating T cells [154, 165]. In psoriasis, E-selectin blockade, which inhibits T cell 
migration into the skin, does not lead to resolution of symptoms [166], suggesting that TRM are 
mediating the disease rather than circulating T cells that enter the skin from the blood. Further, 
psoriatic lesions developed when non-lesioned skin from psoriasis patients was transferred onto 
immunodeficient mice [167], suggesting that pathogenic TRM were contained within the skin and 
that lesions can develop without any recruitment from circulation. Finally, a recent article that 
examined T cells from biopsies of psoriasis and vitiligo lesions showed that CD8+CD103+ TRM 
producing IL-17 (which drives the development of psoriasis) were overrepresented in psoriatic 
lesions, while TRM producing IFN- and expressing cytotoxic molecules (which together drive 
the development of vitiligo) were overrepresented in vitiligo lesions [168].  
These skin diseases  represent illnesses where the involvement of TRM is well-
characterized. However, there are many other diseases where evidence suggests TRM 
involvement, although further studies are needed to conclusively determine this. These include gut 
diseases such as Crohn’s, brain diseases such as multiple sclerosis and schizophrenia, rheumatoid 
arthrisis, and asthma and allergic airways disease to name a few [121, 122]. Ongoing studies will 
elucidate the roles of TRM in these and potentially additional conditions; however, at present there 
is sufficient evidence to state that TRM have a critical role in human disease in addition to 




TRM generation and maintenance 
It is well established in mice that TRM generation occurs in response to infection at many 
different tissue sites, and this is true for both CD4+ and CD8+ TRM in barrier, lymphoid, and other 
tissues [10, 103, 105-110, 112]. The current literature suggests that CD8+ TRM develop from 
effector T cells that enter the affected tissue early during infection, and once inside the tissue a 
number of signals promote the development of a CD103+ TRM phenotype and prevent tissue 
egress [10, 102, 148]. In the skin for example, peak influx of TRM precursors occurs around 1 
week post infection, and these effector cells transition into fully developed TRM by about day 30, 
including acquiring CD69 and CD103 expression and progressively diverging from other memory 
subsets transcriptionally [110, 140]. Another study showed that only early effector cells and not 
memory T cells have the ability to enter the intestinal mucosa, and these early effectors were the 
cells that developed into TRM in the gut [123]. The authors also showed that in humans only early 
effectors expressed gut homing molecules following yellow fever vaccination, suggesting that in 
both humans and mice there is a limited time window when TRM precursors have the ability to 
seed tissues. This concept is reinforced by other studies showing that TRM are maintained without 
the need for replenishment from circulating memory T cells [124, 126]. The ability of effector T 
cells to enter a particular tissue may depend on homing receptors such as α4β7 in the case of the 
intestine, and the anatomic location of the draining lymph node has a large influence on which 
homing molecules effector T cells express [122]. Inflammatory signals generated at the site of 
infection may also have a role in recruiting effector T cells into the tissue [169, 170].  
Which cells are the precursors to the TRM? One study that examined the development of 
CD8+CD103+ TRM in multiple tissue sites demonstrated that these TRM arose from KLRG1low 
precursors that entered the epithelium during early infection [110]. A number of other studies have 
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confirmed low KLRG1 expression on CD8+ TRM, both in mice and humans [136, 142, 169]. 
Finally, one study found that TRM and TCM subsets in mice had completely overlapping TCR 
repertoires [171], suggesting that naïve cells gave rise to TCM and TRM in parallel. This further 
suggests that TRM arise from cells that have gone through the effector phase, as direct 
differentiation from naïve to TRM or TCM would not produce the result of overlapping TCR 
repertoires.   
Once in the tissue, effector T cells respond to signals that drive the development of a TRM 
phenotype, including upregulation of CD69 and CD103. It was established some time ago that 
TGF-β can drive CD103 expression [172],  and a number of further studies have confirmed that 
TGF-β promotes CD103 upregulation and TRM development [106, 110, 136, 139, 169, 173, 174]. 
It should be noted however that TGF-β may only be important for CD103+ TRM, as CD103– TRM 
have been shown to develop in a TGF-β independent manner and represent a distinct subset [133]. 
While CD103+ CD8+ TRM exist in epithelial layers, CD103-CD8+ TRM exist below in the lamina 
propria layer where they cluster with CD4+ T cells and macrophages and show signs of TCR 
engagement [113, 133]. This suggests that these cell clusters may provide signals for CD103- TRM 
retention and/or formation, while CD103 TRM in the epithelium are more dependent on TGF-β  
[175]. Finally, other cytokines that can induce CD103 expression include TNF, IL-15, and IL-33 
[110, 139], and other factors that can drive CD69 upregulation include TNF and type I interferons 
[122]. 
Aside from KLF2, which has a role in regulating T cell migration by controlling the 
expression of S1PR1 (as described above), several transcription factors have been found to be 
differentially expressed by TRM and/or important for the formation of TRM. The transcription 
factors T-bet and Eomes, which are key controllers of TCM and TEM development [72], may also 
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play important roles in TRM development [148]. For example, CD103+TRM in the skin, gut, lung, 
and brain all have reduced expression of T-bet and Eomes compared with circulating memory T 
cells [108, 110, 140]. In fact, one recent study showed the progressive downregulation of these 
transcription factors during the development of CD8+CD103+ TRM, and further that forced 
expression of either Eomes or T-bet inhibited TRM formation [106]. Downregulation of T-bet 
enabled responses to TGF-β [106], which has been shown to promote the expression of CD103 
and in some cases CD69 [110, 136, 139, 173, 174]. However, while downregulation of both T-bet 
and Eomes occurred during TRM formation, some residual T-bet expression still was required to 
maintain TRM populations (by maintaining CD122 expression to be able to respond to IL-15 
signals), while Eomes was completely downregulated [106]. Another recent study similarly found 
that T-bet downregulation was necessary for promoting TRM development by allowing 
responsiveness to TGF-β [169]. The role that T-bet and Eomes play in human TRM development 
and maintenance is the subject of ongoing research.  
Recently, the transcription factor homolog of BLIMP-1 in T cells (Hobit) was shown to 
play a key role in TRM development in mice [109]. The authors show that Hobit is highly 
expressed by TRM at all sites (but not by circulatory memory T cells), and that Hobit deficiency 
resulted in reduced TRM formation mice [109]. Blimp1 was another transcription factor the 
authors investigated, and while Blimp1 deficiency by itself did not impair TRM formation, 
combined Blimp1 and Hobit deficiency acted in a synergistic manner and resulted in significant 
inhibition of TRM development following infection [109]. The authors showed these results held 
in several infection models in different tissues and that Hobit and Blimp1 also mediate tissue 
residency for other cells types like NK cells and NKT cells, suggesting that these are universal 
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mediators of tissue residency. The role these transcription factors play in human TRM 
development is not known.  
So far, this section has focused on how TRM precursors develop into mature TRM as well 
as the signals and transcriptional regulators involved in this process. It has also been shown that 
CD4+ T cell help is critical for the generation of protective CD8+CD103+ TRM in the lung 
following influenza infection in mice [169]. This effect was dependent on IFN- produced by the 
CD4+ cells, and, in the absence of CD4+ T cells help, CD8+ TRM precursors failed to localize to 
the epithelium and did not downregulate of T-bet. These results are consistent with another study 
which showed that CD4+ T cells were important for driving the migration of CD8+ effector T cells 
into the infected tissue site [170]. Because the CD4+ T cells entered the lung approximately 1 day 
prior to CD8+ T cells in the first study [169], the IFN- produced by CD4+ T cells is likely what 
drove the recruitment of CD8+ effectors. In support, it was shown that IFN- promotes the 
production of CXCR3 ligands [170], and CXCR3 drives CD8+ T cell entry into the lung [176]. 
When CD8+ precursors fail to localize properly to the epithelium, they are not exposed to signals 
such as TGF-β which induce CD103+ upregulation and TRM development. Overall, these studies 
highlight the critical role CD4+ T cells play in the recruitment of CD8+ effectors to the infection 
site and promotion of CD8+ TRM development.  
Less is known about CD4+ TRM generation, although it is well established that protective 
CD4+ TRM are also generated in response to virus [105, 118, 124, 126]. While these studies did 
not directly examine mechanisms of CD4+ TRM generation, our laboratory examined the kinetics 
of the CD4+ T cell response to influenza in the lung and showed a large initial increase in non-
resident cells following infection followed by the development of CD4+ TRM over the course of 
a few weeks [124], similar to dynamics established for CD8+ TRM. The absolute numbers of the 
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CD4+ TRM in the lung diminished as time passed following infection; however, CD4+ TRM were 
still detected 120 days after a single infection [124], indicating long-term maintenance in the 
absence of ongoing infection/inflammation. Further, these studies have revealed other interesting 
aspects of CD4+ TRM. In terms of localization, CD4+ TRM in the reproductive tract appear to 
persist in the lamina propria layer (as opposed to the epithelial layer) where they exist in memory 
lymphocyte clusters (MLCs) along with CD103-CD8+ TRM, DCs, and macrophages [126, 175]. 
Chemokines secreted by macrophages within the MLCs help retain the CD4+ TRM [126]. In the 
lung, CD4+ TRM form clusters around the airways while circulating CD4+ memory T cells are 
spread more diffusely through the parenchyma [124]. Overall, these studies suggest that the 
kinetics and long-term persistence of CD4+ TRM is similar to CD8+ TRM, but that CD4+ and CD8+ 
TRM may respond to different signals for development and/or maintenance.    
While TRM have typically been studied in the context of infection, it should also be noted 
that TRM can be generated in response to other stimuli such as vaccination. In one study, the 
authors generated HSV-specific TRM in the genital tract by using a vaccination strategy that 
involved infecting the mice with HSV at a distant skin site and then applying topical chemokines 
to the genital tract to bring effector T cells to that site [117]. This effectively pulled effector T cells 
into the genital tract, leading to the development of CD8+ TRM that were protective against 
subsequent HSV infection. Interestingly, there was no inflammation in the genital tract during the 
initial vaccination as measured by increased numbers of other leukocytes such as DCs, NK cells, 
granulocytes, or monocytes [117]. Overall, this study demonstrates a vaccination strategy that can 
generate protective TRM in the complete absence of local inflammation or antigen. Another study 
from our laboratory showed that CD4+ and CD8+ TRM protective against influenza could be 
generated by live attenuated virus vaccination [118]. While TRM generation in this study did 
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involve response to live virus, this strategy further highlights the possibility of generating 
protective TRM without the inflammatory damage associated with a typical primary response. 
Overall, these studies highlight the potential for harnessing TRM for clinical purposes to protect 
against infections where protection cannot be adequately achieved with conventional antibody-
based vaccines. 
TRM have been shown to accumulate with increasing antigen exposure [103, 111, 147]. 
For example, while a single infection or inflammatory insult in the skin results in only localized 
TRM formation [143, 177], repeated insults lead to widespread TRM formation including at 
previously unaffected sites as well as greater densities of TRM at the site of infection [103, 147]. 
Because protection is correlated with density of TRM and because TRM need to be present within 
a relatively local area to defend against reinfection, these data suggest that multiple pathogen 
exposures may be required to establish widespread and effective protection against secondary 
infection. Further, these data may provide an explanation for why higher proportions of TRM 
phenotype cells are found in human tissues compared with mice, particularly in lymphoid tissue 
sites, as the human tissues investigated have been experienced years or several decades of 
continuous and diverse pathogen exposures. Finally, there is also evidence in both humans and 
mice that TRM formation is developmentally regulated. A recent study from our laboratory 
showed reduced formation of TRM in the lungs of infant mice compared with adult mice following 
influenza infection [178]. This effect was T cell intrinsic, as adoptively transferred infant T cells 
had a reduced ability to establish TRM in adult hosts. Another study from our lab showed reduced 
CD103 expression by TRM in infants compared with children [16]. This could either be a result 
of decreased antigen exposure, T cell intrinsic defects in TRM general in infants, or both. Overall, 
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however, it is clear that both antigen exposure and development play an important role in TRM 
formation.  
Numerous studies have demonstrated that TRM can persist long-term in tissues without 
ongoing infection [103, 123, 124, 143], and studies have examined the signals that promote this 
TRM maintenance and survival within the tissue. Interestingly, there is evidence that TRM can be 
generated and maintained in the absence of antigen and that these TRM are protective against 
subsequent infection [117, 143, 174]. However, these studies focused on CD8+ TRM in epithelial 
sites, and signaling requirements for TRM in different sites may be different. The signaling 
requirements for CD4+ TRM may also be different, as the one study mentioned did not find long 
term retention of CD4+ cells in the genital tract when there was no inflammation or antigen, unlike 
for CD8+ TRM [117]. CD4+ TRM may be maintained by memory lymphocyte clusters, as 
mentioned above, in which CD4+ TRM exist below the epithelium in clusters with antigen 
presenting cells and CD8+ TRM. Within these clusters, CD4+ TRM receive ongoing signals in the 
form of chemokines and low grade antigen from macrophages, which may promote their long term 
survival and maintenance [175].   
The homeostatic signals for TRM maintenance have not yet been defined. One study found 
that IL-15 signals are required for TRM formation [110], and another study found that residual T-
bet expression was required for longer term TRM survival via maintaining CD122 expression 
(which is a receptor for IL-15) [106]. Together, these findings suggest that IL-15 is critical for 
both generation and maintenance of TRM, at least for CD8+ TRM in barrier tissues and in mice. 
However, another study found that IL-15 was not required for the generation or maintenance of 
CD8+ TRM populations in secondary lymphoid tissues [112]. Therefore, it is not clear whether 
maintenance signals for TRM differ from those required for TEM or TCM persistence, which 
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require IL-7 and IL-15 for long-term maintenance [179]. It is also not known whether  maintenance 
requirements of TRM differ in barrier vs. lymphoid tissues. Finally, there is also evidence that aryl 
hydrocarbon receptor signaling may be important for the maintenance of CD8+ TRM populations 
in the skin [152]. 
A recent article reported that uptake of exogenous free fatty acids via the transporters 
FABP4 and FABP5 is necessary for CD8+ TRM survival in vivo [140]. In the setting of FABP4 
and FABP5 deficiency, TRM survival was impaired. However, FABP4 and FABP5 deficiency 
also resulted in reduced TRM numbers at early time points, suggesting the importance of these 
transporters both for TRM generation and long-term maintenance. Notably, CD8+ TRM from 
human skin also exhibited increased expression of FABP4 and FABP5 [140], suggesting that 
preferential use of free fatty acids may be a universal property of CD8+ TRM in barrier sites.  
 
Tissue residency in other T cells subsets 
Tissue residence may not be unique to memory T cells. There is evidence that naïve T cells 
can persist in tissues, and particularly within lymph nodes. Clonal analysis of naïve T cells in 
spleen and lymph nodes of individuals revealed no overlap between the TCR repertoires of naïve 
T cells from different lymphoid sites, regardless of age [15]. Even naïve T cell clones that were 
modestly expanded were largely limited to a single lymphoid site, in contrast with expanded 
memory populations which showed high overlap between sites [15]. These data suggest that naïve 
T cells take up long term residence in lymph nodes where they can expand in situ, with lymph 
nodes serving as reservoirs for their maintenance. Given that naïve T cells lack expression of 
canonical TRM markers, we propose that retention mechanisms for naïve T cells in lymph nodes 
may be more dependent on cytokine signaling rather than specific cell-cell interactions.   
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The concept of tissue residency has also been described for Tregs. In mice, tissue Tregs in 
fat, lung, and muscle serve key roles in metabolic homeostasis and tissue repair and exhibit distinct 
phenotypes and transcriptional profiles compared with lymphoid Tregs [180]. In human tissues, a 
proportion of Tregs (40-50%) express the TRM marker CD69 [16]. Tregs residing in human skin 
also express skin-homing receptors CLA, CCR4, and CCR6 [181]. Increased proportions of Tregs 
which differentially produce IL-17 have been identified in psoriatic skin lesions compared to 
unaffected skin [182], suggesting roles for Tregs in controlling local homeostasis. Tregs have also 
been identified in human fat, with decreased Tregs correlating with obesity [183]. Human tissue 
Tregs in lymph nodes may preserve homeostasis as their depletion results in increased T cell 
proliferation and cytokine production ex vivo [16, 184]. More studies are required to dissect the 
importance and functional role of human tissue Tregs in maintaining homeostasis.  
 
Outstanding Questions about TRM  
Overall, current research suggests that therapeutic modulation of TRM can have broad 
implications for infectious disease therapy, vaccination, autoimmunity, and cancer, and this has 
sparked considerable research on TRM in recent years. However, there are still a number of 
unanswered questions about TRM biology. For example, the developmental relationship between 
TRM and other memory subsets is unclear, and it is also not known if TRM represent a terminally 
differentiated subset with the inability to proliferate. Further, the majority of studies on TRM are 
conducted in mice and examine responses in barrier tissues, and therefore the characteristics of 
TRM in lymphoid tissues and in humans are not well-defined. In humans, reliable phenotypic 
markers of TRM have not been established. Further, the transcriptional and functional 
characteristics that define TRM in humans is not known, as well as how these properties vary for 
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CD4+ and CD8+ TRM and for TRM from different tissues. In fact, at the start of this research, 
transcriptional profiling had not been performed comparing human TRM to other memory subsets, 
or on TRM from lymphoid tissues. Finally, interpretation of TRM studies is further complicated 
by the fact that TRM are heterogeneous; different groups of TRM have been described based on 
function, homing receptor profiles, and cell surface phenotype, and some of these TRM subtypes 
are developmentally district and have unique subatomic localizations [133, 155, 168, 185]. 
Therefore, data about one subset of TRM cannot always be extrapolated to another TRM subset. 
Overall, the aims of this thesis seek to fill several gaps in our current understanding of human 






Section 1.6: Thesis aims 
AIM 1: Define phenotypic, functional, and transcriptional signatures of human TRM.  
 As described above, while many aspects of TRM biology are well-characterized in mice, 
major gaps exist in our understanding of human TRM. First off, reliable phenotypic markers of 
TRM in humans have not been established. It is also not known whether TRM represent a distinct 
memory subset in humans, with unifying transcriptional, phenotypic, or functional characteristics 
for CD4+ and CD8+ from different tissues. In fact, even in mice CD4+ TRM and TRM from 
lymphoid sites have not been completely characterized; in particular, whole transcriptome 
profiling of these subsets has not been performed. We hypothesize that human TRM can be 
identified by the expression of CD69, and that human TRM represent a distinct memory subset 
with unique transcriptional, phenotypic, and functional properties relative to circulating memory 
subsets. In order to address this, there are five specific subaims:  
1. Investigate the distribution of CD69 and CD103 expression by memory T cells 
across human tissues.  
2. Determine if CD69 expression identifies human TRM.  
3. Identify transcriptional, phenotypic, and functional properties of human TRM from 
spleen and lung tissues, and for both CD4+ and CD8+ lineages. 
4. Compare the transcriptional properties of human and mouse TRM 
5. Establish a core gene signature that is common to TRM from multiple tissue sites, 
CD4+ and CD8+ lineages, and mouse and human species.  
 
Here, we demonstrate that CD69 is exclusively expressed by memory T cells in tissues and 
that CD69+ memory T cells do not show features of activation. Transcriptionally, CD69+ memory 
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T cells in tissues share key homologies to mouse TRM and were distinct from CD69- memory T 
cells in tissues, which were similar to circulating blood TEM. Together, these data suggest that 
TRM are contained within the CD69+ fraction of memory T cells in tissues while CD69- memory 
T cells in tissues are circulating. Next, we identify a core transcriptional profile of 31 genes that 
defines the human TRM subset in lung and spleen and is common to both CD4+ and CD8+ TRM. 
We also that show TRM in mice also have differential expression of these genes, suggesting that 
this core signature identifies universal properties of the TRM subset. Based on this core signature, 
TRM in humans had a unique profile of adhesion and homing molecules, including upregulation 
of specific integrins and downregulation of specific homing receptors that mediate tissue egress. 
Functionally, while CD4+ and CD8+ human TRM in multiple sites had an enhanced ability to 
produce certain effector cytokines, these TRM also exhibited increased expression of inhibitory 
molecules such as PD-1, produced higher levels of the anti-inflammatory cytokine IL-10, and 
exhibited reduced proliferation compared with circulating TEM, suggesting a dual functional role 
encompassing protection and regulation. Overall, these results establish that human TRM 
identified by CD69 expression are transcriptionally, functionally, and phenotypically distinct from 
their circulating counterparts. 
 
 
AIM 2: Investigate the functional and transcriptional bases for human TRM heterogeneity.  
Our data from the first aim suggested substantial heterogeneity within the human TRM 
subset, both functionally and phenotypically [186]. This finding is consistent with prior studies in 
both mice and humans, showing that functionally and phenotypically distinct subsets of TRM 
exist, with different subsets have different developmental pathways, transcriptional profiles, 
subanatomic locations, and roles in protection and disease [10, 108, 133, 155, 168]. Therefore, 
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even though as a whole TRM represent a subset with critical roles in pathogen clearance and 
human disease, understanding how different TRM subsets function is vital before clinical 
strategies targeting TRM can be implemented.  
Heterogeneity based on the ability to efflux fluorescent dyes has not been characterized 
with the human TRM subset. However, the importance of this trait is underscored by that fact that 
the capacity to efflux fluorescent dyes is associated with increased self-renewal properties for 
hematopoeitc stem cells [187, 188]. As numerous studies have reported that TRM can persist long-
term in tissues, an efflux(+) subset may present of a subset of TRM poised for longevity and serve 
as a reservoir for renewal of other TRM subsets. Notably, the ability to efflux dyes has been 
demonstrated T cells, both in mucosal-associated invariant T cells (MAIT) [189, 190] as well as 
non-MAIT T cells in tissues such as bone marrow and intestines [191, 192]. We hypothesize that 
TRM with the ability to efflux dyes exist in both lymphoid and mucosal tissues, and that efflux(+) 
TRM represent a functionally distinct subset of TRM. There are four specific subaims: 
1. Determine if efflux(+) memory T cells exist within healthy human tissues. 
2. Establish the unique phenotypic properties of the efflux(+) subset. 
3. Establish the unique functional properties of the efflux(+) subset, including 
cytokine producing and cytotoxic abilities, proliferative capabilities, and 
responses to homeostatic cytokines.  
4. Characterize the transcriptional profile of efflux(+) TRM, and determine how 
efflux (+) TRM respond transcriptionally to stimulation.  
  
In this study, we describe a functionally distinct subset of human CD8+ TRM defined by 
the capacity to efflux fluorescent dyes that are not MAIT T cells. Efflux(+) TRM were found in 
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multiple tissue sites including spleen, lymph nodes, lung, and bone marrow. Compared with 
efflux(-) TRM, efflux(+) TRM showed evidence of reduced proliferative turnover (as measured 
by Ki67), increased CD127 expression, and decreased expression of activation (HLA-DR) and 
exhaustion markers (PD-1, CTLA-4), suggesting that efflux(+) TRM exist in a more quiescent and 
less activated state within tissues. Transcriptional profiling supported these results, with 
differential expression of genes controlling the cell cycle, and further suggested that efflux(+) 
TRM have a unique profile of adhesion and migration markers that promotes long-term retention. 
Functionally, efflux(+) TRM produced reduced quantities of inflammatory cytokines and 
underwent less cytotoxic degranulation after stimulation compared with efflux(-) TRM. Moreover, 
efflux(+) TRM had higher proliferative capacity after stimulation and exhibited greater responses 
to IL-7 signaling. Interestingly, efflux(+) TRM had an enhanced capacity for IL-17 production and 
showed evidence of IL-17 signaling transcriptionally. Together, these results establish efflux(+) 
and efflux(-) TRM are unique subsets that may exhibit non-redundant functions during the immune 
response. Specifically, efflux(+) TRM may have a program that promotes longevity and retention 
and therefore serve as a reservoir of TRM capable of proliferation upon infection, while efflux(-) 
TRM may be poised for secretion of effector cytokines and for direct cytotoxic function to rapidly 




CHAPTER 2: Materials and Methods 
Section 2.1: Acquisition and isolation of T cells from human tissues 
Acquisition of human tissue samples from organ donors 
Human tissues were obtained from deceased organ donors at the time of organ acquisition 
for clinical transplantation through an approved research protocol and material transfer agreement 
with LiveOnNY, the organ procurement organization for the New York metropolitan area. All 
donors were free of chronic disease and cancer, Hepatitis B, and Hepatits C, and were HIV-
negative. Isolation of tissues from deceased organ donors does not qualify as “human subjects” 
research, as confirmed by the Columbia University IRB. For isolation of blood from living 
volunteers, blood was drawn via venipuncture from consented volunteers, as approved by the 
Columbia University IRB.  
The procedure for acquiring tissue samples from research consented organ donors involves 
coordinating the activities of transplant surgeons, transplant coordinators, our laboratory’s on-call 
surgeons, and laboratory researchers. First, our laboratory’s on-call surgeons are notified by 
transplant coordinators when a researching consented organ donor meeting our laboratory’s 
criteria becomes available. Our surgeons are notified of the time of operation and travel to the 
hospital where the organ donor is located. After the transplant team finishes harvesting organs that 
are used for life-saving clinical transplantations, the laboratory’s surgeons are allowed to use the 
same incisions to harvest organs for research purposes. The current protocol and agreement with 
LiveOnNY allows us to obtain the following tissues: blood, bone barrow, thymus, spleen, lung 
lymph nodes, mesenteric lymph nodes, inguinal lymph nodes, pancreas, pancreatic lymph nodes, 
duodenum, jejunum, ileum, colon, appendix, peyer’s patches, lung, salivary glands, tonsils, and 
fat (Figure 2.1). These organ donor tissues are flushed with cold preservation solution and 
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transported to the lab in saline, typically arriving within 2-4 hours of organ extraction. Upon arrival 
in the laboratory, these organs are placed in complete RPMI (RPMI containing 10% FBS, 
glutamine, and penicillin-streptomycin) at 4°C and are processed immediately, as detailed below. 
 
Isolation of lymphocytes from human tissues 
The methods for isolation of lymphocytes described below are based on findings in mice 
[193, 194] and have been optimized and published by former members of the lab and me over a 
number of years [13-19, 186]. The basic protocols which were further optimized in this study, 
including  the isolation of lymphocytes without enzymatic digestion are detailed below.     
Blood samples were first centrifuged to remove plasma. Blood (after plasma is removed) 
and bone marrow were diluted 2:1 with complete RPMI and centrifuged through lymphocyte 
separation medium (LSM, Corning). The lymphocyte containing buffy coat layer was removed 
and red blood cell lysis was performed using ACK buffer for 5 minutes on ice (Corning).  
Spleen samples were chopped into small pieces and placed into 50 ml conical tubes with 
25 ml digestion media (RPMI containing 10% FBS, glutamine, penicillin-streptomycin, 
collagenase D [1 mg/ml], trypsin inhibitor [1 mg/ml], and DNase I [0.1 mg/ml]), and incubated 
with mechanical shaking at 37°C for 1 hour. Lung and gut tissue were carefully inspected to 
exclude lymph nodes and then chopped into small pieces and placed in digestion media as above 
for 2 hours. Digested tissue was disrupted using the gentleMACS tissue dissociator (Miltenyi 
Biotech) and then passed through a stainless steel tissue sieve (10 to 150 mesh size), followed by 
pelleting through centrifugation. Residual red blood cells (RBC) were lysed via incubation for 5 
min in ACK lysis buffer (Lonza), and dead cells and debris were removed by centrifugation 
through a solution of RPMI containing 30% Percoll (GE Healthcare Life Sciences). A second RBC 
46 
 
lysis was performed if necessary. Cells were then pelleted and washed with complete RPMI, and 
the final cell suspension was filtered using a 70µm cell strainer (Corning).  
For lymph nodes, fat tissue was removed followed by chopping into small pieces and 
digestion as above for 1 hour. Digested tissue was disrupted using the gentleMACS tissue 
dissociator (Miltenyi Biotech) and then filtered through a 70µm cell strainer (Corning). 
 
Isolation of lymphocytes from solid tissues without enzymatic digestion 
Non-enzymatic isolation was performed using the Bullet Blender Tissue Homogenizer 
(Next Advance). Tissue samples were chopped into small pieces (<5mm) using scissors and 4-5g 
of tissue was placed in a 50ml conical tube along with complete RPMI to a total volume of 10ml, 
followed by addition of 7-8 4.8 mm stain steel beads (Product SSB48). Tissues were homogenized 
in the bullet blender for 2 minutes at speed setting 3-4. Following homogenization, the mixture 
was filtered through a 70m Cell Strainer (Corning). ACK buffer was used for RBC lysis, and 
followed by an additional filtration through a 70m Cell Strainer (Corning).  
 
Cryopreservation of lymphocytes  
Lymphocyte suspensions were cryopreserved in Cryogenic Vials (Corning) in a solution 
of 10% dimethylsulfoxide (DMSO) in FBS at a concentration of 10 million cells/mL per vial. Vials 
containing the cell suspensions were placed into Mr. Frosty Cryo Freezing Containers (Nalgene) 
and placed in a -80°C freezer, which allows for cooling a rate of 1°C/min. After reaching -80°C, 
vials containing frozen cell suspensions were transferred to liquid nitrogen. The frozen 
lymphocytes are viable for years after storage in liquid nitrogen and the Farber lab has 
cryopreserved lymphocyte suspensions from multiple tissue sites from over 300 donors.   
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To thaw cryopreserved cell suspensions, each vial was removed from liquid nitrogen and 
immediately placed in a 37°C water bath until the cells suspension was fully thawed. Cell 
suspensions were passed through a 100m filter paper, and warm complete RPMI was added 
slowly. This protocol has been demonstrated to optimize cellular viability [195]. Finally, to 
minimize clumping of cell suspensions, 0.1 mg/mL DNase was added during this step and the 





Figure 2.1. Tissue sites received from organ donors.  
 
Note: some organ images taken from Google Image search results.  
49 
 
Section 2.2: Flow cytometric analysis of human T cells 
Flow cytometric analysis and cell sorting 
For flow cytometry analysis, single-cell suspensions were stained with fluorochrome-
conjugated antibodies (See Table 2.1 below for a list of all antibodies used for flow cytometry in 
this study) in staining buffer (PBS/1% fetal bovine serum/0.1% sodium azide). Control samples 
included unstained, single fluorochrome–stained compensation beads (UltraComp eBeads, 
eBioscience) and fluorescence minus one (FMO) controls. Stained cells were acquired using a BD 
LSRII or BD Fortessa. Data were analyzed using FlowJo software (Tree Star) and FCS Express 
(De Novo Software). FCS express software was used for generating t-SNE plots from flow 
cytometry data.  
For identification of cytomegalovirus (CMV) specific T cells, samples from HLA-A2 
haplotype donors were labeled with IE1-VLE peptide tetramers (Proimmune). For phospho-flow 
cytometry, cells were first fixed with 4% PFA for 15 minutes followed by permeablization with 
ice-cold methanol. 
For intracellular staining for detection of cytokines and transcription factors, cells were 
fixed and permeabilized using the Fixation/Permeabilization Solution Kit (BD Biosciences) for 
detection of cytokines and Foxp3/Transcription Factor Staining Buffer (Ebiosciences) for 
detection of transcription factors. 
For isolation of subsets by fluorescent-activated cell sorting, lymphocyte suspensions were 
enriched for T cells using the MojoSort Human CD3 T cell Isolation Kit (Biolegend), stained for 
surface markers (as described above) in sort buffer (PBS/1% fetal bovine serum), and sorted using 




Staining with mitochondrial dyes for detection of efflux(+) T cells  
T cells were labeled with Mitotracker Green FM (50nM) or CMXRos (25nM) (Thermo 
Fischer) for 15 minutes in complete media (10% FBS in RPMI) at 37°C, shielded from light. Dye 
efflux was blocked by performing fluorescent labeling reactions in the presence of 25-50uM 




Table 2.1: List of antibodies used for flow cytometry.  
Reactivity Target Clone Company 
Human CCR5 J418F1 Biolegend 
Human CCR6 11A9 BD Biosciences 
Human CCR7 G043H7 Biolegend 
Human CCR9 L053E8 Biolegend 
Human CD101 BB27 Biolegend 
Human CD103 ber-ACT8 Biolegend 
Human CD107a eBioH4A3 eBioscience 
Human CD127 A019D5 Biolegend 
Human CD161 HP-3G10 eBiosciences 
Human CD19 SJ25C1 Biolegend 
Human CD25 BC96 Biolegend 
Human CD27 M-T271 BD Biosciences 
Human CD28 CD28.2 eBiosciences 
Human CD3 OKT3 Biolegend 
Human CD3 SK7 BD Biosciences 
Human CD38 TU66 BD Biosciences 
Human CD39 A1 Biolegend 
Human CD4 OKT4 Biolegend 
Human CD4 RPA-T4 Biolegend 
Human CD45RA Hl100 Biolegend 
Human CD49a TS2/7 Biolegend 
Human CD57 HNK-1 7Biolegend 
Human CD62L DREG-56 Biolegend 
Human CD69 FN50 Biolegend 
Human CD8 RPA-T8 Tonbo 
Human CD8 SK1 BD Biosciences 
Human CTLA4 L3D10 Biolegend 
Human CX3CR1 2A9-1 Biolegend 
Human CXCR6 K041E5 Biolegend 
Human Eomes WD1928 eBiosciences 
Human HLA-DR LN3 Biolegend 
Human IFN-gamma B27 BD 
Human IL-10 JES3-9D7 Biolegend 
Human IL-17 BL168 Biolegend 
Human IL-2 MQ1-17H12 BD 
Human Ki67 MKI67 Biolegend 
Human Live/Dead Marker n/a Biolegend 
Human Live/Dead Marker n/a Biolegend 
Human MDR1 UIC2 Biolegend 
Human PD-1 EH12.1 Biolegend 
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Human pSTAT5 pY694 BD Biosciences 
Human Tbet eBio4B10 eBiosciences 
Human Tim3 B8.2c12 Biolegend 
Human TNF MAb11 BD 
Human Va7.2 3C10 Biolegend 






Section 2.3: Functional Assays  
T cell stimulations and cytokine analysis 
For quantification of cytokine production by different T cell subsets, sorted cells were 
plated in 96-well round-bottom plates at 105cells/well in complete RPMI medium and stimulated 
using anti CD3/CD28/CD2 beads (T cell activation/expansion kit, Miltenyi Biotech) for 48 or 72 
hours. Supernatant cytokine levels were measured using the BD Cytometric Bead Array (Human 
Th1/Th2/Th17 Cytokine Kit) (see details below).  
For detection of cytokine production by intracellular staining, CD4+ or CD8+ T cells from 
spleen and lung tissues were stimulated with PMA (50ng/ml) + ionomycin (1 µg/ml) for 3 hours 
at 37ºC in the presence of BD Golgistop (containing Monensin). Cytokine production was assessed 
by intracellular staining for cytokines as described above. To quantify degranulation (CD107a 
expression), cells were labeled with anti-CD107a antibody before stimulation with 
PMA/ionomycin. 
 
Details of Cytometric Bead Array (CBA) 
CBA uses the dynamic range of detection in flow cytometry to analyze the levels of 
multiple cytokines at the same time via detection of fluorophores attached to antibody coated beads 
[196]. The protocol has two main steps: first, antibody coated beads that bind to cytokines are 
added to the samples, and second, a fluorochrome conjugated reagent is added that binds to the 
anti-cytokine beads. Samples are then incubated for 3 hours in the dark, washed to remove beads 
that did not bind cytokines, and then analyzed by flow cytometry. The APC intensity of the beads 
is used to identify which cytokine is being detected, and the PE intensity is proportional to the 
concentration of the cytokine. Finally, a standard curve is created by using serial dilutions of a 
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sample of known concentration provided by the manufacturer. The Th1/Th2/Th17 kit used in these 
experiments simultaneously detects the expression of IL-2, IL-4, IL-6, IL-10, TNF, IFN-gamma, 
and IL-17. Samples were diluted 2:1 with the assay diluent provided in the kit in order to bring the 
cytokine concentrations within the range of detection.  
  
Proliferation Assays  
For proliferation assays, cells were isolated via cell sorting as described above and then 
were labeled with Cell Trace Violet (Thermo Fisher) according to the manufacturer’s instructions. 
Labelled cells were plated at 100,000 cells/well and stimulated with anti CD3/CD28/CD2 (T cell 
activation/expansion kit, Miltenyi Biotech) beads for 4 days.  
 
Detection of responses to Il-7 via phospho-flow cytometry 
Sorted cells were rested in RPMI medium without serum for 2 hours. Cells were then 
transferred to complete media supplemented with 50ng/mL IL-7 (PeproTech) and stimulated for 
20 minutes before phospho-flow cytometry for detection of p-STAT5 as described above.  
 
Section 2.4: Whole transcriptome profiling by RNA Sequencing 
RNA Extraction from T cells and RNA Sequencing 
An overview of the workflow for RNA-Sequencing (RNA-Seq) from sample preparation 
in the laboratory to analysis of data is shown in Figure 2.2. T cell subsets were sorted as described 
above and RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen), according to 
manufacturer’s instructions. RNA concentration and quality was assessed using an Agilent 2100 
Bioanalyzer instrument (Agilent Technologies). For the majority of samples, >400ng of total RNA 
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was submitted for sequencing. RNA-Seq libraries were prepared using standard TruSeq with poly-
A pulldown and sequenced them on the Illumina HiSeq 2500 with 101bp single-end reads at the 
Columbia Genome Center. For samples with less than 100ng total RNA, the Clontech SMART-
Seq v4 Ultra Low Input RNA Kit for cDNA amplification was used.  
 
Analysis of Data 
RNA-Seq reads were mapped using TopHat [197] with default parameters to the human 
reference genome build hg19, data quality control performed using RNA-SeQC [198], read counts 
computed using HTSeq [199], and per-gene Fragment Per Kilobases Per Million reads (FPKM) 
estimated using Cufflinks [200]. Data are available on GEO (For data presented in Chapter 3, 
accession: GSE94964). 
Downstream statistical analysis was done using R programming language. We used EdgeR 
[201] for differential gene expression analysis, using donor information as a covariate to control 
donor-specific effects. We considered genes as significantly differentially expressed between two 
groups if FDR≤0.05 and absolute value of log2 fold change >1. For other analyses and 
visualization purpose, we first normalized gene read counts with DESeq2 [202], and then removed 
the donor and sequencing batch effect with function ComBat in sva [203] package. We performed 
Principal component analysis (PCA) using function prcomp in R, with centering, scaling, and cor 
options on. We plotted heatmap with Z-score of log base 10 normalized read counts with samples 
clustered by unsupervised hierarchical clustering function hclust in R and visualized with 
heatmap.2 in the gplots package. Complete linkage method was used for clustering, with the 
distance between samples defined by Euclidean distance. For analyses presented in Chapter 4, 
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DESeq2 was used instead of EdgeR to compute differential expression, and cutoffs for significance 
were the same as above.  
A number of methods were used for biological interpretation of differential expression 
results. First, pathway analysis was performed using Ingenuity Pathway Analysis software (IPA, 
Qiagen). For IPA analysis, differential expression data from EdgeR or DESeq2 was uploaded to 
IPA software. The entire dataset (approximately 25000 genes) was uploaded to IPA, and then 
within IPA a significance cutoff was set such that the software only analyzes the genes that meet 
the defined criteria. In general, the top 1000 most significant genes by FDR were used for analysis, 
based on advice from the company’s scientist. The dataset uploaded to IPA contains the gene 
names, fold changes, expression levels, p-values, and FDR values, and the analysis takes all of 
these variables into account. Within the analysis results, the canonical pathways and cellular 
functions tabs were used to interpret data. The canonical pathways function lists pathways that are 
predicted to be enriched based on the gene expression data, along with a p-value and a z-score that 
indicates directionality of the pathway. In certain cases, the software is not able to predict the 
directionality of a pathway, even if the p-value is significant. This situation may arise if several 
differentially expressed genes are involved in the pathway but the fold changes are not all 
consistent with up or downregulation of that entire pathway. The cellular functions tab of IPA lists 
certain functions that are predicted to be enriched based on the differential expression data, and 
these functions may be for example migration or proliferation.  
Pathway analysis was also performed using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) [204, 205]. For DAVID online software, the list of differentially 
expressed genes was first uploaded. In some cases, the list of genes that met our criteria for 
differential expression was too short for DAVID to do pathway analysis; in this situation, the top 
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300 differentially expressed genes by FDR value were uploaded. After uploading the dataset, we 
used the gene ontology function within the functional annotation chart feature. Similar to IPA, this 
result displays a list of pathways predicted to be enriched based on the differentially expression 
genes. Unlike IPA however, DAVID only takes into account the actual gene list but not 
information about fold changes or expression levels. Therefore, pathways results cannot be 
interpreted in terms of directionality.  
The pathways listed by DAVID and IPA were used to determine the functional relevance 
of the genes that were differentially expressed. However, pathway results produced by these 
software are often non-specific and sometimes dozens or even 100+ significant pathways are 
generated. Therefore, biological interpretation of the RNA-Seq data was also based on a manual 
review of the differentially expressed genes as follows. First, IPA software was used to annotate 
the list of differentially expressed genes. The dataset uploaded to IPA contains the gene ID, and 
IPA can create a table that fills in the full gene name, identify the location of the gene product (e.g. 
nucleus, plasma membrane, etc.), and assign a category that the gene product (e.g. enzyme, 
cytokine, etc.) This table was exported and served as a basis for manual interpretation. For many 
genes, IPA was unable to assign a location or category, in which case we would search the 
literature for data about the gene and its product (and in particular in T cells), and then assign a 
category. This analysis allowed us to group all of the differentially expressed genes into ~10 broad 
categories, and then examine the individual genes that contributed to each category. An example 
of this type of analysis is shown in Chapter 4, where we have manually assigned 133 differentially 
expressed genes into 9 categories and displayed select genes from these categories. Integrating this 
analysis with the pathway analysis allows for a more thorough interpretation of the data, 
particularly when the results from these two analyses are consistent as is the case in Chapter 4. In 
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that specific example, the categories of genes by manual annotation largely align with the functions 
associated with the enriched pathways, and visualization of the individual genes contributing to 
each category provides insight into exactly how the biology of the two groups are different.  
Manual interpretation and integration of multiple sources was also used to examine the 
connectivity between key genes. The diagram in Fig. 3.5B which shows connectivity between 
genes shown in Fig. 3.5A was created using IPA software, STRING Protein database, GeneCards, 
and Pubmed literature searches. For IPA, the Networks and Pathways functions were used to 
examine connections between the gene list in Fig. 3.5A and literature references provided by IPA 
were checked manually before using predicted or established relationships. For STRING [206], 
only results in the “Known Interaction” category were used. All of the genes listed in the core 
signature were put into GeneCards and search results were examined for relationships between 
genes. For select genes, a PubMed search was conducted to determine if there was an established 
role of these genes in T cells. Pathways listed in Fig. 3.5B that encompass multiple genes were 
determined using IPA, ConsensusPathDB [207], and Pathcards. 
 
Identification of lineage- and tissue-specific genes within transcriptional profiles 
This section provides a detailed methodology for the analysis that was done for analysis of 
data presented in Chapter 3 for identification of lineage or tissue specific genes as shown in Figs. 
3.13 and 3.14. Among the genes that were differentially expressed in any lineage subset (CD4+ or 
CD8+) of 69+ vs. 69– cells from any tissue site (spleen or lung), we defined CD4+ specific genes 
by the following criteria: (a) differentially expressed with statistical significance (FDR < 0.05 and 
absolute value of log2 fold change >1) in CD4+ 69+ vs. 69– comparison, (b) log2 fold change has 
the same direction in all CD4+ 69+ vs. 69– comparisons (both spleen and lung samples), and (c) 
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not differentially expressed with any marginal significance (p-value > 0.05) in CD8+ 69+ vs. 69– 
comparison. We defined CD8+ specific genes similarly by switching CD4+ with CD8+. Among the 
genes that are differentially expressed in any tissue subset (lung or spleen) of 69+ vs. 69– cells of 
a certain lineage (CD4+ or CD8+), we defined lung specific genes by the following criteria: (a) 
differentially expressed with statistical significance (FDR < 0.05 and absolute value of log2 fold 
change >1) in lung 69+ vs. 69– comparison, (b) log2 fold change has the same direction in all lung 
69+ vs. 69– comparisons (both CD4+ and CD8+ samples), and (c) not differentially expressed with 
any marginal significance (p-value > 0.05) in spleen 69+ vs. 69– comparison. We defined spleen 
specific genes similarly by switching lung with spleen. 
 
Gene set enrichment analysis 
We obtained previous published mouse microarray expression data (from Mackay et al., 
2013, Wakim et al., 2012) which included TRM and TEM samples as input into GSEA [208], and 
tested the null hypothesis that genes identified as part of the human TRM signature have uniform 
distribution in ranks by the absolute value of log fold change between mouse TRM and TEM on 
the x-axis. We rejected the null hypothesis if the p-value was smaller than 0.05. 
 
Identification of TCR Repertoire Sequences using TRUST 
TRUST is a computational method to infer CDR3 sequences of T cell receptors using 
RNA-seq data based on de novo assembly [209]. The input file used for TRUST was the bam file 
that was generated using TopHat. The following 3 criteria were applied when parameterizing the 
aligners: 1) Both mapped reads and unmapped reads were included. 2) Local alignment was 
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disabled. 3) The number of mismatch tolerated for mapped reads was <=2. The following 




Figure 2.2. RNA-Sequencing workflow used in this study.  
(A) Left: Workflow for processing samples in laboratory. First, following isolation of lymphocytes 
from tissues, the cell population of interest was isolated by cell sorting. RNA was extracted from 
cell pellets using the RNAEasy Kit from Qiagen. RNA samples were analyzed for concentration 
and purity using the Agilent Bioanalyzer, followed by which frozen samples were dropped at the 
Columbia Genome Center. Right: Workflow for RNA-Sequencing at Columbia Genome Center. 
First, library preparation and sequencing on the Illumina HiSeq 2500 were performed. Next, read 
alignment was performed followed by calculation of read counts and FPKM values. Finally, data 
was released via an online link. Upon request, the Genome Center performed differentiation 
expression analysis using DESEQ2 as well as PCA analysis.  
(B) Workflow for biological interpretation of RNA-Seq data. First, differential expression analysis 
was performed using DESEQ2 or EdgeR. The listed of differentially expressed (DE) genes was 
interpreted both using pathway analysis or by manual interpretation. Principal Component 
Analysis (PCA) was used for visualization of samples. Gene set enrichment analysis (GSEA) was 








Section 2.5: Imaging of human lymphoid tissues 
Fresh human LLN isolated from organ donors were fixed immediately in 1.0% 
paraformaldehyde and PBS (pH 7.4) containing 0.1M L-Lysine (Sigma Aldrich), incubated in 20% 
sucrose at 4°C, and then embedded in Tissue-Tek OCT compound. 8-10µm thick sections were 
cut using a Leica CM 1950 cryostat. For staining, sections were first permeabilized using 0.1% 
Triton X-100 (Sigma-Aldrich). Next, samples were incubated in blocking buffer (PBS + 20% 
Blocking One reagent) at room temperature. Staining was performed using fluorochrome-
conjugated antibodies in blocking buffer at 4°C. Finally, samples were mounted on coverslips with 
Prolong Diamond Antifade Mountant (Life Technologies). Images were acquired using a EVOS 
FL Auto 2 Imaging System (Thermo Fischer). Antibodies used for imaging included: CD69 (alexa 
fluor 647, clone FN50), CD4 (alexa fluor 594, clone OKT4), and CD8 (alexa fluor 488, clone 




Section 2.6: Statistical tests 
Descriptive statistics (percent, mean, median, SEM) were calculated using Prism 
(Graphpad software). Significant differences in frequencies, ratios, gMFI, and density were 





CHAPTER 3: Human tissue-resident memory T cells are defined by core transcriptional 
and functional signatures in lymphoid and mucosal sites. 
 
ABSTRACT: 
Tissue-resident memory T cells (TRM) in mice mediate optimal protective immunity to 
infection and vaccination, while in humans, the existence and properties of TRM remain unclear. 
Here, we use a unique human tissue resource to determine whether human tissue memory T cells 
comprise a distinct subset in diverse mucosal and lymphoid tissues. We identify a core 
transcriptional profile within the CD69+ subset of memory CD4+ and CD8+ T cells in lung and 
spleen that is distinct from that of CD69˗TEM cells in tissues and circulation, and defines human 
TRM based on homology to the transcriptional profile of mouse CD8+TRM. Human TRM in 
diverse sites exhibit increased expression of adhesion and inhibitory molecules, produce both pro-
inflammatory and regulatory cytokines, and have reduced proliferation compared with circulating 
TEM, suggesting unique adaptations for in situ immunity. Together our results provide a unifying 
signature for human TRM and a blueprint for designing tissue-targeted immunotherapies. 
 
 
Chapter expanded from: 
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Ho, S.H., Lerner, H., Friedman, A.L., Shen, Y., and Farber, D.L. (2017). Human Tissue-Resident 
Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and 
Mucosal Sites. Cell Rep 20, 2921-2934. 
 




Section 3.1: Introduction 
The establishment and maintenance of long term immunity depends on the generation of 
memory T cells which can populate diverse tissue sites. The effector-memory (TEM) subset [93] 
is the predominant subset migrating through multiple tissues [210]; however, a significant fraction 
of TEM phenotype cells persist as non-circulating, tissue-resident subsets (TRM) in multiple sites 
including lungs, intestines, skin, liver, brain, and other mucosal surfaces (for reviews see [8, 10, 
102]). TRM mediate optimal protective responses to site-specific infections through rapid 
mobilization of immune responses in situ [105, 114]. Mouse models have also demonstrated the 
feasibility of targeting TRM in vaccines for generating protective immunity [117, 118]. Given 
their potential importance in immune protection and tissue homeostasis, an understanding of TRM 
identity, function, and regulation in humans is essential for translating strategies to target tissue-
specific responses for protection and immunomodulation.  
Advances in human TRM biology are limited by the lack of assays to distinguish 
circulating and resident memory T cells in tissues. In mice, tissue retention demonstrated by 
parabiosis [103, 104] and in vivo antibody labeling [124, 129] identified phenotypic markers 
associated with tissue residence, including CD69 and CD103. In mice, CD69 is expressed by the 
majority of CD4+ and CD8+ TRM cells in multiple sites [103, 105, 134, 135], while CD103 is only 
expressed by certain subsets of CD8+ TRM [10, 133] and not significantly by CD4+ TRM [124, 
211]. CD69 has also been shown to have tissue-retention functions in lymph nodes through 
sequestration of the sphingosine-1-P receptor (S1PR) that mediates egress of T cells [131, 138] 
and is required for TRM retention in the skin [132]. Whether CD69 can delineate TRM from 
circulating TEM counterparts remains to be established in humans and is a critical outstanding 
question in the field. 
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In human tissues, we and others have identified and characterized TRM phenotype cells 
expressing CD69 and/or CD103 in multiple sites including lungs, liver, lymphoid sites, skin and 
intestines [8, 17, 18, 142, 155, 157, 159, 163, 185].  However, it is not known whether TRM 
represent a distinct subset in humans for both CD8+ and CD4+T cell lineages, with unifying 
functional, phenotypic, and transcriptional signatures across tissues and individuals.  
We have established a unique human tissue resource to obtain blood, multiple lymphoid 
and mucosal tissues from previously healthy organ donors, enabling novel analysis of T cell 
compartmentalization and maintenance throughout life [14, 16-18, 212]. We present here 
transcriptional, phenotypic, and functional analyses which define human TRM as a distinct subset 
in multiple sites. We show that CD69 is a key marker that distinguishes memory T cells in tissues 
from those in circulation, while CD103 is expressed only by a subset of tissue memory CD8+ and 
not by CD4+ T cells. CD69+ tissue memory T cells are transcriptionally and phenotypically distinct 
from CD69– memory T cells in tissues and blood and exhibit a core gene profile comprising 
adhesion, migration, and regulatory molecules with homology to mouse TRM. This core signature 
is shared between human CD4+ and CD8+TRM and in multiple lymphoid and mucosal tissues. 
Further, human TRM have an enhanced capacity for production of certain cytokines and regulatory 
molecules and decreased turnover compared to circulating TEM cells, suggesting long term 
maintenance in situ. Together, our study establishes human TRM as a distinct subset stably 





Section 3.2: Results 
CD69+ memory populations exist only in tissues and do not show evidence of activation. 
To identify the major phenotypic marker distinguishing tissue from circulating memory T 
cells, we assessed CD69 and CD103 expression as markers associated with TRM in mice by 
CD45RA-/CCR7- TEM-phenotype CD4+ and CD8+T cells in blood and 8 additional tissue sites 
of individual donors (Fig. 3.1A, B). (Table 3.1 shows information about all of the donors used in 
this study.) We focused on TEM cells as the major memory subset in tissues that is common to 
both CD4+ and CD8+ T cells, as previously determined [18]. While blood memory T cells were 
predominantly CD69–/CD103–, the majority (>50-90%) of tissue memory CD4+ and CD8+T cells 
in all sites examined including lungs, intestines, salivary glands, tonsils, spleen, and various lymph 
nodes (LN) expressed CD69 (Fig. 3.1A,B). CD103 was expressed predominantly by memory 
CD8+T cells in tissues associated with the oral-gastrointestinal tract (salivary glands, tonsils, 
intestines) and lung, with significantly lower proportions of CD103+CD8+ memory T cells in 
spleen and lymph nodes (10-30%) and few tissue memory CD4+ T cells expressing CD103 (<5-
10%, Fig. 3.1A, B). Together, these findings indicate that CD69 expression distinguishes tissue 
from blood TEM across multiple lymphoid and barrier tissues and CD4/CD8 lineages, while 
CD103 expression is more variable and confined to certain tissue CD8+ T cells. 
Because CD69 is also a marker of early activation [213],  we assessed expression of the 
activation markers CD25, CD38, and HLA-DR by CD69+ and CD69– memory subsets from a 
representative lymphoid (spleen) and mucosal (lung) tissue. There was uniformly low expression 
of CD25, CD38, and HLA-DR on CD69+ TEM similar to expression levels on resting naïve T 
cells (Fig. 3.1C). Previously, we also found maintenance of CD28 and CD127 expression by the 
majority of CD69+ tissue memory T cells, indicative of a quiescent state [18]. Together, our results 
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Table 3.1. List of all donors used in this study. 
Donor Tissues Age Gender 
22 Intestines 19 Male 
82 Blood 3 Female 
87 Lung, Spleen 49 Female 
90 Spleen 51 Female 
93 Intestines 38 Male 
101 Lung 57 Female 
103 Lung 25 Male 
105 Lung, Intestines 20 Male 
108 Spleen 53 Male 
109 Lung, Spleen 43 Male 
117 Lung 32 Male 
142 Spleen, Lung, LLN, MLN, ILN, Intestines 29 Male 
146 Lung, Intestines 23 Female 
147 Blood, LLN, MLN, ILN 36 Female 
149 Lung 55 Male 
150 Lung, Blood, MLN, ILN, LLN, Intestines 39 Male 
156 Blood, LLN, MLN, ILN, Intestines 40 Female 
165 Intestines 29 Female 
172 Blood, Tonsils, Salivary Gland 49 Male 
174 Spleen 35 Female 
175 Lung, Blood, LLN, MLN, ILN, Intestines, Tonsils, Salivary Gland 24 Male 
176 Spleen, Lung, LLN, MLN, ILN, Intestines, Tonsils, Salivary Gland 64 Male 
177 Spleen, LLN, ILN, Intestines, Tonsils, Salivary Gland 52 Female 
178 Spleen, Blood, LLN, MLN, Intestines, Salivary Gland 51 Male 
181 Spleen, MLN, LLN, Intestines, Tonsils, Salivary Gland 46 Male 
182 Spleen, Lung, LLN, MLN, Intestines, Tonsils, Salivary Gland 46 Male 
183 Spleen, Lung, Blood, LLN, MLN, ILN, Intestines, Tonsils, Salivary Gland 69 Female 
185 Spleen 57 Male 
190 Lung, Spleen 69 Female 
191 Lung 29 Male 
194 Lung, Spleen 53 Male 
195 Lung, Blood, LLN, MLN 37 Female 
196 Lung 45 Female 
198 Lung 23 Female 
199 Spleen, Lung, LLN, MLN, ILN, Intestines 50 Male 
200 Spleen, Lung, Blood, LLN, Intestines 55 Male 
201 Spleen, Lung, Blood, LLN, MLN, ILN, Intestines, Tonsils, Salivary Gland 21 Male 
202 Spleen, Lung, Blood, LLN, MLN, ILN, Intestines, Tonsils, Salivary Gland 50 Male 
203 Spleen, Lung, Blood, LLN, MLN, ILN,  Tonsils, Salivary Gland 70 Male 
204 Lung 30 Male 
206 Blood, salivary Gland 50 Male 
207 Spleen, Blood, LLN 23 Male 
209 Lung, Blood, LLN, MLN, ILN, Intestines, Salivary Gland 59 Male 
212 Spleen 48 Male 
216 Lung, Blood, MLN, ILN, LLN, Intestines 34 Male 
217 Lung, Spleen 49 Male 
219 Lung, Spleen 50 Male 
220 Lung, Spleen 64 Male 
223 Lung, Spleen 29 Female 
225 Spleen 54 Male 
226 Lung, Spleen 66 Female 
227 Lung 26 Male 
232 Spleen 53 Male 
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233 Lung, Spleen 26 Female 
235 Spleen 50 Male 
236 Lung, Spleen, LLN, Tonsils, Salivary Gland 75 Female 
237 Lung, Spleen, Blood, Intestines, MLN, ILN, LLN, Tonsils, Salivary Gland 22 Male 
241 Lung 19 Male 
244 Lung, Spleen 36 Male 
245 Lung, Spleen 50 Female 
247 Lung 45 Female 
250 Lung, Spleen 39 Female 
254 Lung, Spleen, LLN 49 Female 
255 Lung, Spleen, Gut 63 Female 
257 Lung, Spleen 19 Male 
259 Lung, Spleen, LLN 46 Male 
262 Lung, Spleen 73 Male 
265 Lung, Spleen 24 Male 
267 Spleen 70 Female 
270 Lung, Spleen 23 Female 
273 Lung, Spleen 67 Female 
275 Spleen 31 Male 
277 Lung 21 Male 
285 Lung, Spleen 53 Male 
286 Spleen 46 Male 
288 Lung, Spleen 32 Male 
289 Lung, Spleen 58 Male 
291 Lung, Spleen, Gut 26 Female 
293 Lung, Spleen, Gut 53 Female 
294 Lung, Spleen, Blood 1.5 Female 
296 Lung, Spleen, Gut 62 Female 
297 Lung, Spleen, Gut 59 Female 
298 Lung, Spleen 59 Female 
299 Spleen 20 Male 
300 Lung 56 Male 
302 Lung, Spleen, Blood 56 Male 
303 Lung, Spleen, Blood 64 Male 
304 Lung 68 Male 
305 Spleen 28 Female 
306 Spleen 71 Female 
308 Lung, Spleen 68 Male 
309 Lung, Spleen 45 Female 
311 Lung, Spleen 52 Female 
312 Spleen 50 Female 
315 Lung 63 Male 
316 Lung 42 Female 
320 Lung, Spleen, Blood 55 Female 
321 Lung, Spleen, Blood, Intestines, MLN, Salivary Gland, Tonsils 17 Female 
324 Spleen 56 Male 
327 Lung, Spleen, Blood, MLN, LLN, Salivary Gland 52 Female 
328 Lung, Spleen, Blood, MLN, Salivary Gland, Tonsils 52 Male 
332 Spleen, Lung, Blood, MLN, Tonsils, Intestines, ILN, LLN, Salivary Glands 38 Male 
Live Donor 1 Blood 30 Male 
Live Donor 2 Blood 32 Male 




Figure 3.1. CD69+ memory T cells are prevalent in tissues and do not show features of 
activation.  
(A) Expression of CD69 and CD103 by CD4+(top) and CD8+(lower) memory T cells (CCR7-
CD45RA-) within each indicated site from one individual (donor 332) representative of 6 donors. 
LLN: Lung lymph node, ILN: inguinal lymph node, MLN: mesenteric lymph node.  
(B) Frequency of CD69+CD103+ (grey) and CD69+CD103+ (blue) cells in CD4+ (left) and CD8+ 
memory T cells in each tissue compiled from 16-22 donors.  
(C) Activation profile of T cells from human tissues. Flow cytometry plots show expression of 
CD25, CD38, and HLA-DR by naïve T cells (CCR7+ CD45RA+, blue line), and CD69– (black) 








Human CD69+ tissue memory T cells comprise a transcriptionally distinct subset with features 
of tissue residency.  
Based on the phenotype analysis above, we hypothesized that human tissue-resident 
memory T cells could be found within the CD69+ subset of tissue memory T cells. We isolated 
CD4+ and CD8+ TEM cells from the spleen and lungs of 3 previously healthy organ donors (sorting 
strategy shown in Fig. 3.2; donor information in Table 3.1), fractionated them into CD69+ and 
CD69– subpopulations for whole transcriptome profiling by RNA-Seq, and analyzed the resultant 
profiles of CD69+ and CD69- subsets for each lineage and tissue. (Quality control summary of all 
RNA-Seq samples is shown in Table 3.2) Principal component analysis (PCA) revealed that the 
transcriptome of CD69+ cells was distinct from that of the CD69– subset for CD4+ and CD8+ 
memory T cells in spleen and lung tissue for all three donors analyzed (Fig. 3.3A). This result 
indicates that CD69 expression defines a transcriptionally distinct subset of memory T cells in 
tissues.  
Applying the criteria for significance (FDR≤0.05 and absolute value of log2 fold-change 
≥1), for CD4+ samples we identified 327 genes differentially expressed between lung CD69+ and 
CD69– subsets and 221 genes differentially expressed between spleen CD69+ and CD69– subsets, 
of which 77 genes (29 upregulated, 48 downregulated) were differentially expressed in both tissues 
(Fig. 3.3B, C). For CD8+ samples we identified 329 genes differentially expressed between lung 
CD69+ and CD69– subsets and 459 genes differentially expressed between spleen CD69+ and 
CD69– subsets, of which 133 genes (39 upregulated, 94 downregulated) were differentially 
expressed in both tissues (Fig. 3.3B, C). The expression differences in these key genes were similar 
between three donors (Fig. 3.3C). 
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The genes differentially expressed by human CD69+ and CD69–TEM cells (Fig. 3.3C) 
included key molecules associated with mouse CD8+TRM from infection models [108-110, 139]. 
Notably, downregulation of S1PR1 and its associated transcription factor KLF2 are required for 
CD8+TRM establishment in mice [139], and we found striking downregulation of S1PR1 (8-16-
fold) and KLF2 (2-16-fold) transcripts for all CD69+ compared with CD69– subsets in every donor 
for both CD4+ and CD8+T cells in lung and spleen (Fig. 3.3D). In addition, human CD8+CD69+ 
subsets exhibited upregulation of ITGAE (CD103), ITGA1 (CD49a), ICOS, and the transcription 
factor IRF4, also found to be upregulated by mouse CD8+TRM in different systems [148]. 
Together, these results show that the CD69+ tissue memory T cells comprise a transcriptionally 
distinct subset enriched for features of tissue residency. 
We further compared the transcriptional profiles of tissue memory T cell subsets with 
circulating TEM cells isolated from the blood of three healthy volunteers. PCA analysis using the 
gene signature in Fig. 3.3C resulted in clustering of blood TEM with CD69– tissue TEM, distinct 
from CD69+ samples which clustered together (Fig. 3.3E). By contrast, PCA analysis using an 
equal number of randomly selected genes as a negative control yielded no clustering pattern (Fig. 
3.4). This grouping suggests that CD69 expression by memory T cells in tissues distinguishes 





Figure 3.2. Sorting strategy for RNA-Sequencing.  
(A) Schmatic shows samples that were isolated for RNA-Sequencing. Cell sorting was used to 
isolate populations of interested from the spleen and lung of 3 organ donors and from the blood of 
3 healthy volunteers. Samples were sent for RNA-Sequencing at the Columbia Genome Center. 
(B) Freshly isolated lymphocyte suspensions were enriched for T cells by negative selection to 
remove B cells, NK cells, monocytes, and other leukocytes using the BD Mojosort kit. T cells 
were then labelled with fluorophore conjugated antibodies as described in methods. Flow 
cytometry plots show sorting strategy for isolation of CD45RA-CCR7-CD69+ and CD45RA-















Name Number of Reads Number of unique Mapped Reads Median FPKM (isoforms) Mean FPKM (isoforms) 
Num of 
transcripts 
(FPKM > 1) 
Num of 
transcripts 
(FPKM > 0.1) Num of Genes (FPKM > 1) Num of Genes (FPKM > 0.1) Donor Tissue T cell lienage CD69 Batch 
BD001 35128448 31505812 0.3 14.2 16708 22127 12629 15984 233 spleen CD4 - b1 
BD002 38022555 34754087 0.324 14.1 16926 22372 12750 16024 233 spleen CD4 + b1 
BD003 32218460 29651306 0.356 13.2 17082 22496 12888 16234 233 spleen CD8 - b1 
BD004 38356407 35458425 0.346 13.2 17016 22406 12775 15995 233 spleen CD8 + b1 
BD005 32346693 24542330 0.322 16.6 16513 22436 12538 16425 233 lung CD4 - b1 
BD006 37692355 32861480 0.342 15.6 16608 22850 12581 16452 233 lung CD4 + b1 
BD007 33819380 30956211 0.363 13.6 16902 22845 12673 16447 233 lung CD8 - b1 
BD008 24895230 4787100 1.17E-03 1.60E+01 1.57E+04 1.90E+04 1.26E+04 1.53E+04 233 lung CD8 + b1 
BD009 32632736 28499541 0.347 15.4 16801 22342 12681 16209 226 spleen CD4 - b1 
BD010 27990247 22016708 0.346 15.9 16953 22372 12892 16444 226 spleen CD4 + b1 
BD011 30145116 26596999 0.248 16.3 16256 21739 12322 15770 226 spleen CD8 - b1 
BD012 33916030 30378438 0.303 15.4 16587 22169 12531 15988 226 spleen CD8 + b1 
BD013 27811140 20844044 0.38 16.1 16778 22864 12791 16907 226 lung CD4 - b1 
BD014 32406219 25795053 0.364 14.6 16605 23048 12637 16826 226 lung CD4 + b1 
BD015 25070885 15584406 0.371 16.1 16740 22654 12841 16965 226 lung CD8 - b1 
BD016 28302772 22382985 0.303 15.3 16170 22422 12361 16462 226 lung CD8 + b1 
BD017 15491995 9105649 0.0509 30.6 13841 19050 11631 15923 250 spleen CD4 - b2 
BD018 16938399 14248078 0.369 18.5 16408 24227 12653 19073 250 spleen CD4 + b2 
BD019 17495605 14309647 0.22 18.5 16274 21201 12504 16154 250 spleen CD8 - b2 
BD020 22814984 16748291 0.126 19.4 15328 20303 11863 15461 250 spleen CD8 + b2 
BD021 26232006 20770805 0.266 17.3 16463 21505 12669 16130 250 lung CD4 - b2 
BD022 34216681 30317405 0.286 15.4 16076 22409 12236 16427 250 lung CD4 + b2 
BD023 28590077 25954675 0.254 14.6 16399 21649 12331 15841 250 lung CD8 - b2 
BD024 30669374 27681087 0.238 14.8 16205 21547 12222 15764 250 lung CD8 + b2 
BD025 22788441 18669677 0.212 12.3 16968 20737 13407 16385 1 blood CD4 - b3 
BD026 29014993 25437404 0.433 15 17695 22256 13419 16674 1 blood CD8 - b3 
BD027 23088478 19134440 0.335 17.5 17282 21597 13280 16498 2 blood CD4 - b3 
BD028 21458544 17375388 0.302 23.8 17049 21557 13061 16387 2 blood CD8 - b3 
BD029 20881994 17975570 0.418 23.4 17515 22455 13643 17446 3 blood CD4 - b3 
BD030 20976929 18496160 0.375 16.7 17352 22078 13306 16867 3 blood CD8 - b3 
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Figure 3.3. CD69 expression defines a transcriptionally distinct memory subset in humans 
with features of tissue residency.  
Whole transcriptome profiling by RNA sequencing was performed on CD69– and CD69+ subsets 
of CD4+ and CD8+ memory T cells from spleen and lungs of 3 donors (Donors 226, 233, 250; see 
methods).  
(A) Principle Component Analysis (PCA) of paired CD69+ and CD69– samples from spleen and 
lung and for CD4+ and CD8+ subsets, based on the global transcriptome (~20000 genes). 
(B) Diagram shows the number of significant differentially expressed genes (FDR≤0.05 and log2 
fold-change ≥1) between CD69– and CD69+ samples within each tissue for CD4+ and CD8+ T 
cells showing overlap between tissues.  
(C) Heat map showing normalized expression levels of the overlap genes identified in (B) for 
CD4+ (77 genes) and CD8+ (133 genes) CD69– vs. CD69+ subsets from spleen (S) and lung (L).  
(D) Transcriptional downregulation of S1PR1 and KLF2 in all CD69+ vs. CD69– subsets. 
Normalized expression levels of S1PR1 (top) and KLF2 (bottom) transcripts in CD69– and CD69+ 
samples from spleen (S) and lung (L) of each donor are shown. Individual donors are indicated by 
distinct symbols, and lines connect samples from identical donors within a tissue. **** FDR≤10-
5, *** FDR≤10-3.  
(E) PCA of CD69+ (red) and CD69- (black: tissue, blue: blood) memory subsets based on the 







Figure 3.4. PCA of randomly selected genes. 
As a negative control, PCA was performed on an equal number of randomly selected genes as the 





























A core gene signature of human CD69+ memory T cells. 
Based on the gene expression analysis above, we identified 31 core genes with consistent 
significant differential expression by CD4+ and CD8+ CD69+ compared with the corresponding 
CD69– subset from lung, spleen, and blood (Fig. 3.5A). (Table 3.3 provides details about the genes 
identified in Fig. 3.5A). This core signature includes upregulated expression of genes encoding 
specific integrin and adhesion markers ITGAE (CD103), ITGA1 (CD49a), and CRTAM (cytotoxic 
and regulatory T cell molecule), chemokine/chemokine-receptors CXCR6 and CXCL13, and 
molecules with known inhibitory functions in T cells including PDCD1 (PD-1) [214], the dual-
specificity phosphatase DUSP6 that turns off MAP Kinase signaling [215], and IL10 (IL-10). 
Additional cytokine/cytokine receptor genes upregulated in CD69+ compared with CD69– 
samples were IL2 (IL-2) and IL23R, which signals for IL-17 production [216]. Downregulated 
genes in the core signature include the homing receptors S1PR1 and its associated transcription 
factor KLF2 which together control T cell homing and tissue retention [139], the related Kruppel-
like transcription factor KLF3, the lymph node homing receptor SELL (CD62L), and CX3CR1, 
the fractalkine receptor shown to be upregulated by mouse CD8+ T cells during infection [217]. 
Other genes in the core signature included controllers of G-protein signaling such as RAP1GAP1 
and RGS1, shown to modulate T cell trafficking [218], and the kinase STK38, which regulates 
MAP kinase and NF-B signaling in T cells [219]. 
Pathways represented within the core signature include those controlling T cell adhesion 
and migration, proliferation, development, and activation (Table 3.4) that interconnect as 
diagrammed in Fig. 3.5B. Many of the upregulated genes map downstream of TCR signaling, 
including CD69, adhesion molecules (ITGA1, ITGAE, CRTAM), and activation-induced 
molecules IL2 (IL-2), IL10 (IL-10), and PDCD1 (PD-1) that can regulate proliferation and T cell 
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activation (Fig. 3.5B). Differential upregulation or downregulation of specific chemokines and 
chemokine receptors (CXCL13, CXCR6, CX3CR1, SELL, S1PR1) and modulation of G-protein 
mediated signaling (Fig. 3.5B) indicates that tissue residence involves specific tuning of migratory 
properties. Overall, these results establish that human CD69+ tissue memory T cells maintain a 
core signature impinging on multiple signaling pathways affecting cellular migration, function, 
and proliferation. 
The relative transcript levels of key genes within the core gene signature (ITGA1 (CD49a), 
CXCR6, ITGAE (CD103), CXCR6, CX3CR1, and PDCD1 (PD-1)) showed differential regulation 
between CD69+ and CD69– subsets that was consistent across tissues, lineages, and diverse donors 
(Fig. 3.5C-G). We also validated differential surface protein expression by flow cytometry for each 
marker from 8-20 additional donors (Figs. 3.6, 3.7). Interestingly, for a number of genes (ITGAE, 
CX3CR1, PDCD1), there was an expression gradient from blood to tissue CD69– to CD69+ 
subsets, with blood memory cells exhibiting lower (ITGAE, PDCD1) or higher (CX3CR1) 
expression than CD69– subsets from tissues (Fig 3.5D, F-G), suggesting some differences between 
CD69– subsets in blood and tissues. Together, these data establish CD49a, CD103, CXCR6, 
CX3CR1, and PD-1 as core surface markers that distinguish human CD69+ and CD69– memory 





Figure 3.5. A core gene signature defines tissue CD69+ memory T cells distinct from 
circulating CD69– cells in tissues and blood.   
(A) Heatmap shows normalized expression of genes with significant differential expression 
between CD69+ and CD69– memory T cells for all subsets (CD4+, CD8+) and tissues (spleen, 
lung).  
(B) Network analysis of the core gene set in (A) showing known and predicted interactions 
(activating, inhibitory) between proteins encoded by the core genes that are upregulated (red) or 
downregulated (green) by TRM compared with TEM with key pathways indicated in the shaded 
boxes. Relationships were determined using IPA software, String Protein database, GeneCards, 
and Pubmed literature searches.  
(C-G) Normalized mRNA expression levels of ITGA1 (C), ITGAE (D), CXCR6 (E), CX3CR1 
(F), and PDCD1 (G) by CD4+ and CD8+ CD69+ and CD69- memory subsets in blood (B), spleen 
(S) and lung (L) of each individual donor. *FDR≤0.05, ** FDR≤10-2, ***FDR≤10-3, 
****FDR≤10-5. Each donor is represented by a unique shape as indicated. See also Figures 3.6 










Figure 3.6. Expression of CD49a, CD103, and CXCR6. 
Left: Histograms show expression of CD49a (A), CD103 (B), and CXCR6 (C) in CD69+ and 
CD69– memory T cells from spleen and lung of one representative donor. Right: Graphs show 
compiled flow cytometry data for CD49a (A, n=15 donors), CD103 (B, n=20 donors), and CXCR6 















Figure 3.7. Expression of PD-1, CD101, and CX3CR1. 
Left: Histograms show expression of CX3CR1 (A), PD-1 (B), and CD62L (C) in in CD69+ and 
CD69– memory T cells from spleen and lung of one representative donor. Right: Graphs show 
compiled flow cytometry data for CX3CR1 (A, n=8 donors), PD-1 (B, n=15 donors), and CD62L 


















Table 3.3. Details about genes in core signature. 
 
 
Symbol Gene Name Location Type 
CA10 carbonic anhydrase 10 Other enzyme 
CRTAM cytotoxic and regulatory T-cell molecule Plasma Membrane other 
CX3CR1 C-X3-C motif chemokine receptor 1 Plasma Membrane G-protein coupled 
receptor 
CXCL13 C-X-C motif chemokine ligand 13 Extracellular Space cytokine 
CXCR6 C-X-C motif chemokine receptor 6 Plasma Membrane G-protein coupled 
receptor 
DUSP6 dual specificity phosphatase 6 Cytoplasm phosphatase 
FAM65B family with sequence similarity 65 member B Cytoplasm other 
IL2 Interleukin 2 Extracellular Space cytokine 
IL10 interleukin 10 Extracellular Space cytokine 
IL23R interleukin 23 receptor Plasma Membrane transmembrane 
receptor 
ITGA1 integrin subunit alpha 1 Plasma Membrane other 
ITGAE integrin subunit alpha E Plasma Membrane other 
KCNK5 potassium two pore domain channel subfamily K 
member 5 
Plasma Membrane ion channel 
KLF2 Kruppel like factor 2 Nucleus transcription 
regulator 
KLF3 Kruppel like factor 3 Nucleus transcription 
regulator 
KRT72 keratin 72 Cytoplasm other 
KRT73 keratin 73 Extracellular Space other 
NPDC1 neural proliferation, differentiation and control 1 Extracellular Space other 
PDCD1 programmed cell death 1 (PD-1) Plasma Membrane phosphatase 
PTGDS prostaglandin D2 synthase Cytoplasm enzyme 
RAP1GAP2 RAP1 GTPase activating protein 2 Cytoplasm other 
RGS1 regulator of G-protein signaling 1 Plasma Membrane other 
S1PR1 sphingosine-1-phosphate receptor 1 Plasma Membrane G-protein coupled 
receptor 
SBK1 SH3 domain binding kinase 1 Other kinase 
SELL selectin L (CD62L) Plasma Membrane transmembrane 
receptor 
SOX13 SRY-box 13 Nucleus transcription 
regulator 
STK38 serine/threonine kinase 38 Nucleus kinase 
TSPAN18 tetraspanin 18 Other other 
TTC16 tetratricopeptide repeat domain 16 Other other 
TTYH2 tweety family member 2 Other ion channel 
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Table 3.4: Significant pathways common to all CD69+ subsets. 
  
Pathway p-value Ratio Direction Genes from dataset 
Sphingosine-1-phosphate 
Signaling 
2.1E-04 0.139 Down S1PR5,ADCY3,ADCY6,RHOH,PDGFB,S1PR4,PLCD1,S1PR1 +9 more 
Integrin Signaling 1.2E-03 0.105 Down PXN,TSPAN5,ARHGEF7,ABL1,ITGAE,PPP1CB,ITGA5,ITGAL + 16 more 
Leukocyte Extravasation 
Signaling 
1.5E-03 0.105 Down VAV2,VCAM1,PXN,ABL1,ITGA5,NCF4,ITGAL,RHOH,ITGB2 +14 more 
Actin Cytoskeleton Signaling 3.1E-02 0.083 Down VAV2,PXN,ARHGEF12,ARHGEF7,PPP1CB,ITGA5,IQGAP1 +12 more 
Cell Cycle: G1/S Checkpoint 
Regulation 
1.7E-03 0.156 n/a TP53,CDKN2D,FOXO1,CCND3,SMAD3,CDKN1A,ABL1,ATR,E2F2,ATM 
Cyclins and Cell Cycle 
Regulation 
7.4E-03 0.128 Up TP53,CCNH,CDKN2D,CCND3,PPM1L,CDKN1A,ABL1,ATR,E2F2,ATM 
Notch Signaling 1.3E-02 0.158 Up NOTCH4,JAG2,DTX3,RBPJ,NOTCH1,NUMBL 
NF-κB Signaling 1.3E-02 0.094 Down MYD88,TGFBR3,NFKB1,TANK,NTRK2,NTRK3,CARD10,TLR6 +9 more 
Tec Kinase Signaling 7.9E-03 0.10 Down VAV2,ITGA5,NFKB1,RHOH,FAS,BLK,YES1,GNA15,PIK3R6 +8 more 
STAT3 Pathway 3.6E-02 0.11 Down PTPN6,NTRK2,NTRK3,TGFBR3,CDKN1A,IGF1R,FGFRL1,PDGFRB 
Protein Kinase A Signaling 3.6E-04 0.095 Up CAMK4,PTPN13,SMAD3,DUSP6,PDE4A,UBASH3B +29 more 
RhoA Signaling 2.6E-02 0.098 n/a LPAR6,ARHGEF12,ARHGAP9,LPAR2,EPHA1,IGF1R +6 more 
Pathway analysis was performed using IPA software and table displays 
pathways that showed enrichment in all CD69+ vs. CD69– groups. P-values, 
ratios, and genes from dataset are taken from Lung CD8 CD69+ vs. CD69– as 
a representative example.  
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The human CD69+ tissue memory core signature bears key homologies with mouse TRM  
To determine whether the core transcriptional profile common to CD69+ memory T cells 
in spleen and lungs defined a TRM signature, we compared the RNA-Seq profile of the human 
tissue and blood subsets with that of mouse antigen-specific CD8+ TRM isolated from skin and 
intestines following infection (Mackay et al. 2016). PCA of whole transcriptomes shows species-
specific transcriptional differences between human and mouse T cells dominating, with all human 
samples clustering together distinct from mouse TRM/TEM, with cells from the two mouse 
infection models also transcriptionally distinct (Fig. 3.8A, left). When analyzed based on the 
human core gene signature in Fig. 3.5, CD4+CD69+ and CD8+CD69+ subsets from human spleen 
and lung cluster together with mouse CD8+ TRM from skin and gut in the two different infection 
models, and are distinct from all TEM/CD69- counterparts (Fig. 3.8A, right). Gene set enrichment 
analysis (GSEA) [220] also revealed a strong enrichment of the differentially expressed genes in 
human CD4+CD69+ and CD8+CD69+ subsets within the gene signatures of TRM from mouse 
brain [108], and mouse skin and lung [110] (Fig. 3.8B). Taken together, our results show that the 
gene signature of human CD69+ tissue memory T cells exhibits key features of TRM and likely 
contain the human TRM subset. 
A recent report showed that mouse CD8+ TRM in multiple tissues exhibit biased expression 
of the Hobit (homologue-of BLIMP in T cells) transcription factor, which can drive TRM 
differentiation in vivo [109]. As Hobit was not part of the core gene set in our analysis, we 
specifically analyzed the expression level of Hobit (ZNF683) by human CD69+ memory T cells 
compared with mouse TRM. In mouse TRM, Hobit levels were higher than the housekeeping gene 
GAPDH and comparable to CD69 transcript levels. By contrast, for human CD69+ memory T 
cells, Hobit transcript levels were below median gene expression and significantly lower than 
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GAPDH and CD69 levels (Fig. 3.8C). These results suggest distinct molecular control of human 
and mouse TRM differentiation, despite similar core signatures. 
We also measured the levels of the transcription factors Eomes and T-bet, based on data in 
mice that showed that CD8+ TRM downregulate these transcription factors [106, 148]. Consistent 
with these finding, we found that human within the CD8+ lineage, CD69+ memory T cells had 
lower expression of both Eomes and T-bet compared with CD69- memory T cells (Fig. 3.9). 
Within the CD4+ lineage, CD69+ memory T cells had lower expression of T-bet compared with 
CD69- memory T cells (Fig. 3.9B). Both CD69+ and CD69- CD4+ memory T cells had low 
(<25%) expression of Eomes with no significant differences. Overall, these data suggest that there 
may be some similarities in the transcriptional regulation of human and mouse TRM, and that 




Figure 3.8. Comparison of the human and mouse TRM transcriptome.   
(A) PCA was performed using RNA-Seq data presented here (black symbols) compared to mouse 
herpes simplex virus (HSV)-specific CD8+ TRM from skin and CD8+ TEM from spleen (“mouse 
HSV”, yellow) and LCMV-specific CD8+ TRM from intestine and CD8+ TEM from spleen 
(“Mouse LCMV”, red) (Mackay et al. 2016). Left: PCA comparing whole transcriptomes of each 
dataset comprising 15571 common genes between human and mouse. Right: PCA comparing the 
human and mouse datasets based on expression of genes in the core signature (Fig. 3.5). 
(B) Gene set enrichment analysis (GSEA) comparing our human CD8+ (left) and CD4+ (left) gene 
sets to published microarray data of CD103+ brain TRM vs. spleen TEM (top row), gut TRM vs. 
spleen TEM (middle row), and lung TRM vs. spleen TEM (middle row) (Wakim et al. 2012; 
Mackay et al. 2013). In each plot, the x-axis shows the genes ranked with absolute value of log 
fold change between TRM vs. TEM and y-axis shows running enrichment score (ES) comparing 
the ranked list of genes with indicated p values.  
(C) Comparison of Hobit gene expression in mouse and human datasets. Violin plots show Z score 
of gene expression levels from mouse TRM (from Mackay et al. 2016) and human CD69+ memory 
T cells (this study). Red dots represent Hobit, blue dots represent the housekeeping gene GAPDH, 










Figure 3.9. T-bet and Eomes expression by human memory T cells. 
Flow cytometry was used to measure the expression of Eomes (A) and T-bet (B). Left 
panels: representative flow cytometry histograms showing of Eomes and T-bet in CD69+ and 
CD69- memory T cells in the spleen and lung of one representative donor. Right panels: Bar graphs 











Reduced clonal overlap and proliferative turnover of CD69+ compared with CD69– memory T 
cells. 
We compared the TCR repertoires of lung and spleen CD69+ and CD69– memory T cell 
subsets using a recently developed algorithm TRUST (TCR repertoire utilities for solid tissue) 
[209] to extract TCR sequences from the RNAseq reads (see extended methods). Between 0.1% 
and 0.3% of mapped reads could be assigned to the TCR region (data not shown), with detection 
of several hundred to over 1000 unique clonotypes per sample (Fig. 3.10). From these data, we 
measured clonal diversity (# unique clonotypes per mapped reads) and overlap between sites. 
Overall, CD69– and CD69+ cells exhibited similar clonal diversity with CD4+ subsets maintaining 
higher clonal diversity compared to CD8+ memory subsets  (Fig. 3.11A), consistent with previous 
findings showing increased clonality of memory CD8+  compared to CD4+T cells from lymphoid 
sites [18]. Clonal overlap between sites was minimal (<1%) for CD4+ subsets, while CD8+CD69+ 
cells exhibited significantly reduced overlap between lung and spleen compared to CD8+CD69– 
cells (Fig. 3.11B), indicating that CD69+ memory T cells are more clonally segregated within the 
tissue compared with CD69– cells. These results provide some additional evidence that CD69+ 
memory T cells may be more retained in tissue site compared with CD69– cells.  
We hypothesized that the biased maintenance of CD69+ clones in certain sites may indicate 
reduced turnover. The frequency of CD69+ cells expressing Ki67, a marker of proliferating cells, 
was markedly reduced relative to CD69– cells in both spleen and lung (Fig. 3.11C). Examination 
of CD57 expression, a marker of replicative senescence and terminal differentiation [221], 
revealed lower CD57 expression by CD8+CD69+ compared to CD8+CD69– cells in both spleen 
and lung (Fig. 3.11D). Taken together, these data suggest that human CD69+ memory T cells 
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undergo reduced proliferative turnover and have reduced clonal overlap compared with CD69– 
cells.  
 
Human CD69+ memory T cells have a distinct functional profile 
We investigated cytokine production by CD69+ and CD69– cells based on differential 
transcript expression of genes encoding IL-2, IFN-, IL-17 and IL-10 identified as significantly 
upregulated by CD69+ versus CD69– memory T cells for both CD4+ and/or CD8+ subsets (Fig. 
3.12; see also 3.3C and 3.5A). IL-2 and IL-10 were produced by a consistently higher proportion 
of CD69+ compared with CD69– memory T cells for both CD4+ and CD8+ subsets in spleen and 
lung (Fig. 3.11E-F), consistent with increased IL2 and IL-10 transcription being part of the core 
signature (Figs. 3.5A, 3.12). IFN- was produced by spleen and lung memory CD4+ and CD8+ T 
cells, with spleen CD69+ memory T cells exhibiting increased IFN- production compared with 
CD69– cells, while lung CD69+ and CD69– cells had comparable IFN- production (Fig. 3.11G, 
left). IL-17 was produced more extensively by lung CD4+ and CD8+CD69+ compared with lung 
CD69– memory T cells, and not significantly by spleen CD69+ and CD69– cells (Fig. 3.11G, 
right). Together these results indicate that the functional capacity of CD69+ memory T cells 
comprise core features (e.g., IL-2, IL-10 production) along with subset and tissue influences.  
 
The functional profile of CD103+CD69+ memory T cells 
CD103 is a cell surface molecule that promotes retention by binding E-Cadherin on 
epithelial cells [222] and it is often used as a marker of TRM [10]. Therefore, to determine how 
the functional properties of CD103+ and CD103- cells varied within the CD69+ fraction, these 
populations were stimulated with PMA/Ionomycin and cytokine production was measured via 
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intracellular staining. These experiments were restricted to CD8+ cells because of the low 
percentage of CD103+ cells within the CD4+ fraction (Fig. 3.1). In both the spleen and lung, a 
higher fraction of CD103+ cells produced IL-2 and IL-17 in response to stimulation compared 
with CD103- cells (Fig. 3.13). There was no significant difference in the fraction of cells from 
either group that produced IFN-(Fig. 3.13). These results indicate that CD103+ cells may have 
a superior ability to produce certain activating and pro-inflammatory cytokines compared with 





Figure 3.10. TCR repertoire overlap.  
RNAseq was performed on CD69+ and CD69– memory T cells and CDR3 sequences were 
inferred from data using TRUST. Venn diagrams show degree of overlap between samples from 
each donor. The total number within each oval represents the total number of unique clones within 






Figure 3.11. TCR clonal analysis, turnover, and function of CD69+ and CD69– cells.  
(A) CD8+ T cells have reduced TCR repertoire diversity compared with CD4+ cells. CDR3 
sequences were inferred from RNA-Seq data using TRUST. Graph shows the number of unique 
CDR3 calls (clonotypes) in each sample per 103 reads mapped to the TCR region. (B) Increased 
tissue overlap of TCR clones within CD8+ CD69– compared to CD69+ memory T cells. Graph 
shows percentage of overlapping clones between lung and spleen samples from each donor, 
calculated by dividing the total number of overlapping clones by the total number of unique clones 
present in both tissues. See also Figure 3.9. (C) Reduced proliferative turnover by CD69+ memory 
T cells. Left: Representative flow cytometry plots of intracellular Ki67 expression from spleen and 
lungs of one individual donor. Right: Ki67 expression compiled from 10 donors depicted as mean 
frequency expressing Ki67 ±SEM. (D) Increased CD57 expression by CD69– compared with 
CD69+ cells. Left: CD57 expression by CD69– and CD69+ memory T cell subsets from spleen 
and lung of one representative donor. Right: CD57 expression compiled from 11 donors displayed 
as mean percent positive ±SEM. * p≤0.05, ** p≤0.01. (E-G) Distinct functional profile of CD69+ 
cells. CD4+ and CD8+ CD69– and CD69+ memory T cells isolated from spleens and lungs were 
stimulated with PMA/Ionomycin and cytokine production was assessed by intracellular cytokine 
staining (ICS) (for IL-2, IFN-, IL-), or were stimulated with anti-CD3/CD28 beads (for IL-
10) and IL-10 levels in the supernatant were assessed by BD cytokine bead array. (E) Graph shows 
mean frequency of CD69– and CD69+ cells producing IL-2. (F) Graph shows mean ±SEM IL-10 
production in pg/ml. (G) Graph shows mean frequency of CD69– and CD69+ cells producing IFN-
 (left) and IL-17A (right) ±SEM. n=6 donors spleen, 10 donors lung for IL-2, IFN-, IL-, 






Figure 3.12: Transcript levels of cytokines. 
(A) Normalized mRNA expression levels of IL2 (left), IFNG (middle), and IL17A (right) in 
CD69+ and CD69- memory subsets in spleen (S) and lung (L) of each individual donor. 
*FDR≤0.05, ***FDR≤10-3.  
(B) Normalized mRNA expression levels of IL10 in CD69+ and CD69- memory subsets in spleen 








Figure 3.13. Cytokine production by CD103+ and CD103- human CD69+ memory T cells. 
CD8+CD69+ memory T cells from spleens (n=6 donors) and lungs (n=10 donors) were 
stimulated with PMA/Ionomycin for 3 hours and cytokine production was assessed by intracellular 
cytokine staining. Graphs show production of IL-2 (left), IFN-g (middle) and IL-17A (Right) 
depicted as mean frequency expression cytokine ±SEM, stratified by CD103+ (orange) and 






The TRM transcriptional profile is conserved across lineages and tissues 
Isolation of both CD4+ and CD8+ memory subsets from two tissue sites of individual 
donors enabled us to assess lineage- and tissue-specific gene expression patterns. To identify 
lineage-specific genes, we compared differential gene expression by CD8+ CD69+ vs. CD69– and 
CD4+ CD69+ vs. CD69– subsets for each tissue site. The majority of genes showed similar 
differential expression in terms of direction and magnitude of fold change when looking at CD69+ 
vs. CD69– subsets from either CD8+ or CD4+ lineages (Fig. 3.14A). From a total of 907 genes that 
were differentially expressed by at least one of our CD69+ vs. CD69– pairs, there were 4 protein-
coding genes that showed differential expression in CD4+ but not in CD8+ subsets, and 27 genes 
that showed significant differential expression in CD8+ but not in CD4+ subsets (Figs. 3.14A and 
3.15A-B). Together, these results indicate that human CD4+ and CD8+memory T cells have similar 
overall gene expression profiles. 
We applied a similar type of analysis as above to identify genes specific to lung or spleen 
memory T cells (Fig. 3.14B). Only 10 genes showed differential expression in CD69+ vs. CD69– 
in lung but not spleen samples, and 12 genes that showed significant differential expression in 
CD69+ vs. CD69– in spleen but not lung samples (Fig. 3.14B; 3.15C-D). Notably, CD101 was 
transcriptionally upregulated in lung compared to spleen memory T cells. CD101 is a cell surface 
immunoglobulin superfamily protein which inhibits T cell activation and modulates T cell function 
[223-225]. Examination of CD101 surface expression by flow cytometry revealed increased 
expression by CD8+CD69+ compared with CD69– cells in both lung and spleen, with minimal 
upregulation by CD4+ tissue memory subsets (Figs. 3.14C, 3.15E). These results indicate that 
CD101 could be a new additional marker for CD8+TRM. 
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The chemokine receptor CCR9 emerged as one of the few a spleen-specific genes. As 
CCR9 has been shown to be critical for homing to the intestine [226], we measured surface 
expression of CCR9 on intestinal tissue as well as spleen and lung. A significant fraction of 
intestinal CD4+CD69+ and CD8+CD69+ cells (≥20%) expressed CCR9, while other samples had 
lower expression (<10%) of CCR9 (Fig. 3.16). There was also measurable proportion of splenic 
CD8+CD69+ memory T cells that upregulated CCR9 (8-10%) compared to negligible expression 
by spleen CD8+CD69–  cells, and low expression by all lung memory T cells (Fig. 3.16). This 
biased upregulation of CCR9 by splenic CD8+CD69+ was manifested by an increased ratio of 
CCR9 MFI in CD8+CD69+compared to CD8+CD69– cells in spleen but not lung (Fig. 3.16). Our 
data showing transcriptional upregulation and modest surface expression suggest that CCR9 may 





Figure 3.14. Lineage and tissue-specific transcription and phenotypic profiles in human 
CD69+ memory T cells.  
(A) Analysis of lineage-specific gene expression in CD69+ and CD69– memory T cells. Scatter 
plots display log2 fold change of CD4+CD69+ vs. CD69– on the x axis and CD8+ subsets on the 
y axis from lung (left) and spleen (right). Grey dots represent genes with significant differential 
expression in any paired CD69+ vs. CD69– sample. Orange dots (“CD4 specific”) represent genes 
with significant differential expression in CD4+ CD69+vs. CD69– but not in CD8+ samples. Green 
dots (“CD8 specific”) represent genes with significant differential expression in CD8+CD69+ vs. 
CD69– but not in CD4+ samples.  
(B) Analysis of tissue-specific genes in CD69+ and CD69– memory T cells. Scatter plots display 
log2 fold change of lung CD69+ vs. CD69– samples on the x axis and spleen samples on the y 
axis for CD4+ (left) and CD8+ (right) T cells using the same strategy as in (A) with red dots 
denoting “spleen specific” and blue dots denoting “lung specific” transcripts in the paired analysis.  
(C) CD101 expression in human tissues. Representative plots show CD101 expression in CD69+ 
(black outline) and CD69– (shaded) cells from one individual donor. Data are representative of 15 











Figure 3.15. Tissue- and lineage- specific genes. 
(A-D) Heatmaps show normalized expression of genes that showed differential expression when 
comparing CD69+ vs. CD69– memory T cell within CD4+ samples but not CD8+ samples (A); 
comparing CD69+ vs. CD69– memory T cells within CD8+ samples but not CD4+ samples (B); 
comparing CD69+ vs. CD69– memory T cells within lung samples but not spleen samples (C); 
and comparing CD69+ vs. CD69– memory T cell within spleen samples but not lung samples (D). 
(E) Expression of CD101. Graphs show compiled flow cytometry data as mean frequency of 










Figure 3.16. CCR9 Expression in CD69+ and CD69- memory T cells. 
Left: representative flow cytometry plots show CCR9 expression in the spleen, lung, and 
gut of one representative donor. Right: Ratio of mean fluorescence intensity (MFI) for CCR9 in 









TRM are a phenotypically distinct subset across multiple tissues.  
We asked whether multiple elements within the core signature together distinguished tissue 
memory subsets in spleen and lung using t-distributed scholastic neighbor embedding (t-SNE) 
analysis [185, 227], a dimensionality reduction method used to visualize high-dimensional data in 
two dimensions such that cells expressing similar markers will be close to each other. Based on 
the expression of 6 markers defined as part of the core TRM signature (Fig. 3.5), CD49a, CD103, 
CXCR6, CX3CR1, PD-1, and CD101, we found that CD69+ and CD69– subsets were located in 
distinct regions of the t-SNE plots for both CD4+ and CD8+T cells in each tissue (Fig. 3.17A), and 
in density plots compiled from both sites (Fig. 3.17B, top). Manual gating within each dominant 
cluster reveals that CD69– subsets exhibit elevated expression of CX3CR1 and low expression of 
CD49a, PD-1, CD101, CD101, and CXCR6 compared to CD4+ and CD8+CD69+ subsets 
exhibiting high expression of CD49a, PD-1, and CXCR6, and low expression of CX3CR1, with 
CD8+CD69+ subsets having high expression of CD103 and CD101 (Fig. 3.17B). These results 
further support the designation of tissue CD69+ memory T cells as TRM and the CD69– subset as 
TEM. 
We assessed how multiple phenotypic properties of the core signature were distributed in 
diverse sites within an individual, including in intestines, mesenteric lymph nodes, tonsils, and 
blood in addition to lung and spleen (Figs. 3.17C-D and 3.18). We initially generated t-SNE plots 
using concatenated data from all six tissue sites, revealing phenotypically distinct TEM and TRM 
subsets across multiple tissues (Fig 3.17C). In density plots, CD4+ and CD8+TEM cells were 
localized to the same region of the t-SNE, suggesting that TEM phenotypes are conserved across 
lineages and tissues (Fig. 3.17C). By contrast, CD8+TRM and CD4+TRM appeared at different 
regions within the t-SNE density plots distinct from TEM cells, (Fig. 3.17C). Notably, there was 
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a broader range of phenotypes based on these markers within the CD4+TRM subset compared with 
the tighter clustering of CD8+TRM phenotypes, suggesting increased heterogeneity of CD4+ tissue 
memory T cells. 
To compare the pattern of subset phenotypes between tissues, we assigned distinct colors 
to CD8+TRM, CD4+TRM and TEM populations. Plotting all tissue samples on the same t-SNE 
reveals the localization of each cell population (Fig. 3.17D, left), with TEM cells and CD4+ and 
CD8+TRM cells maintaining their distinct clustering patterns and localization in each site (Figs. 
3.17D, right, and 3.18). In blood, TEM cells clustered in a similar pattern as TEM in other tissues 
(Fig. 3.17D, right), providing additional evidence that TEM in tissues are circulating. Notably, 
CD8+TRM cells exhibit a focused clustering pattern in all tissues, suggesting that human TRM 
cells represent a unique subset in multiple sites. CD4+TRM cells in all tissues exhibited a broader 
array of phenotypes suggesting increased heterogeneity of CD4+TRM compared to CD8+TRM 





Figure 3.17. TRM are a phenotypically distinct subset across multiple tissues. 
Simultaneous expression of CD49a, CD103, CD101, CXCR6, CX3CR1, PD-1, and CD69 was 
visualized using t-SNE analysis.  
(A) CD69+ and CD69- memory T cells are phenotypically distinct in spleen and lung. Plots show 
CD69+ memory T cells (color coded green) and CD69- memory T cells (color coded black) from 
spleen and lungs of an individual donor (Donor 321) representative of 5 donors.  
(B) Defining the phenotype of TRM and TEM clusters. Regions with high cellular density were 
manually gated within TEM (CD69–), CD4+ TRM (CD69+), and CD8+ TRM (CD69+) fractions 
(top row). Histograms show expression levels of CD49a, CD103, CD101, CXCR6, CX3CR1, and 
PD-1 within gated regions (bottom row). (C-D) The core TRM phenotype is observed across 
multiple tissues. Phenotype analysis as in (A) was performed using lung, intestine, spleen, 
mesenteric lymph node (MLN), tonsils, and blood samples from one representative donor (Donor 
332).  
(C) Plots show CD4+ (left) and CD8+ (right) TRM and TEM subsets from all tissues with cell 
number density color coded.  
(D) Plots shows cells from all tissues (left large plot) or each individual site (Right smaller plots) 
color coded by cell type (CD4+ TRM, red; CD8+ TRM, green; TEM, black) of one donor 









Figure 3.18. t-SNE analysis of TRM and TEM from additional donor. 
The expression of CD49a, CD103, CD101, CXCR6, CX3CR1, and PD-1 was analyzed on 
CD69+ (TRM) and CD69– (TEM) memory T cells from multiple tissues and donors. t-SNE 
analysis was performed using lung, intestine, spleen, mesenteric lymph node (MLN), tonsils, and 
blood samples from one representative donor. t-SNEs are color coded by cell type and CD4+ TRM 
are shaded red, CD8+ TRM are shaded black, and TEM samples are shaded black. Left: t-SNE 
shows cells from all tissues from one donor. Right: t-SNEs show cells from each individual tissue. 





Section 3.3: Discussion 
In this study we provide key insights into TRM biology through a comprehensive analysis 
of human CD4+ and CD8+ tissue memory subsets in lymphoid and mucosal tissues within and 
between multiple human donors. Our results establish that human tissue memory T cells 
fractionated based on CD69 expression exhibit a core signature of 31 genes conserved across 
tissues and lineages, with key homologies to the transcriptional profile of mouse TRM. We 
demonstrate that human TRM persist in multiple lymphoid, mucosal and peripheral tissue sites, 
exist within both CD4+ and CD8+ lineages, and exhibit unique functional signatures compared 
with circulating TEM cells including proinflammatory and regulatory capacities, and low turnover. 
Together, our results suggest that human TRM are a distinct developmental subset uniquely 
adapted for in situ immunity.   
A definitive phenotypic marker for human TRM has not previously been defined. 
Transcriptional profiling has been reported for mouse CD8+TRM in which CD8+ memory T cells 
isolated from a barrier site (skin, intestine or lung) were compared with spleen [109, 110]. In 
human studies, CD8+TRM isolated based on CD103 expression from individual tissues (lung, 
skin) have been profiled in comparison to blood subsets [142, 168]. Here, we employed an 
innovative and comprehensive approach to assess differences in putative circulating and resident 
populations within tissues by directly comparing CD69+ memory subsets from a lymphoid and 
mucosal site (spleen and lung) with the corresponding CD69- subset from each tissue as well as 
CD69– TEM from blood for both CD4+ and CD8+ lineages. While CD103 has been used to define 
CD8+ TRM in mice [102] and humans [142], our results demonstrate that CD69 expression can 
delineate tissue from circulating memory T cells based on the following results: First, CD69 is the 
major marker that distinguishes memory T cells in diverse tissues from those in circulation for 
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CD4+ and CD8+ T cells, while CD103 expression is limited to a subset of tissue CD8+T cells. 
Second, CD69+ tissue memory T cells are a transcriptionally and phenotypically distinct subset 
that share core features with mouse TRM while human tissue CD69– cells share features with 
circulatory blood T cells. Finally, core phenotypic markers associated the CD69+ subset such as 
CD49a, PD-1, CXCR6, and CD101 delineate TRM cells across multiple mucosal and lymphoid 
tissues.   
Although we found the TRM signature to be enriched within the CD69+ subset of human 
tissue memory T cells, the role of CD69 in determining tissue residence remains unclear. In mouse 
models, the majority of TRM cells in barrier sites express CD69; however, TRM cells lacking  
CD69 expression have been detected [104], and CD69+ cells in the thymus were shown to 
recirculate during homeostasis [228]. However, the extent of CD69 expression by tissue memory 
T cells appears to be a function of antigen and pathogen exposure. We consistently find higher 
frequencies of CD69 expression by human tissue memory T cells compared to that found in mouse 
models maintained in spf conditions, particularly in lymphoid sites [18, 105]. Interestingly, T cells 
in “dirty” pet store mice had significantly higher frequencies of CD69 expression by T cells in 
tissues that was similar to humans [229]. In our results, we consistently see separation of 
transcriptional profiles between CD69+ and CD69– subsets (Fig. 3.3), suggesting that delineation 
between these subsets in humans may be more defined than in mouse spf models due to the history 
of antigen exposure.  
The core TRM gene signature identified here includes canonical genes and proteins 
associated with tissue residence in mice including downregulation of S1PR1, KLF2, and CD62L, 
upregulation of specific adhesion molecules (CD49a, CRTAM), modulation of specific chemokine 
receptors (increased CXCR6, decreased CX3CR1), and upregulation of inhibitory or regulatory 
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molecules (PD-1, DUSP6, IL-10). We also found TRM to exhibit a distinct functional profile 
encompassing both pro-inflammatory, activating, and regulatory functions conserved between 
diverse individuals, tissues, and lineages. This core signature is depicted in Figure 3.19. We further 
identified a novel marker CD101, with immunomodulatory function that is expressed by CD8+ 
TRM in multiple sites and could be useful in conjunction with other markers to identify TRM. We 
found phenotypic heterogeneity based on the core markers, particularly among CD4+TRM, and 
additional tissue heterogeneity has been reported in CyTOF profiling of human tissue T cells [185]. 
CD103 expression by mouse intestinal TRM [133] and CD49a in human skin memory T cells 
[168], have been shown to delineate distinct functional capacities, and dissecting human TRM 
heterogeneity will be an important area of focus in future studies.  
The dominant presence of TRM in human tissues suggests a key protective role in situ. Our 
results reveal that human TRM possess dichotomous functional capacities, not only being poised 
for enhanced production of IL-2 and pro-inflammatory cytokines, but also producing IL-10 and 
exhibiting reduced proliferation and increased expression of inhibitors of T cell activation (i.e., 
PD-1, CD101). This may enable potent mobilization of immune responses in situ through pro-
inflammatory cytokines but prevent excessive inflammation and cellular proliferation to limit 
inflammation-induced tissue damage. Moreover, the quiescent, inhibited state of TRM as assessed 
by the low turnover could promote longevity and prevent inappropriate activation to non-
pathogenic antigens to which many human tissues are continually exposed. 
Our findings show that in humans, TRM exist in multiple tissue sites and within CD4+ and 
CD8+ T cell lineages. While TRM have been detected in mouse LN [111, 112], the majority of 
mouse lymphoid memory CD4+ and CD8+ T cells in mice are circulating, particularly those in the 
spleen. The predominance of TRM-phenotype cells in all human lymphoid tissues examined here 
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including spleen, lymph nodes, and tonsils may reflect their long-term persistence over decades 
and/or continual pathogen exposure, consistent with a recent study identifying memory T cells 
specific for persistent viruses in human tonsils [157]. TRM persistence in diverse sites may be due 
to the aggregate experience of numerous antigens over the human lifespan.  
Interest in TRM is rapidly expanding to the study of many diseases, from infection to 
cancer to inflammation and autoimmunity. In humans, it is essential to identify and analyze these 
cells and determine whether they are functioning aberrantly in disease sites. Our study elucidates 
major unifying features of all tissue memory T cells in multiple healthy tissue sites within an 
individual. These results will serve as a valuable baseline from which to detect and study the role 
of tissue memory T cells in diseases, and for promoting tissue immunity in vaccines, cell- and 









Figure 3.19. A core signature of human TRM. 
In this study, we identify a core transcriptional, functional, and phenotypic signature of 
human tissue-resident memory T cells (TRM). This core signature is depicted below and includes 
a unique profile of homing receptors, which help TRM avoid tissue egress or home to the tissue 
site; expression of specific adhesion markers, which promote tissue retention; and a unique 
functional profile, through which TRM have the ability to produce effector cytokines but also 







CHAPTER 4: Dye efflux capacity defines a functionally distinct subset of human CD8+ 
tissue resident memory cells. 
 
ABSTRACT: 
Tissue-resident memory T cells (TRM) accelerate pathogen clearance at various tissue 
sites. However, TRM are heterogeneous, and the functional role of different TRM subsets is not 
well defined. Here, we describe a functionally distinct subset of CD8+ TRM found across human 
tissues defined by the capacity to efflux fluorescent dyes. Efflux(+) TRM showed evidence of 
quiescence both transcriptionally and phenotypically, including heightened expression of CD127, 
reduced turnover, decreased expression of activation and exhaustion markers, and elevated 
expression of immunosuppressive markers. Further, efflux(+) TRM expressed a unique profile of 
adhesion and migration markers suggestive of enhanced long-term tissue retention. After TCR 
stimulation, efflux(+) TRM produced less pro-inflammatory cytokines and underwent less 
cytotoxic degranulation compared with efflux(-) TRM. Moreover, efflux(+) TRM retained a 
higher proliferative capacity and exhibited greater responses to IL-7. Notably, efflux(+) also had 
an enhanced capacity for IL-17 production and showed evidence of Th17-associated signaling 
transcriptionally. Overall, these results suggest that efflux(+) and efflux(-) TRM may cooperate to 
mediate tissue immunity in humans; efflux(+) TRM are programmed for longevity and tissue-
retention to maintain a reservoir capable of proliferation, while efflux(-) TRM exhibit heightened 
effector function for generating rapid pro-inflammatory and cytotoxic responses. The 
identification of these potentially clinically relevant TRM subsets could guide the development of 




Section 4.1: Introduction 
Memory CD8+ T cells provide lifelong protection against pathogens. Human memory T 
cells are heterogeneous, with different subsets exhibiting distinct tissue homing, recirculation, and 
self-renewal properties [6]. Tissue-resident memory T cells (TRM) are a subset of memory cells 
residing in peripheral tissues, where they are the key mediators of pathogen protection in situ [10]. 
TRM provide superior protection against invading pathogens compared with circulating memory 
T cells, and TRM have also emerged as key targets for vaccination strategies [10, 116, 117]. 
Further, TRM have been specifically implicated in diseases such as psoriasis and vitiligo [121]. 
These properties make TRM attractive clinical targets; however, recent studies have demonstrated 
that TRM are highly heterogeneous, encompassing multiple unique subsets [133, 155, 168, 185, 
186]. Understanding the role of these different subsets in immune responses is therefore necessary 
before therapeutic modulation of TRM can be achieved.  
In a prior study, we identified substantial phenotypic heterogeneity within human TRM 
[186]. Indeed, phenotypic variability based on markers such as CD103 and CD49a can identify 
TRM subtypes with different functional roles [155, 168]. Additionally, TRM subsets identified by 
these markers are transcriptionally and developmentally distinct and can occupy non-overlapping 
subanatomic niches [133, 155, 168]; this suggests that the TRM compartment actually comprises 
multiple distinct subsets that are identified together based on tissue-retention properties. Recently, 
a subset of memory T cells with the ability to efflux fluorescent dyes has been reported in human 
tissues including the bone marrow [192], gut [191], and skin [230]. The ability to efflux fluorescent 
dyes is associated with increased self-renewal properties within hematopoetic stem cells [187, 
188], but the role of effluxing TRM is not well characterized. Therefore, we investigated whether 
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the ability to efflux fluorescent dyes can distinguish a functionally distinct TRM subset with 
properties of quiescence and self-renewal. 
Here, we utilized a unique human tissue resource to investigate heterogeneity of CD8+ 
TRM across multiple tissues obtained from healthy organ donors. We identify a population of 
CD8+ memory T cells in lymphoid and non-lymphoid tissues with the ability to efflux fluorescent 
mitochondrial dyes. Efflux(+) cells prenominated within the TRM compartment, where they 
expressed a canonical TRM signature including elevated CD103 and CD49a and reduced S1PR1 
expression. Further, efflux(+) TRM had reduced expression of Ki67 and exhaustion/senescence 
markers, as well as a transcriptional profile associated with increased longevity within tissues. 
Following TCR stimulation, efflux(+) TRM produced less pro-inflammatory cytokines and 
underwent less cytotoxic degranulation compared with efflux(-) TRM, but retained a greater 
capacity to proliferate. Uniquely, efflux(+) also had an enhanced capacity for IL-17 production 
along with transcriptional features of IL-17 signaling following stimulation. Together, these results 
establish TRM with the ability to efflux dyes as a functionally distinct subset, and suggest that 





Section 4.2: Results 
Memory CD8+ T cells across healthy human tissues efflux fluorescent dyes 
We sought to characterize this heterogeneity within the CD8+ memory T cell compartment 
with fluorescent dyes and surface marker phenotyping. The predominant memory (CD45RO+) 
population across human tissues is TEM-phenotype CD45RA-CCR7- [17, 156] (Figure 4.1). T 
cells isolated from healthy human tissues were labeled with either Mitotracker Green or CMXRos, 
fluorescent dyes used for mitochondrial labelling (hereafter denoted “Mito Dye”). Two distinct 
populations, Mito Dye high and low, were observed within memory CD8+ T cells across human 
tissue sites (Figure 4.2A). Equivalent results were obtained with both Mitotracker Green, which 
labels total mitochondrial mass [231], and CMXRos, which is dependent on mitochondrial 
membrane potential (Figure 4.3A), suggesting that changes in relative mitochondrial state are not 
responsible for the observed differences in dye staining. To determine whether the Mito low subset 
was due to dye efflux, we stained cells in the presence of increasing concentrations of cyclosporine 
A (CSA), a competitive inhibitor of efflux pumps [232]. Only a single Mito high population was 
observed when cells were labeled in the presence of CSA (Figure 4.2B). Further, compared with 
Mito high cells, Mito low cells expressed higher levels of MDR1 (ABCB1) (Figure 4.3B), a cell 
surface transporter that mediates efflux of fluorescent dyes and xenobiotics in hematopoietic stem 
cells [233]. Thus, the Mito low subset constitutes a population with dye efflux capacity and will 
be referred to hereafter as “efflux(+)”, with the corresponding Mito high subset being referred to 
as “efflux(-).” 
We found that the ratio of efflux(+) to efflux(-) populations differed across tissue sites, 
with the lowest frequency of efflux(+) memory T cells observed in the blood (≤40%) and the 
highest frequency observed in spleen and lung (>60%) (Figure 4.2C). To assess whether efflux(+) 
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cells specific for clinically relevant human pathogens could be detected, we analyzed 
cytomegalovirus (CMV)-specific cells with tetramers and dye labeling. Efflux(+) cells were 
detected amongst tetramer positive cells at similar ratios in multiple tissue sites (Figure 4.2D), 






Figure 4.1. Identification of Memory T cell subsets in Humans.  
Plot shows CCR7 and CD45RA expression in the spleen of one representative donor, after gating 
for CD3+ CD8+ cells. Labelling within each of the four quadrants denotes the memory T cell 




Figure 4.2. A subset of memory CD8+ T cells across human tissues effluxes fluorescent 
dyes.  
Human T cells from the indicated tissue sites were loaded with Mito Dye and analyzed by flow 
cytometry to identify memory (CCR7- CD45RA-) CD8+ T cells.  
(A) Mitotracker fluorescence within memory CD8+ T cells across healthy human tissues. Plots are 
representative of at least 3 donors per tissue site.  
(B) Cyclosporin A (CSA) inhibits Mito Dye efflux. CD8+ T cells from spleen were labeled with 
Mito Dye as in Panel A in the presence or absence of CSA at the indicated concentrations. Results 
are representative of at least 3 different donors.  
(C) Frequency of efflux(+) and efflux(-) subsets within memory CD8+ T cells across tissue sites. 
Bars indicate standard error of the mean (SEM).  
(D) A subset of CMV antigen-specific CD8+ T cells across tissues efflux dyes. Upper: Mitotracker 
fluorescence in memory CD8+ T cells from indicated tissue sites labeled with tetramer specific to 
CMV antigen. Lower: Frequency of efflux(+) cells within tetramer positive population. Results 
























Figure 4.3. Dye efflux yields populations with high and low mitochondrial fluorescence 
staining.  
(A) FACS analysis of CMXRos (upper) and Mitotracker green (lower) staining within CD8+ 
memory T cells from the spleen and lung of the same donor. Numbers within plots indicate 
percentage of total cells in the Mito dye high or low gates.  
(B) Efflux(+) populations have elevated expression of MDR1. Left: Expression of the drug efflux 
pump MDR1 by MitoDye hi (black line) and low (red line) populations. Right: quantification of 
MDR1 MFI in MitoDye hi and low memory CD8+ T cells. ***p≤0.001.  
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Tissue resident phenotype of efflux(+) CD8+ memory T cells 
Based on the finding that tissues contained high fractions of efflux(+) cells, we sought to 
determine if there was a correlation between efflux capacity and tissue residency. We measured 
the expression of CD69, a marker commonly used to identify tissue-resident memory T cells 
(TRM) in both mice [10] and humans [186], on efflux(+) and efflux(-) memory subsets in tissues. 
(Hereafter, we use TRM and TEM to refer to CD69+ and CD69- memory T cells, respectively.) 
Interestingly, while both TRM and TEM fractions contained efflux(+) cells, TRM were highly 
enriched for dye-effluxers compared with TEM in multiple human tissues (Figure 4.4A). Across 
multiple tissues and donors, 60-80% of TRM were efflux(+) and 20-40% of TRM were efflux(-) 
(Figure 4.4A). This suggests heterogeneity within TRM based on efflux status, with the majority 
of TRM being efflux(+) but a considerable fraction of efflux(-) TRM being present across donors 
and tissues.  
We further characterized the phenotype of efflux(+) cells for markers that we previously 
defined as part of a core signature of human TRM [186]. We found that TRM expressing the 
adhesion markers CD103 and CD49 were predominantly efflux(+) (Figure 4.4B-C). Further, 
efflux(+) TRM had elevated expression of CD101 (Figure 4.4C), a marker we previously identified 
on human CD8+ TRM [186] that inhibits T cell proliferation [223]. Taken together, the TRM-
associated phenotype of efflux(+) cells suggests unique adaptations to maintain residence and 
longevity within tissues.  
Given the previously described association of MAIT cells with dye efflux [189, 190], we 
sought to confirm that our observations were relevant to the diverse range of polyclonal memory 
CD8+ T cells. MAIT cells, defined by invariant expression of Vα7.2 as well as the marker CD161, 
have been detected in human liver, gut, and skin, but not in lymph nodes [168, 189], and their 
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presence in spleen has not been described. Within efflux(+) TRM, only a minor fraction were 
MAIT cells, and further these MAIT cells were largely CD103 negative (Figure 4.5). Taken 
together, these results indicate that human polyclonal CD8+ TRM comprise the majority of 




Figure 4.4. CD8+ TRM have heightened capacity for dye efflux across human tissues.  
(A) Top row: Representative plots of CD69 expression by efflux(+) (Mito low) and efflux(-) (Mito 
high) subsets of memory CD8+ T cells in the indicated tissues. Bottom row: Compiled frequency 
of efflux(+) cells within the TRM (CD69+) and TEM (CD69-) compartments of memory CD8+ T 
cells in each tissue site.  
(B) CD69+ CD103+ TRM have extensive efflux capacity. Upper: Representative plots showing 
CD103 expression amongst efflux(+) and efflux(-) TRM (CD69+) Lower: Quantification of 
efflux(+) cells amongst CD103+ and CD103- TRM (CD69+) in the spleen and lung.  
(C) Efflux(+) cells are enriched for TRM phenotypic markers. Upper: Representative plots show 
expression of CD49a and CD101 amongst efflux(+) and efflux(-) TRM (CD69+). Lower: 
Frequency of CD49a and CD101 expressing cells within efflux(+) and efflux(-) TRM. For all: 








Figure 4.5. MAIT cells are a minor subpopulation of CD69+ human memory CD8+ T cells.  
Identification of the MAIT (mucosal associated invariant T cell) populations in spleen. Tissues 
were stained to identify MAIT CD8+ T cells by CD161 and Vα7.2 TCR clonotype expression. (A) 
Plot shows CD161 and Vα7.2 expression within CD8+ TRM in the spleen of one representative 
donor.  
(B) Plots show CD103 expression within MAIT (CD161+, Vα7.2+) and polyclonal (non-MAIT) 
T cells.  
(C) Compiled frequency of MAIT T cells within CD69+ (TRM) and CD69+CD103+ memory 




Unique transcriptional characteristics of efflux(+) TRM 
Heterogeneity within human TRM has been described based on surface markers [155, 168, 
186]. Given that efflux(+) cells represent a significant subset within the TRM compartment (Figure 
4.4), we sought to characterize the significance of dye-efflux capability by TRM through whole 
transcriptome profiling by RNA sequencing (RNA-Seq). Efflux(+) and efflux(-) CD8+ TRM 
(CD69+CD45RA-CCR7-) were isolated by FACS sorting from the spleen of 3 previously healthy 
organ donors (aged 32, 32, 59) and samples were sent for RNA-Seq at the Columbia Genome 
Center. (See Table 4.1 for RNA-Seq QC summary.) Principal-component analysis (PCA) revealed 
that efflux(+) TRM were transcriptionally distinct from efflux(-) TRM (Figure 4.6A). While 
differences along the first principal component could be attributed to donor variation, consistent 
differences between efflux(+) and efflux(-) were seen on the second principal component 
accounting for 21% of the variation in gene expression (Figure 4.6A). This suggests unique 
transcriptional properties of efflux(+) TRM that are maintained across diverse donors.  
Differential expression was assessed using DESeq2 [202], and after applying criteria for 
significance (false discovery rate [FDR] ≤ 0.05 and absolute value of log2 fold change > 1), 133 
differential expressed genes were detected when comparing efflux(+) and efflux(-) TRM (Figure 
4.6B). Notably, this number was smaller than the 300-400 differentially expressed genes we 
previously reported when comparing the TRM subset to the TEM subset in human tissues [186]. 
Expression levels of these genes within efflux(+) TRM were consistent across all three donors 
(Figure 4.6D), suggesting that these represent invariant properties of the efflux(+) TRM subset.  
To interpret the biological significance of these differentially expressed genes, we used 
DAVID online functional annotation analysis [204, 205]. Notably, the pathway with the greatest 
enrichment within our gene set was phospholipid translocation (Figure 4.6C), consistent with the 
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ability of efflux(+) TRM to efflux fluorescent dyes. DAVID analysis further revealed that the 
genes differentially expressed by efflux(+) TRM were implicated in the regulation of key T cell 
pathways controlling function, cytokine responses, and adhesion and migration (Figure 4.6C-D). 
Additionally, pathways involved in regulating proliferation were also enriched with significant 
values (data not shown), although these were not among the top 10 enriched pathways.  
TRM exhibit unique adhesion and migration properties, and pathways involved in 
chemotaxis and cell adhesion were among the top enriched pathways (Figure 4.6C). Consistent 
with the observed differences in CD49a and CD103 expression (Figure 4.4), efflux(+) cells had 
increased expression of the genes ITGAE (encoding CD103) and ITGA1 (encoding CD49a), as 
well as NCAM1, MCAM1, CDH4, and ANK1. Efflux(+) cells also had elevated LAYN expression, 
a receptor for hyaluronic acid in the extracellular matrix, recently associated with Tregs and CD8+ 
T cell inhibition [234]. Efflux(+) TRM also exhibited differential expression of a number of 
homing receptors (Figure 4.6E). Notably, efflux(+) TRM had reduced expression of S1PR1, the 
downregulation of which is required for CD8+ TRM differentiation in mice [139], and whose 
downregulation by human TRM has also been established [142, 186]. Together with increased 
expression of canonical TRM markers such CD49a and CD103, these results suggests that 
efflux(+) TRM may have an enhanced capacity for tissue residency compared with their efflux(-) 
counterparts. Efflux(+) TRM additionally upregulated CCR9, CCR1, and CCR6, and 
downregulated CCR4 and CCR8 compared with efflux(-) TRM, which could promote differential 
migratory properties between these subsets.  
We observed differential expression of key transcription factors by efflux(+) and efflux(-) 
TRM (Figure 4.6E), indicative of distinct functional and regulatory pathways in these two subsets. 
Efflux(+) TRM had increased expression of TLE1 (Figure 4.6E), a transcriptional regulator 
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associated with Notch/RBPJ signaling [235], a pathway essential for TRM formation (Hombrink 
et al., 2016). Notably, efflux(+) cells had elevated RORC and RORA expression (Figure 4.6E), two 
transcription factors that drive Tc17-type responses in CD8+ T cells [236]. Consistent with an 
increased capacity for Type 17 responses, efflux(+) cells expressed high levels of IL17A, as well 
as IL23 and IL17 receptors (Figure 4.6E), two critical regulators of Type 17 responses. Efflux(+) 
TRM also upregulated the adhesion marker MCAM1 (Figure 4.6E), which has been associated 
with IL17-producing Tc17 CD8+ T cells [237]. 
Analysis of genes associated with cell cycle and apoptosis control suggested increased 
quiescence and longevity of efflux(+) TRM compared with efflux(-) TRM. Notably, efflux(+) 
expressed lower levels of ZNF365 (Figure 4.6E), encoding a zinc finger protein involved in 
genome replication and mitotic progression, previously found to be highly expressed by circulating 
TEM compared with CD103+ TRM [142, 238]. Elevated levels of CD101, SPRY1, and SPRY2, 
genes with documented roles in suppressing T cell proliferation and TCR-mediated calcium 
signaling [223, 239], coupled with reduced levels of Cyclin B2 (CCNB2), further reinforced that 
efflux(+) may persist in a quiescent state.  
In addition to differential expression of a number genes involved in T cell function, 
efflux(+) cells expressed higher levels of the newly described, human-specific CD28 analogue 
TMIGD2 (CD28H) [240], as well as higher levels of CD9, which also delivers costimulatory 
signals for T cell activation [241, 242] (Figure 4.6E). These data, coupled with lower expression 
of genes encoding inhibitory receptors PDCD1 and CTLA4 (Figure 4.6E), suggest that efflux(+) 
TRM show less evidence of senescence and exhaustion and thus may respond differentially to 
TCR stimulation during TRM re-activation.  
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A number of nutrient, ion, and xenobiotic transporters were expressed at higher levels in 
efflux(+) TRM, which could be important for homeostasis in barrier tissues and promote longevity 
via efflux of toxins and waste products and/or import of nutrients (Figure 4.6E). Additionally, 
consistent with reduced CTLA4 and PDCD1 expression, efflux(+) TRM had lower expression of 
a number of genes encoding MHC class II molecules (Figure 4.7), which mark recent T cell 
activation [243], further suggesting that efflux(+) TRM are resting within tissues. Finally, 
efflux(+) TRM upregulated genes encoding killer cell lectin-like receptors (Figure 4.7), which 
modulate T cell activation [244]. Overall, these data indicate that efflux(+) TRM have a unique 
transcriptional program that promotes quiescence and longevity within tissues, comprised of genes 




Table 4.1. RNA-Seq QC Summary  
Donor Efflux Status Stimulation Number of Reads Mapped Reads Mapping Ratio Mapped Reads Exome
1 + - 47115590 44261623 93.94% 31724353
1 - - 48910042 45861860 93.77% 33954253
2 + - 50373890 47168098 93.64% 31752401
2 - - 47420384 44770755 94.41% 31054564
3 + - 26035498 24508180 94.13% 17898923
3 - - 25419455 23766652 93.50% 16902512
1 + + 31011637 29086355 93.79% 21959690
1 - + 28933389 27136830 93.79% 20289527
2 + + 26957605 25228879 93.59% 19680387
2 - + 23111752 21714831 93.96% 16286040
3 + + 22326495 21026323 94.18% 16081927
3 - + 23048327 21621291 93.81% 15904273
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Figure 4.6. Efflux(+) TRM have unique transcriptional properties.  
Whole transcriptome profiling by RNA sequencing was performed on efflux(+) and efflux(-) TRM 
from the spleen of 3 donors.  
(A) PCA of efflux(+) and efflux(-) TRM samples, based on the global transcriptome.  
(B) Differential expression assessed by DESEQ2. The number of genes with significant different 
expression is displayed, with the number of genes upregulated in efflux(+) displayed in black, and 
the number of genes downregulated in efflux(+) TRM shown in white.  
(C) Functional annotation analysis by DAVID online software. Select gene ontology (GO) terms 
with significant adjusted p-Values (adj. p) are displayed, along with fold enrichment. 
Directionality of pathways was not assessed.  
(D) Heatmap shows normalized expression levels of all genes with significant differential 
expression, as assessed in B.  
(E) Log2 fold changes of select genes when comparing expression in efflux(+) TRM to efflux(-) 
TRM. Genes are grouped into categories, as indicated by the bold text to the left of each plot. Data 






Figure 4.7. Fold Changes of Additional Gene Categories.  
Log2 fold changes when comparing expression in efflux(+) TRM to efflux(-) TRM of additional 
genes not displayed in Figure 4.6. Genes are grouped into categories, as indicated by the bold text 
to the left of each plot. Data from each donor is indicated by a unique shape throughout the plots, 




Efflux(+) TRM Exhibit a Resting Phenotype  
We next sought to validate differences observed at the transcriptional level through flow 
cytometric analysis of steady state efflux(+) and efflux(-) subsets, in particular of markers related 
to turnover, history of TCR activation and cytokine responses, and functional costimulation. We 
also determined expression of these markers on TEM to determine if efflux status is associated 
with unique properties exclusively within TRM or across memory subsets. We first measured the 
expression of CD127 (IL-7 receptor). IL-7 is critical for memory T cell homeostasis [245], and 
expression of CD127 delineates memory T cells capable of responding to IL-7 from those with a 
prior history of IL-7 responses in human tissues [156]. Efflux(+) TRM had elevated CD127 
expression compared with efflux(-) TRM (Figure 4.8A), while TEM efflux(+) and efflux(-) cells 
had similar, lower levels of CD127, suggesting that efflux(+) TRM have elevated capacity for 
cytokine responses. We then assessed the expression of the co-receptors CD27 and CD28, which 
are downregulated following TCR stimulation. Within the TRM compartment, efflux(+) TRM had 
a reduced frequency of CD27+ and CD28+ cells compared with efflux(-) TRM (Figure 4.9). 
However, dye efflux did not correlate with CD27 or CD28 downregulation for conventional TEM 
(Figure 4.9). 
To confirm the quiescent cell cycle transcriptional profile we observed in RNA-Seq 
analysis, we analyzed expression of CD57, a marker of replicative senescence and cytotoxicity 
[246], and Ki67, a marker associated with cellular proliferation. TEM globally expressed more 
CD57 than TRM, as previously documented (Figure 4.8B) [142, 186]. We found that efflux(+) 
TRM and TEM both had significantly lower expression of CD57 compared with their efflux(-) 
counterparts, though for TEM, the difference was only significant in the lung (Figure 4.8B). 
Further, efflux(+) TRM cells expressed lower levels of Ki67 compared with efflux(-) TRM (Figure 
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4.8C). This lower proliferative rate was also evident in the efflux(+) TEM subset (Figure 4.8C). 
These data suggest that efflux(+) subsets are less proliferative at steady-state compared with 
efflux(-) subsets. 
Based on the result that efflux(+) TRM have differential expression of a number of genes 
encoding exhaustion and inhibitory markers, we measured the expression of PD-1 and CTLA-4. 
In the lung, spleen and bone marrow, efflux(+) TRM expressed lower levels of PD-1 than efflux(-
) TRM from the same tissue (Figure 4.8D). Amongst splenic TRM, efflux(+) cells had lower 
CTLA4 expression compared with efflux(-) TRM (Figure 4.9C). Finally, efflux(+) TRM also 
expressed lower levels of the activation marker HLA-DR (Figure 4.9D).  
Alongside canonical Foxp3+ CD4+ T regulatory cells, regulatory CD8+ T cells have also 
been described in humans [247], including one subset that expresses CD39 [248, 249], an 
ectonucleotidase that catalyzes the production of immunosuppressive adenosine and promotes T 
cell anti-inflammatory function [250, 251]. We found that CD39 was expressed almost exclusively 
by efflux(+) TRM, and further that CD39 expressing efflux(+) TRM were almost all CD103+ 
(Figure 4.8E). These findings suggest that a subset of efflux(+) TRM could have additional 
immunomodulatory functions, and are consistent with CD101 upregulation by efflux(+) TRM 
(Figure 4.4). 
Taken together, these phenotypic differences, coupled with the efflux(+) transcriptome, 
establishes efflux(+) TRM as a resting subset with less evidence of exhaustion within tissues that 
retains the ability to respond to cytokine signaling. Further, although some differences were 
observed between TEM subsets, larger, more consistent differences were found in efflux(+) and 
efflux(-) TRM, indicating that efflux status delineates a distinct subset primarily within the TRM 
fraction.    
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Figure 4.8. Efflux(+) TRM exhibit a resting phenotype at steady-state. 
(A) Left: Histograms of CD127 expression by TRM and TEM subsets from the spleen of one 
representative donor. Right: Compiled frequencies of CD127 efflux(+) and efflux(-) subsets of 
TEM and TRM from bone marrow (BM) and spleen.  
(B) Left: Histograms of CD57 expression by efflux(+) and efflux(-) TRM and TEM subsets from 
the spleen of one representative donor. Right: Compiled frequencies of CD57+ TRM and TEM 
from spleen, lung, and bone marrow.  
(C) Left: Expression of Ki67 within TRM and TEM subsets from the spleen of one representative 
donor. Right: Frequency of Ki67+ cells in efflux(+) and efflux(-) TRM and TEM  
(D) Left: Expression of PD-1 by TRM and TEM subsets from the spleen of one representative 
donor. Right: Compiled expression of PD-1 in efflux(+) and efflux(-) TRM and TEM from 
different tissue sites.  
(E) Left: Expression of ectonucleotidase CD39 by splenic TRM and TEM subsets from one 
representative donor. Middle: Representative plot of CD39 and CD103 expression within TRM. 
Right: Compiled expression of CD39 in efflux(+) and efflux(-) TRM and TEM from spleen. 






Figure 4.9. Additional phenotypic analysis of efflux(+) CD8+ TRM.  
(A-B) TCR stimulation history assessed by costimulatory receptor downregulation. Left: 
Representative histograms of CD27 (A) and CD28 (B) expression in splenic CD8+ TRM. Right: 
Compiled frequencies of CD27+ (A) and CD28+ (B) cells within efflux(+) and efflux(-) subsets. 
(C) Left: Expression of CTLA-4 by TRM and TEM subsets from the spleen of one representative 
donor. Right: Compiled expression of CTLA-4 in efflux(+) and efflux(-) TRM and TEM.  
(D) Left: HLA-DR expression by efflux(+) and efflux(-) TRM and TEM from spleen. Right: 
Compiled HLA-DR expression by efflux(+) and efflux(-) TRM. *p≤0.05, ***p≤0.001, n.s. not 




























The Transcriptional Response of TRM to TCR stimulation 
A number of the genes differentially expressed by efflux(+) TRM at steady-state are closely 
linked to T cell function (Figure 4.6); therefore, to investigate the unique functional properties of 
efflux(+) TRM, we performed RNA-Seq after TCR stimulation. However, the transcriptional 
response of TRM as a whole to stimulation is not well-characterized. Therefore, we first analyzed 
how TRM respond transcriptionally to short-term 12-hour TCR stimulation before analyzing the 
individual response of efflux(+) TRM. 
Applying the criteria for significance we found 1139 genes to be differentially expressed 
between stimulated and unstimulated TRM, with these genes showing consistent expression 
differences across donors (Figure 4.10A-B). Interestingly, more genes were downregulated (789 
genes) than were upregulated (340 genes) following stimulation (Figure 4.10A-B). Notably, the 
number of differentially expressed genes is several fold higher than even the number of genes 
differentially expressed between memory and naïve T cell subsets [252] or the number genes 
differentially expressed between TRM and TEM in humans (Figure 4.10C) [186]. These data 
suggest that TRM are poised for a robust transcriptional response to stimulation on time scales as 
short as 12 hours.  
The magnitude of the transcriptional response to stimulation raises the question is whether 
TRM lose TRM-like properties after stimulation, and in particular those properties which allow 
for tissue retention. To address this, we compared the genes that were differentially expressed 
following stimulations (from our current dataset) to the genes that are differentially expressed 
between TRM and TEM (using our previously published dataset in [186]). Interestingly, very few 
genes overlapped between these two datasets (Figure 4.10C), implying that transcriptional changes 
following stimulation are unrelated to the genes that define the TRM subset. Of the TRM defining 
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genes that changed following stimulation, the majority changed in a direction such that their 
expression moved farther away from TEM (Figure 4.10C), suggesting that if anything the TRM 
transcriptional program was further reinforced during stimulation. TRM are characterized by low 
expression of the homing receptors S1PR1 and CCR7 and reduced expression of the associated 
transcription factor KLF2, which together help TRM avoid egress cues [10, 139]. Following 
stimulation, CD8+ TRM further downregulated these genes (Figure 4.10D), implying that the 
migratory program of TRM is reinforced to allow these cells to carry out functions in situ. Taken 
together, these results suggest that while TRM undergo large transcriptional changes upon 
activation, these cells remain TRM and do not losing defining features of the subset.  
Pathway analysis was done to interpret the biological significance of the transcriptional 
changes after stimulation. There was significant enrichment of pathways controlling cytokine 
responses, regulation of cell cycle/proliferation, and metabolism (Figure 4.10E), with the Sirtuin 
Signaling Pathway emerging as the top result (Figure 4.10E). Sirtuins are a family of NAD(+)-
dependent protein deacylases that sense the cellular metabolic state and have critical roles in 
controlling metabolism, stress responses, and cell cycle progession/apoptosis [253]. The induction 
of cell cycle and metabolism-related pathways are indicative of a global remodeling of TRM 
homeostatic programs following TCR stimulation. Other genes related to T cell function and 
cytokine signaling were also differentially expressed following stimulation (Figure 4.10F), 
including a number of a proinflammatory cytokines (IL17F, LTA (lymphotoxin alpha), and IL13) 
and the cytotoxic molecule GZMB (encoding granzyme B). TRM also upregulated a number of 
chemokines, consistent with their reported functions of recruiting leukocytes to the site of infection 




Figure 4.10. The transcriptional response of TRM to stimulation.  
(A) Bar graph shows number differentially expressed (DE) genes when comparing unstimulated 
TRM with stimulated TRM. Genes upregulated after stimulation are displayed in black, and genes 
downregulated after stimulation are shown in white.  
(B) Heatmap shows normalized expression of all 1129 differentially expressed genes, as assessed 
in A.  
(C) TRM characteristics are preserved after stimulation. Venn diagram shows overlap between 
genes that are differentially expression when comparing stimulated vs. unstimulated TRM (current 
dataset) and genes that are differentially expressed when comparing human spleen CD8+ TRM and 
TEM (from Kumar et al., 2017). Pie chart on the right displays proportion of the overlapping genes 
that change in the same direction comparing stimulated vs. unstimulated TRM and when 
comparing human spleen CD8+ TRM and TEM.  
(D) TRM downregulate egress receptors after stimulation. Plot shows log2 fold changes of CCR7, 
S1PR1, and KLF2 when comparing stimulated vs. unstimulated TRM samples.  
(E) IPA analysis. Select pathways that had significant p-values (≤0.01) are displayed. Direction of 
enrichment in stimulated samples is proportional to the color intensity of each bar. (F) Log2 fold 
changes of select genes related to T cell function when comparing stimulated vs unstimulated TRM 








Transcriptional Response of efflux(+) TRM following TCR stimulation 
To determine the contribution of efflux(+) and efflux(-) subsets to the TRM, we compared 
the gene expression profile of both of these subsets before and after TCR stimulation. Again, 
stimulated samples were transcriptionally distinct from unstimulated samples in all donors, for 
both efflux(+) and efflux(-) subsets (Figure 4.11A). Further, consistent with our steady state 
analysis (Figure 4.10), the transcriptional difference between stimulated and unstimulated samples 
was greater than the difference between efflux(+) and efflux(-) subsets, such that these two subsets 
were more transcriptionally similar to each other following stimulation than to their unstimulated 
precursors (Figure 4.11A). When comparing stimulated with unstimulated samples, 487 and 865 
genes had significant differential expression in efflux(-) and efflux(+) subsets, respectively (Figure 
4.11B). We then examined these genes to determine which, if any, were unique to the response of 
either subset. Interestingly, the majority of genes that showed differential expression between 
stimulated and unstimulated samples in either efflux(-) and efflux(+) subsets had a similar 
directionality and magnitude of fold change in the other subset, even if the threshold for 
significance was not met (Figure 4.11C). This suggested that the transcriptional response to 
stimulation was largely similar between the two subsets, a conclusion that is also supported by 
PCA analysis (Figure 4.11A). However, a several genes with significant changes in expression 
exhibited divergent upregulation/downregulation (Figure 4.11D). Of note, efflux(+), but not 
efflux(-), TRM upregulated expression of ITGB8, an integrin critical for local activation of latent 
TGF-β complexes on Tregs [254]. Efflux(+) TRM also upregulated expression of TACR1, 
encoding neurokinin-1-R, the receptor for substance P, a neuropeptide with a role in Type 17 
responses that is potentiated by TGF-β signaling [255]. Taken together, these results implicate 
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TGF-β signaling and Type 17 responses as a critical node for function TRM that may be 
differentially regulated by efflux(+)/efflux(-) subsets. 
We performed IPA analysis to identify pathways that were enriched when comparing 
stimulated and unstimulated samples, and stratified to identify those that were significant in either 
the efflux(+) or efflux(-) subset but not the other, or significant in both but having opposite 
directional changes (Figure 4.11E). TCR stimulation selectively induced AhR signaling in 
efflux(+) TRM, a pathway that integrates signals from environmental metabolites and regulates 
Th17 and Treg-type responses [256, 257]. Crucially, AhR expression is also required for 
persistence and survival of skin TRM [152]. Consistent with a role in conventional Type 1 
responses, efflux(-) cells responded to TCR stimulation with elevated inflammatory HMGB1 
signaling [258]. Interestingly, integrin signaling was significantly downregulated in efflux(-) TRM 
following stimulation (Figure 4.11E), suggesting a loss of certain adhesion properties that could 
facilitate re- entry into circulation or increased tissue mobility. Finally, a number of pathways 
related to cell cycle/proliferation as well as mitochondrial metabolism diverged following 
stimulation (Figure 4.11E), consistent with distinct proliferative and metabolic responses to 
stimulation. Taken together, these results indicate that although efflux(+) and efflux(-) TRM 
exhibit overlapping features to TCR stimulation, key differences in pathways related to the nature 
of the T cell response, including AhR, integrin, and Th17 signaling could mediate unique, non-




Figure 4.11. Dissecting the transcriptional response to stimulation by efflux status.  
(A) PCA of efflux(+) and efflux(-) TRM from the spleen of 3 donors, based on the global 
transcriptome.  
(B) Differential expression assessed by DESEQ2. Bar graph shows number of differentially 
expressed (DE) genes when comparing unstimulated and stimulated samples for both efflux(+) 
and efflux(-) TRM, as indicated.  
(C) Scatterplot displays all genes found to have significant differential expression in stimulated vs 
unstimulated samples as in part B. Value on the X axis represents the log2 fold change of the gene 
between stimulated vs unstimulated efflux(+) samples, and the Y axis represents the log2 fold 
change of the same gene between stimulated vs unstimulated efflux(-) samples. Samples are color-
coded by whether the differential expression was significant in efflux(+) TRM, efflux(-) TRM, or 
both.  
(D) Log2 fold changes of select genes when comparing expression stimulated vs. unstimulated 
samples, for both efflux(+) and efflux(-) TRM. Genes were selected by taking all of the genes in 
part C that has opposite direction changes for efflux(+) and efflux(-) samples after stimulation.  
(E) Pathway analysis of the response to stimulation in efflux(+) and efflux(-) TRM. Genes that 
were differentially expressed between stimulated vs. unstimulated samples were uploaded to IPA, 
for both efflux(+) and efflux(-) TRM. Bar graph displays select pathways that were significant in 








Distinct functional profile of efflux(+) TRM 
Differential expression of key genes involved in the cell cycle and Ki67 protein suggested 
distinct proliferative capacities of efflux(+) and efflux(-) TRM. We sorted efflux(+) and efflux(-) 
TRM and then labeled with cell proliferation dye to monitor cell division following TCR 
stimulation. Efflux(+) memory cells were highly proliferative, and a majority underwent >4 
divisions by day 4 post-stimulation (Figure 4.12A). Conversely, efflux(-) cells proliferated 
markedly less, with a large portion undergoing no divisions. TCR stimulation induces metabolic 
reprogramming and expression of key transcription factors such as IRF4 that regulate proliferation 
and effector cell differentiation [77-79]. Indeed, following TCR stimulation, both efflux(+) and 
efflux(-) TRM that proliferated expressed heightened levels of IRF4 (Figure 4.12B). However, 
while both TRM subsets upregulated IRF4, efflux(-) cells exhibited higher levels of the 
transcription factor across cell divisions compared with efflux(+) TRM. As IRF4 is associated with 
effector function, these results suggest that efflux(-) TRM may have heightened effector function 
following TCR stimulation. 
In the skin, reciprocal expression of CCR6 and CD49a defines subsets of CD8+ TRM with 
heightened production of the inflammatory cytokine IL-17 or elevated cytotoxic potential, 
respectively [168]. We next assessed the capacity of efflux(+) and efflux(-) TRM to producing key 
cytokines following TCR stimulation. Efflux(+) and efflux(-) TRM were sorted from splenocytes 
and stimulated with anti-CD3/CD28/CD2 beads for 48 hours. Supernatants were then harvested 
and assayed for cytokine production (Figure 4.12C). Efflux(-) TRM produced more inflammatory 
cytokines including IFN-γ and TNF-α, as well as autocrine IL-2. Conversely, efflux(+) TRM 
produced more IL-17. Interestingly, levels of IL-10 production were comparable between the two 
subsets (Figure 4.12C). High levels of IFN-γ and TNF-α production suggested that efflux(-) TRM 
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are primed for activation at steady state. We next assessed the cytotoxicity of TRM subsets as 
measured by degranulation following PMA/ionomycin stimulation. Efflux(-) TRM exhibited a 
markedly higher rate of degranulation indicated by retention of CD107a (LAMP1) fluorescence 
compared to efflux(+) TRM (Figure 4.12D). Both efflux(+) and efflux(-) TEM exhibited 
equivalent, high levels of degranulation. Thus, efflux(+) TRM have a lower cytotoxic potential as 
well as decreased proinflammatory cytokine production. 
T-box transcription factors, including T-bet and Eomes, regulate cytotoxicity and cytokine 
production, memory formation, and TRM development in CD8+ T cells [73] [106]. We assessed 
the expression of Eomes and T-bet in TRM and TEM efflux(+) subsets at steady state. While TEM 
subsets expressed comparable amounts of Eomes, efflux(-) TRM expressed higher levels of this 
transcription factor (Figure 4.13). Although TRM expressed distinctly less T-bet than TEM, we 
observed no significant difference between the efflux(+) and efflux(-) subsets (Figure 4.13). These 
results, along with our RNA-Seq analysis, suggest that dye efflux defines a transcriptionally 
distinct subset of TRM.  
As efflux(+) TRM exhibit evidence of quiescence, we sought to determine whether 
heightened responses to IL-7 correlated with this functional profile. We sorted efflux(+) and 
efflux(-) TRM and then stimulated with IL-7 ex vivo before assessing phosphorylation of the 
transcription factor STAT5, a key effector of IL-7 signals [245]. We found that efflux(+) but not 
efflux(-) TRM responded to IL-7 with potent STAT5 phosphorylation, suggesting an increased 




Figure 4.12. Dye efflux marks functionally distinct subsets of TRM.  
(A-B) Proliferative capacity of TRM subsets. Sorted efflux(+) and efflux(-) TRM were labeled 
with cell proliferation dye and stimulated with anti-CD3/CD28/CD2 beads. Proliferation was 
assessed on day 4 of culture. (A) Left: Histogram showing cell proliferation dye dilution at day 4. 
Results are representative of 4 independent experiments. Middle: Quantification of the percent of 
proliferating cells. Right: Quantification of the percent of proliferating cells at each division 
number. *p≤0.05. **p≤0.01 ****p≤0.0001. Two way ANOVA with Sidak’s multiple comparisons 
test. (B) Heightened IRF4 induction in efflux(-) TRM following TCR-stimulation. Left: Plots show 
cell proliferation dye dilution and IRF4 expression at day 4. Rectangular gate identifies activated, 
proliferating cells that have upregulated IRF4. Plots are representative of 3 independent 
experiments. Middle: Histogram shows IRF4 expression within proliferating cells from efflux(+) 
and efflux(-) subsets. Right: Quantification of IRF4 MFI amongst activated proliferating cells. 
(C) Cytokine production following TCR stimulation. Efflux(+) and efflux(-) TRM were sorted and 
stimulated with anti-CD3/CD28/CD2 beads for 72 hours, and cytokines in supernatant were 
quantified using BD CBA.  
(D) Cytotoxicity of efflux(+) and efflux(-) TRM subsets. Sorted cells were pulse labeled with 
CD107a antibody followed by PMA/ionomycin stimulation and flow cytometry analysis. 
Representative plots and quantification of CD107a+ cells within the indicated populations.  
(E) Efflux(+) TRM exhibit increased responses to IL-7. Left: representative histogram of STAT5 
phosphorylation following IL-7 stimulation ex vivo. Right: Quantification of %pSTAT5 positive 
cells amongst efflux(+) and efflux(-) TRM. *p≤0.05. **p≤0.01. ****p≤0.0001. n.s. not significant. 






Figure 4.13. T-bet and Eomes expression  
(A) Left: Histograms of Eomes expression by efflux(+) and efflux(-) TRM subsets from the spleen 
of one representative donor. Right: Quantification of Eomes MFI in indicated TRM/TEM subsets. 
*p≤0.05.  
(B) Left: T-bet expression in efflux(+) and efflux(-)TRM subsets from the spleen of one 





Section 4.3: Discussion 
Subsets of memory T cells cooperate to maintain life-long immunity and exhibit unique 
functional, regulatory, and homing properties. Using healthy primary human tissues, we provide 
evidence for functional heterogeneity within the CD8+ TRM compartment. These subsets were 
identified by their differential capacity to efflux fluorescent dyes and could be readily extracted 
and sorted from a variety of tissues for downstream application. Critically, efflux(+) and efflux(-) 
subsets were functionally distinct, exhibiting key differences both at steady-state and following 
TCR stimulation. Efflux(+) cells differentially express transcription factors related to Type 1 and 
Type 17 inflammatory responses, including Eomes, RORC, and RORA, indicating that key 
regulators of lymphocyte cell fate decisions may also program distinct subsets of TRM. These 
TRM subsets also exhibited a reciprocal capacity for IFN-γ/TNF or IL-17 cytokine production as 
well as differential propensity toward degranulation. Given potential differences in TRM 
localization, this stratification of function suggests that TRM may be programed toward distinct 
localized responses tailored to specific pathogens in situ.   
It is unclear if efflux(+) and efflux(-) subsets can interconvert during physiological 
homeostasis and immune responses. Efflux(+) cells retain a higher proliferative potential 
following TCR stimulation and may constitute a resting pool of cells that repopulates the more 
effector-like efflux(-) subset to promote strong Type 1 inflammatory responses. In support of this, 
efflux(+) TRM had transcriptional and phenotypic features of quiescence and longevity, including 
expression of the immunomodulatory receptors CD39 and CD101, reduced expression of 
activation and exhaustion markers, and expression of genes involved in cell cycle control; 
efflux(+) TRM also exhibited increased responses to IL-7. Nevertheless, our results demonstrate 
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that a portion of TRM are not fully terminally differentiated and can undergo substantial 
proliferation during re-activation.  
The stratification of function between TRM subsets suggests that cooperation may mediate 
complete immunity. Specifically, efflux(-) TRM may be primarily responsible for IFN-/TNF 
secretion and cytotoxic functions, while efflux(+) TRM may mediate Type 17 inflammation and 
serve as a proliferative reservoir to replenish the TRM compartment. However, transcriptional data 
also indicates substantial overlapping functions between the subsets, suggesting a model in which 
certain functions, e.g. IL-10 production, are universal properties of TRM, while others are 
primarily mediated by a specific TRM subset. The division of labor between TRM subsets may 
also be driven by subanatomic differences, as suggested by distinct adhesion molecule and 
migratory receptor expression. Further studies will be necessary to fully determine how TRM 
subsets cooperate to achieve full immunity.  
Our analysis of transcriptional responses to TCR stimulation have implications for TRM 
biology as a whole. TRM preserve their core profile while undergoing a massive and rapid 
transcriptional response to TCR stimulation. In fact, TRM further downregulated already low 
levels of egress receptors like S1PR1 and CCR7, suggesting a reinforcement of tissue retention 
properties to enforce in situ responses to stimulation. Overall, these properties establish TRM as a 
subset designed for rapid response to pathogens and whose function is exclusively meant to be 
carried out within the tissue.  
Efflux pumps expel of toxic xenobiotics from the cell interior and have been implicated in 
the persistence of human lymphocytes during chemotherapy [190]. TRM persist in peripheral 
tissue sites for years or even decades, where they are exposed to a range of foreign agents, 
particularly in sites such as skin and lung. Given our data that efflux(+) TRM show evidence 
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quiescence and longevity, heightened expression of functional drug efflux pumps could be crucial 
for TRM survival and homeostasis in these peripheral tissues. Furthermore, this trait also presents 
the possibility of therapies that specifically target efflux(+) TRM, as efflux capacity may mediate 
differential susceptibility to chemotherapy and drug treatments [259]. Given that efflux(+) TRM 
exhibit increased IL-17 production as well as Th17-associated signaling, specifically targeting 
efflux(+) cells in psoriasis might be an optimal therapy that spares protective TRM while 
eliminating pathogenic TRM. Previously, there has been interest in the possibility of “targeted” 
immune therapies that specifically modulate either TRM or circulatory T cells while leaving other 
aspects of the immune system undisturbed [121]. Our data suggest that this specificity can be taken 
further to target specific TRM subsets. Overall, the identification of these distinct subsets could be 
leveraged toward next generation therapies for infection, cancer, and autoimmunity.  
167 
 
CHAPTER 5: Conclusions 
Defining Core Properties of Human TRM 
Tissue resident memory T cells (TRM) have been the subject of intense research recently 
due to a number of reports that these cells offer superior protection compared with other memory 
subsets [10, 102]. TRM are generated in response to infection at many tissue sites, from which 
they do not recirculate and remain poised to mediate rapid pathogen clearance [10, 102]. In fact, 
upon secondary infection TRM are able to clear pathogens without any contribution from 
circulatory T cells or antibodies. Protective TRM have also been generated in response to 
vaccination [116, 117], suggesting an immunization strategy to protect against pathogens for 
which traditional antibody based vaccines have failed. Finally, TRM have been implicated as the 
drivers of many human illnesses, particularly skin diseases like psoriasis and mycosis fungoides 
[121].  
While these properties make TRM an attractive target for clinical modulation, many gaps 
exist in our knowledge of human TRM. While TRM have been identified in human tissues, the 
majority of studies characterizing TRM have been performed in mice. In particular, unifying 
properties of TRM in humans have not been determined, largely due to the difficulty of obtaining 
human tissues. Reliable phenotypic markers of TRM in humans have not been established, and it 
is not known which phenotypic properties allow TRM to maintain tissue retention in humans. The 
defining transcriptional and functional characteristics that separate TRM from other memory 
subsets in humans is not known, as well as how these properties vary for CD4+ and CD8+ TRM 
and for TRM from different tissues. Finally, the majority of studies in both mice and humans focus 
on CD8+ TRM, meaning that little is known about CD4+ TRM in humans.  
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To address these knowledge gaps, the goal of my current research was to define universal 
signatures of human TRM and to investigate heterogeneity within human TRM. As TRM are not 
found in blood, a major barrier to progress in the field has been access to human tissues. Via a 
novel collaboration with LiveOnNY, the local organ procurement agency, our laboratory is able 
to obtain >15 tissues from healthy organ donors of all ages. Investigation of blood and 8 additional 
tissue sites including barrier (lung, intestine), lymphoid (spleen, tonsils, multiple lymph nodes), 
and exocrine (salivary glands) revealed that CD69 was expressed by CD4+ and CD8+ memory T 
cells in tissues but not in blood. CD103 expression, however, was limited primarily to CD8+ 
memory T cells in barrier tissues. A number of other recent studies examining memory T cells in 
human tissues have confirmed this distribution of CD69 and CD103 expression [14, 157, 158, 163, 
164, 185, 260-262]. Coupled with the result that CD69+ cells did not show features of activation, 
these data establish CD69 as the primary marker distinguishing circulatory from tissue memory T 
cells.  
We performed transcriptional, phenotypic, and functional analysis to determine if CD69 
identifies TRM in humans and to establish core properties of the TRM subset. RNA-Seq analysis 
revealed that CD69+ memory T cells from tissues shared key transcriptional homologies to mouse 
TRM and were transcriptionally distinct from CD69- memory T cells. Further, CD69- memory T 
cells from tissues were transcriptionally similar to memory T cells found in the blood, suggesting 
that the CD69- in tissues represented circulatory cells. Finally, CD69+ memory T cells expressed 
many canonical TRM features, including transcriptional downregulation of S1PR1 and KLF2 and 
elevated surface expression of CD49a. Taken together, these results suggest that CD69 expression 
reliably distinguishes resident from circulatory memory T cells in human tissues.  
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We analyzed transcriptional data from TRM and TEM subsets from spleen, lung, and blood 
to establish a core signature of 31 genes that defined human TRM for both CD4+ and CD8+ subsets 
across tissues. Notably, this core signature was also preserved when examining transcriptional data 
from mouse studies, suggesting that it represented universal properties of the TRM subset. This 
core signature included differential expression of genes that controlled adhesion and migration, 
which may promote tissue retention, genes involved in T cell function, and finally a number of 
genes involved in inhibition of T cell function or control of proliferation. We confirmed the 
expression of many of these at the protein level via flow cytometry. Interestingly, TRM had 
elevated expression of PD-1, reduced turnover as measured by Ki67, and an enhanced ability to 
produce IL-10 compared with TEM. Notably, another recent study comparing CD8+CD103+ lung 
TRM to blood TEM similarly found that TRM upregulate transcripts encoding TNF, IFN-, and 
granzyme B [142], while simultaneously expressing high levels of PD-1, LAG-3, and CTLA-4. 
Anoher study from the same group examining CD4+ TRM from human lung also found similar 
results [263]. We propose that these dual protective and regulatory capabilities are critical for long 
term maintenance; TRM exist in a quiescent state to promote longevity, have anti-
inflammatory/regulatory function to prevent unnecessary activation and tissue damage, but also 
retain the ability to respond quickly upon pathogen invasion. 
Overall these results establish TRM as a distinct memory subset in humans, with unique 
features to maintain long-term tissue residency. Interestingly, we found that TRM from different 
tissues sites were similar, and also found many similarities between CD4+ and CD8+ TRM. This 
suggests a universal TRM program that is engaged to prevent tissue egress. In the absence of 
specific targeting features, this reinforces a model in which early effectors enter the tissue during 
inflammation and engage a TRM program that then promotes residency and prevents exit into the 
170 
 
circulation, regardless of the tissue site. This idea is consistent with mice studies examining early 
TRM development (discussed in Chapter 1). These universal features also suggest that master 
transcriptional regulators of the human TRM program exist, although these are the subject of future 
research. Targeting these master regulators or other conserved TRM features may represent a 









Figure 5.1. Distribution and characteristics of TRM in human tissues. 
(A) Tissue-resident memory T cells (TRM) are localized to several tissues in humans, and can be 
distinguished from circulating memory T cells by expression of CD69. Heatmap shows the fraction 
of memory T cells that express CD69 in specific human tissue sites analyzed. 
(B) Unique characteristics of TRM in humans. TRM cells have a unique profile of transcription 
factor expression, surface expression of homing receptors and adhesion markers to maintain tissue 
residency, and a distinct functional profile with increased expression and ability to secrete both 
pro and anti-inflammatory cytokines. TRM also upregulate a number of inhibitory genes and 





















Defining Heterogeneity within Human TRM 
Having established core features of TRM that are preserved across tissues and subsets, we 
decided to investigate TRM heterogeneity based on the ability to efflux fluorescent dyes. Emerging 
evidence suggests that TRM as a whole comprise multiple, functionally distinct subsets that may 
play unique roles in protection and/or immunopathology [133, 155, 168]. These TRM subsets have 
typically been identified based phenotypic markers. However, it is not known if TRM with the 
ability to efflux fluorescent dyes exist across human tissues. This question is important because 
the ability to efflux fluorescent dyes is associated with longevity and stem-like properties in 
hematopoietic cells [187, 188], and recent evidence suggests that T cells exist with the ability to 
efflux dyes that have unique properties [230].  
We identify a population of CD8+ memory T cells with the ability to efflux fluorescent 
dyes in multiple tissues including spleen, lymph nodes, bone marrow, lung, and blood. Notably 
the TRM fraction within tissues contained a higher proportion of efflux(+) cells than other memory 
subsets. Phenotypic and RNA-Seq analysis of efflux(+) and efflux(-) TRM suggested that 
efflux(+) cells are a unique subset programmed for quiescence and longevity within tissues. 
Efflux(+) had elevated surface expression of CD127, expressed a number of genes associated with 
cell cycle control, expressed immunoregulatory markers (CD101, CD39), and had decreased 
expression of exhaustion andactivation markers (CTLA-4, PD-1, CD57, HLA-DR) and decreased 
turnover. Further, efflux(+) TRM had a unique profile of adhesion and migration markers 
suggesting an improved ability for tissue retention, including increased expression of CD49a and 
decreased expression of S1PR1. 
Following stimulation, TRM underwent massive transcriptional changes that were largely 
similar in both efflux(+) and efflux(-) subsets. However, there were notably differences in the 
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response to stimulation suggesting certain non-redundant functions of these subsets. After TCR 
stimulation, efflux(+) TRM produced less pro-inflammatory cytokines and underwent less 
cytotoxic degranulation compared with efflux(-) TRM. Moreover, efflux(+) TRM retained a 
higher proliferative capacity and exhibited greater responses to IL-7. Notably, efflux(+) also had 
an enhanced capacity for IL-17 production and showed evidence of aryl hydrocarbon receptor and 
Th17-associated signaling transcriptionally. Conversely, efflux(-) TRM had decreased integrin 
signaling and elevated Type 1 inflammatory responses following TCR stimulation. Overall, these 
results suggest efflux(+) TRM maintain a reservoir capable of proliferation via a program for 
longevity and tissue retention, while efflux(-) TRM exhibit heightened effector function for 
generating rapid pro-inflammatory and cytotoxic responses. 
Our data suggests cooperation between TRM subsets to achieve complete immunity. 
Specifically our data suggests that efflux(-) TRM may be primarily responsible for IFN- and 
TNF secretion and cytotoxic functions, while efflux(+) TRM may mediate IL-17 responses and 
possess immunomodulatory function and proliferative capabilities. However, our transcriptional 
data also indicates substantial overlapping functions between these two subsets. Further, we found 
no differences in IL-10 production by these two subsets, suggesting that this anti-inflammatory 
property may be common to all TRM subsets. Overall, this suggest a model in which certain 
functions are split between efflux(+) and efflux(-) TRM and in which these two subsets cooperate 
to achieve full immunity (Figure 5.2). This division of labor may be driven by anatomic 
differences, as efflux(+) and efflux(-) TRM have notable differences in their expression of 
adhesion and migration markers. Additional studies are needed to fully determine how TRM 
subsets cooperate to achieve full immunity.  
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Previous studies have highlighted the possibility of “targeted” immune therapies that only 
modulate TRM while leave other aspects of the immune system undisturbed. Our data suggest that 
this specificity can be taken one step further and that therapies should modulate a specific TRM 
subset. For example, efflux(+) TRM have a superior ability to produce IL-17 than efflux(-) TRM, 
and transcriptionally efflux(+) cells upregulate IL17A and other genes associated with IL-17 
signaling. This suggests that specifically targeting efflux(+) subset in psoriasis might be an optimal 










Figure 5.2. Proposed cooperativity of TRM subsets. 
 Our data suggests a model in which efflux(+) and efflux(-) TRM cooperate to mediate 
immunity. Specifically, efflux(+) TRM represent a subset with greater self renewal capacity. Upon 
stimulation efflux(+) TRM give rise to both more efflux(+) TRM as well as efflux(-) TRM. The 
efflux(-) TRM are primarily responsible for viral clearance and may die following infection. 
Functionally, the efflux(-) are responsible for the bulk of effector cytokine production whil 







Perspectives and outstanding questions 
The current research provides two main advances to the TRM field. First, we define 
universal properties of the TRM subset through simultaneous transcriptional and phenotypic 
analysis of TRM from multiple tissues and of both CD4+ and CD8+ lineages. Such a coordinate 
analysis of multiple TRM subsets had not previously been performed and establishes core features 
of the dominant memory subset in human tissues. Our core signature may have unique applications 
for identification of TRM, such as using the gene set to identify TRM in single cell sequencing 
experiments. Second, we identify a distinct TRM subset not based on a phenotypic marker, but 
based on the ability to efflux dyes. Importantly, our data puts forth a new model in which in TRM 
subsets cooperate to mediate full immunity. Our data also suggests the potential for a more stem-
like TRM that replenishes TRM mediating effector functions. Overall, we establish both core- and 
subset-specific properties of human TRM (Figure 5.3).  
Many outstanding questions remain in the field of TRM. One critical question is the 
developmental relationship between TRM and other T cell subsets. Similar to recent work that has 
been done in humans with naïve and certain memory subsets [99-101], epigenetic profiling of 
TRM compared with other T cell subsets will be critical for establishing the lineage relationships 
between TRM and other subsets. It is also not known whether TRM have the ability to proliferate 
in vivo in response to infection or if TRM represent a terminally differentiated subset. Our results 
suggest that TRM retain proliferative capacity, or at least that certain subsets of TRM do. This 
raises questions about what happens to TRM after stimulation: do TRM remain TRM or do they 
differentiate into other subsets?  
As discussed above, the fact that core features emerge when studying TRM from different 
sites and across multiple studies suggests a dominant transcriptional program that is engaged to 
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prevent tissue egress and promote tissue residency. However, it is not known which transcriptional 
regulators control TRM development in humans. Unlike in mice, evidence does not support a role 
for Hobit in human TRM development. Human TRM exhibit reduced expression of KLF2, Eomes, 
and T-bet [142, 186, 263], and downregulation of these transcription factors in required for TRM 
formation in mice [106, 139]. This suggests that many genes are shut off in the TRM program, 
consistent with our data that more genes are downregulated than upregulated by TRM compared 
with circulating memory T cell subset [186]. However, an important question is what 
transcriptional regulators are upregulated and promote TRM development and maintenance. One 
potential candidate is RPBJ, as suggested by our data [186] and studies from another laboratory 
[142]. Overall, an important area of future research is identifying key transcriptional regulators of 
human TRM development and maintenance.  
Dissecting TRM heterogeneity will be a critical area for future research. Initial studies 
treated TRM as a uniform subset that was distinct from TEM/TCM. However, recent research from 
our laboratory and others has shown that the TRM compartment is comprised of many functionally 
distinct TRM subsets. This suggests a model where TRM is an umbrella termed encompassing all 
tissue-retained T cells rather being a single subset itself. In this model, many distinct TRM subsets 
are retained within the tissue and the sum of all of their functions mediates complete tissue 
immunity. Therefore, future studies will need to move beyond treating TRM as one subset to 







Figure 5.3 Human TRM have core and subset-specific properties. 
Our studies have identified both core and subset-specific properties of human TRM. Core 
features are represented in the middle white circle. Subset specific phenotypic properties are shown 
on the top (efflux(+) TRM) and on the bottom (efflux(-) TRM). Distinct functional and 
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Appendix A. The functional profile of naïve and memory T cells with aging. 
Only data resulting from experiments that I performed is presented in this section, and this data is 
taken from:  
Thome, J.J.C.*, Grinshpun, B*, Kumar, B.V., Kubota, M., Ohmura, Y., Lerner, 
H., Sempowski, G.D., Shen, Y., Farber, D.L. (2016) Long-term maintenance of 
human naive T cells through in situ homeostasis in lymphoid tissue sites. Sci 
Immunol Dec;1(6).  
 
 
Naïve T cells develop in the thymus and coordinate immune responses to new antigens; 
however, mechanisms for their long-term persistence over the human life span remain undefined. 
We investigated human naïve T cell development and maintenance in primary and secondary 
lymphoid tissues obtained from individual organ donors aged 2 months to 73 years. In the thymus, 
the frequency of double-positive thymocytes declined sharply in donors >40 years of age, 
coincident with reduced recent thymic emigrants in lymphoid tissues, whereas naïve T cells were 
functionally maintained predominantly in lymph nodes (LNs). Analysis of T cell receptor clonal 
distribution by CDR3 sequencing of naïve CD4+ and CD8+ T cells in spleen and LNs reveals site-
specific clonal expansions of naïve T cells from individuals >40 years of age, with minimal clonal 
overlap between lymphoid tissues. We also identified biased naïve T cell clonal distribution within 
specific LNs on the basis of VJ usage. Together, these results suggest prolonged maintenance of 




As detailed in Chapter 1, there is a marked decline in thymic function with aging in humans, 
such that there is virtually no output of naïve T cells from the thymus by age 40. However, naïve 
populations are still maintained even into the seventh and eight decade of life, particularly in 
lymphoid tissues. As maintenance of naïve populations shifts from thymic to peripheral 
production, an important question is whether the function of naïve populations is affected.  
To determine how cessation of thymic output affects T cell function, naïve 
(CCR7+CD45RA+) T cells were isolated by cell sorting from donors with active thymic output 
(35 years of age or younger) or from donors without thymic output (50 years of age or older). As 
a comparison group, memory T cells (CCR7-CD45RA-) were also isolated from the same donors 
and tissues. Isolated T cells were stimulated with anti CD3/CD28/CD2 beads for 48 hours and 
cytokine secretion was measured via BD Cytometric Bead Array (for detailed methods, see 
Chapter 2).  
Naïve T cells from all tissue sites from multiple donors above the age of 50 retained the 
capacity to produce IL-2 upon stimulation but produced low levels of IFN-, IL-4, and IL-10 
(Figs. A.A.1, A.A.2 and Table A.A.1). Further, the functional properties of naïve T cells did not 
vary by age. Memory T cells on the other had were able to produce more substantial levels of IFN-
, IL-4, and IL-10 compared with naïve T cells. However, some age related changes were noted, 
with memory T cells from older individuals producing reduced amounts of IL-10 (Fig. A.A.2 and 
Table A.A.1). Overall, these results suggest that CCR7+CD45RA+ phenotype naïve T cells retain 




Figure A.A.1. Naïve T cells retain function with age.  
Naïve and memory CD4+ and CD8+ T cells were isolated from spleen, inguinal lymph nodes (ILN), 
and lung lymph nodes (LLN), stimulated for 48 hours using anti-CD3/CD28/CD2 beads, and the 
cytokine content in supernatants was assessed using the BD Cytometric Bead Array kit.   
(A) IL-2 and IFN- production (in pg/ml; means ± SEM) isolated from donors <35 years of age 
(white bars) and <50 years of age (black bars). n=2-4 donors except spleen CD4+ >50, for which 
n=1. 
(B) Heatmap shows IL-2 and IFN- production by naïve and memory CD4+ and CD8+ T cells 
from the LLN of four individual donors <35 years of age (aged 29, 25, 26, and 34) and four donors 
>50 years of age (aged 54, 56, 52, and 59). Cytokine levels are normalized by donor and indicated 
























Figure A.A.2.  IL-4 and IL-10 Production by Naïve and Memory T cells  
Naïve and memory CD4+ and CD8+ T cells were sorted from spleen, ILN, and LLN and 
stimulated for 48h using anti CD3/CD28/CD2 beads, and the cytokine content in supernatants was 
assessed using the BD Cytometric Bead Array kit for 48 hours (see methods in Chapter 2). IL-4 
(A) and IL-10 (B) production (pg/ml, mean± SEM) by naïve and memory T cells isolated from 
tissues of donors under age 35 years of age (white bars, n=2-5 donors) and over 50 years of age 








Table A.A.1: Tabular data for all cytokines measured in this study   
IL-2 
(pg/ml) 
Donor  D175 D233 D184 D124 D216 D225 D231 D224 D189 
Age 24 26 25 26 34 54 56 52 59 
Spleen CD4 Naïve  19146 9164 4753 11550   10152  
Spleen CD4 TEM  15836 3370 3592 5924 19329 1974 7682  
Spleen CD8 Naïve  8449 401 1039 4684 17078  8990  
Spleen CD8 TEM   2064 190 199 272 5956 97 2647  
ILN CD4 Naïve   23441 4222 259  15921 17161 2880  
ILN CD4 TEM   15425 3058 1511  12135 10569 2681  
ILN CD8 Naïve   9965 306   8008 5390 203  
ILN CD8 TEM  2132 224   10034 693 646  
LLN CD4 Naïve   21653 2442 245 21235 9423 23041 744 25811 
LLN CD4 TEM  5030 12753 2943 1004 8390 9572 12542 1461 18952 
LLN CD8 Naive   8093 38 8 12686 3565 16928 55 16723 
LLN CD8 TEM  179 2530 1325 939 4442 7692 4099 354 10891 
             
IFNγ 
(pg/ml) 
Donor  D175 D233 D184 D124 D216 D225 D231 D224 D189 
Age 24 26 25 26 34 54 56 52 59 
Spleen CD4 Naïve  1703 122 66 212   193  
Spleen CD4 TEM  12127 2137 1246 2244 9513 101 5112  
Spleen CD8 Naïve  2456 251 326 740 1583  1161  
Spleen CD8 TEM   11422 1140 1098 654 10746 76 6872  
ILN CD4 Naïve   1347 67 4  206 160 50  
ILN CD4 TEM   12952 1592 182  3180 1738 845  
ILN CD8 Naïve   1393 220   1281 1544 108  
ILN CD8 TEM  10922 599   12332 914 867  
LLN CD4 Naïve   3032 29 2 349 164 984 34 2516 
LLN CD4 TEM  2626 13164 1090 185 3357 4529 3489 990 8798 
LLN CD8 Naive   2602 120 123 1791 605 2363 41 4362 
LLN CD8 TEM  670 12961 2565 784 7047 12148 6645 1295 13432 
             
IL-4 
(pg/ml) 
Donor  D175 D233 D184 D124 D216 D225 D231 D224 D189 
Age 24 26 25 26 34 54 56 52 59 
Spleen CD4 Naïve  4 3 0 2   11  
Spleen CD4 TEM  884 576 77 110 282 5 731  
Spleen CD8 Naïve  0 0 0 0 0  8  
Spleen CD8 TEM   116 0 4 0 122 0 62  
ILN CD4 Naïve   0 0 0  0 0 14  
ILN CD4 TEM   800 297 20  83 0 481  
ILN CD8 Naïve   0 0   0 0 8  
ILN CD8 TEM  93 0   109 4 62  
LLN CD4 Naïve   1 0 0 0 0 0 11 11 
LLN CD4 TEM  89 432 0 13 139 74 162 806 221 
LLN CD8 Naive   0 0 0 0 0 0 8 0 
LLN CD8 TEM  0 66 0 0 6 59 21 19 231 
             
IL-10 
(pg/ml) 
Donor  D175 D233 D184 D124 D216 D225 D231 D224 D189 
Age 24 26 25 26 34 54 56 52 59 
Spleen CD4 Naïve  114 38 6 9   16  
Spleen CD4 TEM  5819 2532 437 203 573 46 492  
Spleen CD8 Naïve  8 0 0 1 0 
 8  
Spleen CD8 TEM   405 0 23 3 12 0 244  
ILN CD4 Naïve   77 69 0  0 8 14  
ILN CD4 TEM   6179 1998 28  138 283 267  
ILN CD8 Naïve   10 0   0 2 4  
ILN CD8 TEM  2028 12   8 6 28  
LLN CD4 Naïve   280 13 0 23 0 113 6 240 
LLN CD4 TEM  256 6569 1463 28 698 222 658 231 1442 
LLN CD8 Naive   14 0 0 0 0 2 4 22 








Appendix B. Imaging of frozen sections of human lymph nodes 
The localization of TRM within tissues in mice has been investigated in several studies by 
our lab [124] and others [103, 107, 111, 112, 133, 153]. However, the localization of TRM within 
human tissues has not been fully investigated. After HSV infection in humans, resident T cells 
were found to cluster around infected cells [162, 264], however these cells were CD8αα T cells 
and not canonical TRM that express αβ TCR. Another human study examined the localization of 
both CD103+ and CD103- TRM in spleen and tonsils [157]. Altogether, these studies show that 
CD8+ TRM are localized to distinct regions within tissues compared with non-resident T cells, 
consistent with their unique retention capabilities and function to intercept pathogens at sites of 
entry. However, the localization of CD4+ TRM and of CD8+ TRM in other tissue sites such as 
lymph nodes has not been investigated. 
To identify the localization of TRM within lymphoid tissues, we performed fluorescence 
imaging frozen sections of human lung lymph nodes (LLN) and stained for CD4, CD8, and CD69 
(see Chapter 2 for detailed methods). We found that T cells not expressing CD69 were primarily 
located towards the edges of the lymph node, while T cells expressing CD69 were located towards 
the inside of the lymph node (Figure A.B.1). These data suggest a unique localization for TRM 
within lymphoid tissues. However, it should be noted that these data were only based on staining 
a small number of donors (n=3). Further, no memory markers (i.e. CD45RA) were included in the 
staining. This means that CD69+ T cells being detected could represent naïve or TCM cells, or 




Figure A.B.1. Localization of CD69+ and CD69- T cells within human lymph nodes. 
Fixed human LLN was stained for CD4 (green), CD8 (blue), and CD69 (red). Image shown is 
from a single representative donor (donor 229, age 43) at 10x magnification, representative of 3 
donors. 
(A) Image shows full LLN. 
(B) Magnification on outer area containing single positive CD4+ and CD8+ T cells. 
















Appendix C. Role of CRTAM in lung TRM: preliminary data and project proposal 
(Mouse experiments performed by Daniel Paik) 
Preliminary Data and Rationale 
Transcriptionally, the gene CRTAM was one of the most significantly upregulated genes 
in human lung TRM in both CD4+ and CD8+ subsets, showing over 2-fold increase in TRM 
compared with TEM in all donors (Data from Chapter 3, Fig. A.C.1). Crtam (cytotoxic and 
regulatory T cell molecule) is a cell surface adhesion molecule that is expressed by T cells and 
other leukocytes such as NK cells [265-267]. Crtam binds Cadm1, which is found on the surface 
of dendritic cells and other cell types such as epithelial cells, and it has been shown that Crtam 
may play a role in the retention of T cells to certain locations [265-267]. I hypothesize that Crtam 
is required for the generation, retention, and optimal function of lung TRM. Preliminary data also 
indicate that Crtam is expressed exclusively by lung TRM in mouse following influenza infection 
(Fig. A.C.2). Further, Crtam+ cells in mouse have a TRM-like phenotype, being CD49a+ and 
CD62L- (Fig. A.C.2).  
Experimental Plan   
The requirement of Crtam for generation of TRM in the lung can be determined using a 
well-established mouse model for generating and tracking influenza-specific CD4+ T cells that has 
been used by our laboratory to study TRM in the lung (Fig. A.C.3)  [105, 116, 124, 125]. To 
generate antigen specific TRM, purified CD45.2+ ovalbumin (OVA)-specific TCR transgenic OT-
II CD4+ cells are transferred into naïve CD45.1+ B6 host mice which are subsequently infected 
with the OVA-expressing recombinant influenza strain PR8-OVA, leading to an expansion of 
transferred OT-II cells that migrate to the infected lungs (Fig. A.C.3). After 4-8 weeks, the 
recovered flu-memory mice will contain OT-II lung TRM which can be differentiated from host 
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polyclonal TRM by their CD45.2+ congenic marker. In vivo antibody labeling can be used to 
distinguish TRM from circulatory T cells, and this technique that has been extensively validated 
in different labs including our own [104, 105, 116, 124, 125, 129]. A fluorescently labeled antibody 
is injected into a mouse which distributes in the blood and specifically binds to circulating 
leukocytes. Non-circulating leukocytes such as TRM are protected from antibody labeling and fall 
into the negative population, which distinguishes them from fluorescently labeled TEM.  
As lung TRM in mice express Crtam (Fig A.C.2), Crtam knockout mice can be crossed 
with OT-II mice, and the OT-II Crtam-/- T cells can be used investigate the need for Crtam in 
generation of CD4+ lung TRM. (OT-I Crtam-/- T cells can be used to investigate CD8 TRM 
generation.) OT-II Crtam-/- and wild-type OT-II cells can be transferred into host mice and TRM 
generation by these two cells types will be assessed after infection.  
To assess the role of Crtam in protection against secondary infection, host mice containing 
either OT-II CRTAM-/- or wild-type OT-II cells can be infected with PR8-OVA. After 4-8 weeks, 
these mice can be challenged with H3N2 virus X31-OVA to assess heterosubtypic protection. A 
different strain is used to measure protection mediated by T cells, and removes the effect of 
antibodies that are generated during primary infection. Mice can be evaluated for differences in 
weight loss, viral clearance, mortality, and lung injury. Lung viral titers can be calculated as 
described previously [268]. To assess tissue damage, lung histology can be performed using 
hematoxylin and eosin (H&E) to observe necrosis, changes to the lung architecture, and immune 
infiltrates. Changes in lung function can be measured using a mouse-specific pulse oximeter to 
calculate differences in blood oxygen levels [269]. Finally, to assess specifically protection due to 
TRM rather than all T cells, mice can be challenged in the presence of FTY720, which limits 
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leukocyte migration into tissue, and thus restricts the protective response to TRM as we have 




Figure A.C.1. Elevated CRTAM expression by human lung TRM. 
Graph displays normalized mRNA expression levels of CRTAM in blood and lung samples 
from three donors. Lines connect samples from identical donors. Differential expression was 
assessed by EdgeR and * FDR<0.05, ****FDR<10-5. Tissue abbreviations: B=blood, L=lung. 






























Figure A.C.2. Crtam is expressed exclusively by Lung TRM in mice.  
Mice were infected with PR8 (H1N1) influenza and 10 weeks later memory (CD44+) T cells from 
lung and spleen were analyzed for Crtam expression.  
(A) Representative flow cytometry plots showing Crtam expression in circulatory (in vivo 
labelled) and resident (in vivo unlabeled) memory T cells.  
(B) Representative flow cytometry plots showing Crtam coexpression with ITGA1 and CD62L in 






































Appendix D. Accepted Abstracts 
 
2016 Oral Presentation: A core transcriptional and functional profile distinguishes 
resident memory T cells in human.  
 Middle-European Societies for Immunology and Allergology (MESIA)  
 2016 Annual Meeting in Budapest, Hungary  
 Travel Award Recipient 
 
Authors: Brahma V. Kumar, Wenji Ma, Michelle Miron, Tomer Granot, Dustin J. Carpenter, 
Takashi Senda, Yufeng Shen, and Donna L. Farber.  
 
Abstract: 
Tissue-resident memory T cells (TRM) are a non-circulatory subset of T cells that mediate rapid 
responses to secondary infection. TRM have been shown to provide superior protective responses 
compared with circulating memory T cells in mouse studies, and TRM are implicated in tissue-
specific inflammatory diseases in humans. Targeting TRM could be an effective strategy for 
vaccination or immunomodulation; however, little is known about TRM in humans and access to 
tissues is a critical barrier to advances in this field. Here, we investigate whether TRM can be 
identified in human tissue sites and whether TRM represent a distinct memory subset in humans. 
Through our collaboration with the New York organ procurement organization, we obtained 
lymphoid and mucosal tissues from healthy organ donors and used these to isolate cells bearing 
the phenotypic markers of TRM (CCR7-, CD45RA-, CD69+) and effector memory (TEM; CCR7-
, CD45RA-, CD69-) subsets. We performed whole transcriptome profiling by RNA Sequencing 
of TRM and TEM from the lung and spleen of 3 donors, as well as blood TEM from 3 donors, for 
both CD4 and CD8 subsets. CD69+ human TRM were transcriptionally similar to mouse CD8 
TRM, showing downregulation of KLF2 and S1PR1 and upregulation of ITGA1 and ITGAE, and 
all TRM samples clustered together in PCA analysis while spleen and lung TEM clustered with 
circulatory populations from blood, suggesting that the putative marker CD69 identifies TRM in 
humans. We compiled differential expression results between TRM and TEM and identified a core 
transcriptional signature of 80 and 142 genes that define CD4 and CD8 human TRM, respectively. 
TRM show differential expression of genes involved in migration and adhesion, upregulation of 
genes involved in the effector response, and upregulation of several inhibitory genes. Ex vivo 
functional studies support these results and show that TRM have a superior ability to rapidly 
produce IL-2 and effector cytokines such as IFN-γ and TNF compared with TEM. Using flow 
cytometry, we validated the expression of several adhesion markers and homing receptors 
including ITGA1, CXCR6, and CX3CR1, which may mediate tissue residency and could be used 
for identification of human TRM. Pathway analysis suggests that TRM are responding to TCR 
stimulus, cytokine signaling, and chemokine signaling in situ. Finally, by comparing differential 
expression in our dataset to publicly available ChIP-Seq data, we identified transcription factors 
that could represent upstream regulators of the TRM gene signature in both CD4 and CD8 subsets 
and validated the expression of select transcription factors by qPCR and flow cytometry. Overall, 
our data comprehensively characterize the transcriptional and functional properties of both CD4 
and CD8 human TRM and provide insight into mechanisms of tissue targeting and retention in the 




2017 Oral Presentation: Human tissue-resident memory T cells are defined by core 
transcriptional and functional signatures in lymphoid and mucosal sites. 
  Federation of Clinical Immunology Societies (FOCIS)  
2017 Annual Meeting in Chicago, IL 
  FCE Fusion Award Recipient   
Authors: Brahma V. Kumar, Wenji Ma, Michelle Miron, Tomer Granot, Rebecca Guyer, 
Dustin J. Carpenter, Takashi Senda, Harvey Lerner, Yufeng Shen, and Donna L. Farber 
 
Abstract:  
Resident memory T cells (TRM) have been identified in mouse models as having rapid protective 
capacities to site-specific pathogens and are key targets for vaccine-mediated protection. TRM-
phenotype cells are detected in human tissues but defining characteristics of human TRM for CD4 
and CD8 T cells including how TRM differ from circulatory subsets and potential mechanisms for 
site-specific targeting are not defined. We performed whole transcriptome profiling of memory T 
cell subsets from the lung, spleen and blood of 3 donors, for both CD4 and CD8 subsets, as well 
as in-depth phenotypic and functional profiling of memory T cells from 63 additional donors. Our 
results show that TRM are a transcriptionally distinct memory T cell subset in humans that can be 
identified by CD69 expression. We identify 30 core genes that define human TRM including the 
adhesion markers ITGA1 and ITGAE and homing receptors CXCR6 and CX3CR1, and we 
confirmed the surface expression of these genes and others by flow cytometry. TRM upregulated 
several cytokines transcriptionally and had a superior ability to produce IL-2, IL-17, and IFN-
gamma during stimulations compared with circulatory memory T cells. Interestingly, TRM 
showed enrichment of cell cycle inhibition pathways, a result which was supported by reduced 
Ki67 expression in TRM. TRM also upregulated IL-10, DUSP6, and PD-1, together suggesting 
that TRM may exist in an inhibited state to prevent inflammation-mediated tissue damage. Overall, 
our data comprehensively characterize CD4 and CD8 human TRM and provide new insights into 






Appendix E. Abstracts of contributing author manuscripts 
 
Miron, M., Kumar B.V., Meng, W., Granot, T., et al. Human lymph nodes maintain a distinct 
subset of TCF-1hi resident memory T cells throughout life. Science. Submitted.  
 
Tissue resident memory T cells (TRM) predominate in barrier sites and mediate protective 
immunity, while their role in lymphoid tissues is undefined. Here we analyzed human memory 
CD8+T cells in different lymphoid compartments including bone marrow, spleen, and lymph nodes 
(LN) relative to lung within diverse individuals. We identify an organ-specific subset in human 
LN (designated TLN) not found in blood or other tissues, expressing high levels of TCF-1 and 
transcriptionally enriched for signatures of quiescence, self-renewal, and follicular-helper cells. 
High dimensional CyTOF analysis reveals TLN as intermediate in differentiation between naive 
and TRM cells, with circulating TEM cells the most differentiated. TLN exhibit higher TCR 
diversity, lower in vivo turnover, yet higher proliferative responses compared to memory cells in 
other lymphoid or mucosal sites. These findings establish human LN as reservoirs for diverse 




Carpenter, D.J., Granot, T., Matsuoka, N., Senda, T., Kumar, B.V., Thome, J.J.C., Gordon, 
C.L., Miron, M., Weiner, J., Connors, T., et al. (2017). Human immunology studies using organ 
donors: impact of clinical variations on immune parameters in tissues and circulation. Am J 
Transplant. doi: 10.1111/ajt.14434 
 
 
Organ donors are sources of physiologically healthy organs and tissues for life-saving 
transplantation, and have been recently used for human immunology studies which are typically 
confined to the sampling of peripheral blood. Donors comprise a diverse population with different 
causes of death and clinical outcomes during hospitalization, and the effects of such variations on 
immune parameters in blood and tissues are not known. We present here a coordinate analysis of 
innate and adaptive immune components in blood, lymphoid (bone marrow, spleen, lymph nodes), 
and mucosal (lungs, intestines) sites from a population of brain-dead organ donors (2 months-93 
years; n = 291) across eight clinical parameters. Overall, the blood of donors exhibited similar 
monocyte and lymphocyte content and low serum levels of pro-inflammatory cytokines as healthy 
controls; however, donor blood had increased neutrophils and serum levels of IL-8, IL-6, and 
MCP-1 which varied with cause of death. In tissues, the frequency and composition of monocytes, 
neutrophils, B lymphocytes and T cell subsets in lymphoid or mucosal sites did not vary with 
clinical state, and was similar in donors independent of the extent of clinical complications. Our 
results reveal that organ donors maintain tissue homeostasis, and are a valuable resource for 




Granot, T., Senda, T., Carpenter, D.J., Matsuoka, N., Weiner, J., Gordon, C.L., Miron, M., 
Kumar, B.V., Griesemer, A., Ho, S.H., et al. (2017). Dendritic Cells Display Subset and Tissue-
Specific Maturation Dynamics over Human Life. Immunity, 46(3), 504-515. doi: 
10.1016/j.immuni.2017.02.019 
 
Maturation and migration to lymph nodes (LNs) constitutes a central paradigm in 
conventional dendritic cell (cDC) biology but remains poorly defined in humans. Using our organ 
donor tissue resource, we analyzed cDC subset distribution, maturation, and migration in mucosal 
tissues (lungs, intestines), associated lymph nodes (LNs), and other lymphoid sites from 78 
individuals ranging from less than 1 year to 93 years of age. The distribution of cDC1 
(CD141hiCD13hi) and cDC2 (Sirp-α+CD1c+) subsets was a function of tissue site and was 
conserved between donors. We identified cDC2 as the major mature (HLA-DRhi) subset in LNs 
with the highest frequency in lung-draining LNs. Mature cDC2 in mucosal-draining LNs expressed 
tissue-specific markers derived from the paired mucosal site, reflecting their tissue-migratory 
origin. These distribution and maturation patterns were largely maintained throughout life, with 
site-specific variations. Our findings provide evidence for localized DC tissue surveillance and 






Thome, J.J.*, Grinshpun, B.*, Kumar, B.V., Kubota, M., Ohmura, Y., Lerner, H., Sempowski, 
G.D., Shen, Y., and Farber, D.L. (2016). Longterm maintenance of human naive T cells through 
in situ homeostasis in lymphoid tissue sites. Sci Immunol, 1(6). doi:10.1126/sciimmunol.aah6506 
 
 
Naïve T cells develop in the thymus and coordinate immune responses to new antigens; 
however, mechanisms for their long-term persistence over the human life span remain undefined. 
We investigated human naïve T cell development and maintenance in primary and secondary 
lymphoid tissues obtained from individual organ donors aged 2 months to 73 years. In the thymus, 
the frequency of double-positive thymocytes declined sharply in donors >40 years of age, 
coincident with reduced recent thymic emigrants in lymphoid tissues, whereas naïve T cells were 
functionally maintained predominantly in lymph nodes (LNs). Analysis of T cell receptor clonal 
distribution by CDR3 sequencing of naïve CD4+ and CD8+ T cells in spleen and LNs reveals site-
specific clonal expansions of naïve T cells from individuals >40 years of age, with minimal clonal 
overlap between lymphoid tissues. We also identified biased naïve T cell clonal distribution within 
specific LNs on the basis of VJ usage. Together, these results suggest prolonged maintenance of 
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Currently, I am studying tissue-resident memory T cells (TRM) in 
humans. TRM play an important role in defending against pathogens 
at peripheral sites; however, most of our knowledge about TRM 
comes from studies in mice. We obtain human tissues through a 
collaboration with the organ procurement agency, and in my project 
I isolate TRM and compare these cells to other memory subsets to 
determine defining characteristics of human TRM. My data show 
that TRM are a distinct memory T cell subset in humans and can be 
identified by CD69 expression. I further identified unique functional 
and phenotypic properties of TRM in humans. In this project we also 
compare human and mouse TRM and identify a core signature of 31 
genes common to TRM from both species and common to TRM 
from multiple tissues sites.  
 
In subsequent projects, I am now investigating TRM heterogeneity 
based on the ability to efflux fluorescent dyes. Our data suggest that 
effluxing TRM transcriptionally and functionally distinct TRM 
subset with features of quiescence. Our data also suggest that 
effluxing TRM may represent a less differentiated subset that gives 
rise to more effector-like non-effluxing TRM after stimulation.  
 
2011–2012    Research Assistant 
    Laboratory of Attila Bacsi, PhD 




Although ragweed pollen is one of the most common triggers of 
allergic asthma, whole pollen grains are too large to reach the lower 
airways. Dr. Bacsi’s group previously demonstrated the release of 
subpollen particles (SPP) from ragweed pollen, which are small 
enough to penetrate the lower airways, and one of my main projects 
was to investigate mechanisms of SPP induced inflammation. 
Briefly, we found that dendritic cells (DCs), which exist in large 
numbers beneath the airways, are triggered by antigens and enzymes 
found in SPPs. SPPs trigger DC maturation, pro-inflammatory 
cytokine release by DCs, and these DCs are capable of priming T 
cells. We found that the mechanism of DC activation is largely a 
result of reactive oxygen species produced by enzymes contained 
within the SPPs.  
 
2010–2011    Undergraduate Research Assistant 
    Johns Hopkins Hospital, Baltimore 
 
I worked on two clinical projects related to Huntington’s disease 
(HD). In the first project, we examined factors that contribute to 
institutionalization in HD, and in the second project we examined 
how CAG repeat length contributes to disease progression in HD. 
For these projects, I compiled patient data by chart review and 
created databases of patients that were used for studies. I 
performed statistical analyses using these databases. I am a 
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human resident memory T cells in lymphoid and mucosal sites. 
 Columbia Center of Translational Immunology (CCTI) Seminar Series 
Columbia University, New York, NY 
 
2016 Oral Presentation: A core transcriptional and functional profile distinguishes 
resident memory T cells in human.  
 Middle-European Societies for Immunology and Allergology (MESIA)  
 2016 Annual Meeting in Budapest, Hungary  
 Travel Award Recipient 
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 Biannual retreat for the Integrated Graduate Program  
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Other Professional Experience: 
 
2012-2013   Psychiatric Technician 
    Montgomery County Emergency Services, Norristown, PA 
 
I worked at an inpatient psychiatric hospital and that receives all 
involuntary commitments in Montgomery County, PA.  I was 
responsible for interviewing and monitoring a group of 
approximately 8 patients each shift in order to write detailed notes 
about their behavior, responses to medication, and general 
progress. My other responsibilities included obtaining vital signs, 
feeding and bathing low-functioning patients, performing one-on-
one observations for assaultive or suicidal patients, assisting group 
activities, and admitting new patients. 
 
